The Renal Association  by unknown
Kidney International, Vol. 55 (1999), pp. 2091–2116
ABSTRACTS
The Renal Association
London, England
October 13–14, 1997
Characterisation and expression of the PKD-1 protein, polycystin, in rescence is dependent on the formation and integrity of tight junctions
and developed 2–3 hours after E-Cadherin in the calcium switch model.renal and extrarenal tissues. A.C.M. Ong, P.C. Harris, S. Biddolph1, C.
Bowker1, and C.J. Ward, MRC Molecular Haematology Unit, Institute of Preliminary results with anti-polycystin-2 antibodies have demonstrated
a similar pattern of expression to polycystin in the distal tubule andMolecular Medicine, University of Oxford, Oxford, UK and 1Dept of
Paediatric Pathology, John Radcliffe Hospital, Oxford, UK. Studies of collecting duct with more marked vascular endothelial cell staining.
This provides further evidence for their likely functional interaction. Athe nature and expression of the PKD-1 gene product, polycystin, have
been complicated by duplication of the PKD-1 gene, the low expression complete description of the developmental expression of these proteins
during nephrogenesis is also currently underway. Polycystin and poly-of the PKD-1 gene in adult tissues and the lack of antibodies to epitopes
in the duplicated region of polycystin. Using five monoclonal and cystin-2 are therefore widely expressed novel epithelial and endothelial
cell proteins.polyclonal antibodies to epitopes encompassing the whole of the poly-
cystin molecule, we have studied the biochemical and cellular expres-
sion of polycystin, and sought to identify homologues and alternative
splice forms of polycystin. We find that polycystin exists as a 400–500 GDNF/RET in mesenchymal/epithelial paracrine signalling in nephro-
genesis. A.S. Woolf, P.T. Towers, and P. Hardman, NephrourologykDa protein in normal kidney and in a range of renal epithelial cell
lines by immunoblotting, using antibodies to four different epitopes. and Developmental Biology Units, Institute of Child Health, London,
UK. The mammalian kidney derives from 2 parts of the metanephros:No evidence of translated products from the genes (HG) homologous
to PKD-1 nor any major splice forms of polycystin was found. In the ureteric bud, which branches into collecting ducts, and renal mesen-
chyme, which differentiates into nephrons. In 1953 Clifford Grobsteinrenal cells, polycystin could be detected as a cell surface protein but
significant intracellular concentrations were also found by cellular frac- used murine organ culture to show that mesenchyme drives growth
of the ureteric bud. In this study we examined the roles of glial celltionation and immunofluorescence. In normal and PKD-1 fetal tissues,
immunoreactive polycystin was detected in many different cell types line-derived neurotrophic factor (GDNF) and its RTK, RET, in mouse
ureteric bud development. By in situ hybridisation, GDNF was ex-outside the kidney including vascular smooth muscle cells, endothe-
lium, pancreatic, biliary and respiratory ductal epithelia, thyroidal epi- pressed in condensing renal mesenchyme while transcripts for RET
and its accessory receptor (GDNFRa) were detected in ureteric budthelium, endocardium, myocardium, oocytes and Leydig cells. In the
developing mouse kidney, polycystin expression is seen in all nephron branch tips. Using organ culture of whole metanephroi, we found that
an antiserum which blocked GDNF bioactivity prevented branchingsegments but expression becomes restricted to mature distal tubules
and collecting ducts in adult life. These observations clarify the nature morphogenesis, while a ‘super-kidney’, twice the normal size, could
be generated by the addition of recombinant GDNF. The latter ma-of the PKD-1 protein, provide a molecular basis for understanding the
systemic nature of PKD-1 and may explain the known phenotypic noeuvre also elicited ectopic ureters, reminiscent of human duplex
renal tracts. When we attempted primary culture of ureteric bud iso-difference in the nature of renal cysts between ‘early-onset’ cases and
typical adult-onset disease. lated from mesenchyme, epithelia died by apoptosis but this process
could be partially rescued by addition of GDNF. Next we investigated
the effects of RET signalling in the Madin Darby Canine Kidney
Tissue distribution of polycystin and polycystin-2. L. Foggensteiner1, (MDCK) collecting duct cell line. cDNAs for wild type RET and RET/
N. Coleman2, S. Thiru2, J. Bradley1, and R. Sandford1, 1Dept of Medicine, PTC2, a mutant coding for an activated receptor with a phosphorylated
2Dept of Pathology, Addenbrooke’s Hospital, Hills Road, Cambridge. kinase, were lipofected into MDCK cells and stable transfectants iso-
Autosomal dominant polycystic kidney disease is caused by mutations lated after G418 selection. Using RT-PCR, we identified lines which
at three loci two of which, PKD1 and PKD2 have been cloned. The transcribed these genes driven by a CMV promoter. In collagen I gels,
PKD1 gene product, polycystin is a 456Kd integral membrane protein vector-only controls as well as RET expressing lines grew as simple
of unknown function and the PKD2 gene product, polycystin-2 is a cysts. In contrast, RET/PTC2 cells formed cysts with ‘spike-like’ pro-
105kd membrane protein which may function as an ion channel. Prelim- cesses which invaded the matrix, and a similar phenotype was noted
inary evidence suggests that these proteins interact via their C terminal in RET transfected MDCK cells exposed to recombinant GDNF. We
cytoplasmic domains and are involved in a common pathway disruption conclude that GDNF is a potent metanephric growth paracrine factor,
of which leads to ADPKD. Anti-sera to both intra and extra-cellular which is secreted by mesenchyme and which acts by enhancing survival
domains of polycystin have been used to demonstrate the distribution and branching of embryonic collecting duct epithelia.
of this protein in human tissues and cell lines. In normal adult kidney
predominant membrane staining is seen in distal tubular and collecting
duct epithelial cells and in glomerular endothelial cells. Renal tissue Biology of fetal glomerulocystic disease associated with ureteric ob-
struction. R. Attar, P.J.D. Winyard, F. Quinn, P.D.E. Mouriquand, P.with histological evidence of acute tubular necrosis revealed additional
staining of regenerating proximal tubules. Extra-renal expression was Duffy, M.A. Hanson1, P. Foxall 2, and A.S. Woolf, Nephrourology Unit,
Institute of Child Health, Department of Obstetrics and Gynaecology1,seen in biliary, pancreatic, skin and cervical epithelial cells. Polycystin
expression was also demonstrated in cyst-lining epithelial cells from UCLMS and Department of Biochemistry, Birkbeck College2, London
University, UK. Malformations account for most cases of childhoodADPKD kidneys and liver. Confocal immunofluorescence microscopy
of cultured human umbilical vein endothelial cells (HUVEC) and chronic renal failure and are often associated with obstructed urinary
tracts. We hypothesised that prenatal obstruction induces a definedMadine Darby canine kidney (MDCK) cells shows polycystin to be
localised to cell junctions and co-staining with known lateral membrane biological programme which disrupts nephrogenesis. We therefore ex-
amined cellular and molecular events after experimental obstructionproteins is seen. In MDCK cells polycystin expression by immunofluo-
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in fetal sheep. Gestation in this species lasts 145 days and we generated results in a urine pH below 5.5 in normal subjects, NH4Cl is unpalatable
and its ingestion can lead to vomiting. Batlle (Kidney Int. 30:546, 1986)complete unilateral ureteric obstruction at 90 days when only a few
layers of glomeruli had formed. Since fetal human kidneys opposite has suggested that oral administration of the loop diuretic frusemide
can provide an alternative, more acceptable, method of diagnosis. Wenon-functional organs can grow excessively, we also analysed sheep
contralateral organs and kidneys from twin fetuses in which the urinary have assessed both techniques in normal subjects, together with a
modification of Batlle’s method, involving a mineralocorticoid load.tract was not manipulated (n 5 6, all groups). At 10 days, obstruction
generated hydronephrosis and, even after drainage of the pelvis, kidney Eight healthy subjects (5M, age 20–50) with normal glomerular func-
tion as assessed by creatinine clearance were studied, in random order,weight was greater than contralateral or unoperated organs. In ob-
structed kidneys, there was a failure of de novo nephrogenesis as on 4 occasions, as follows: (a) control; (b) oral NH4Cl (100 mg/kg ingested
between 9.00h and 11.00h); (c) oral frusemide (40 mg at 10.55h); andassessed by fewer nephron precursors which expressed PAX2, a tran-
scription factor required for their growth. Deeper in the cortex, we (d) oral frusemide preceded on the previous evening by 1 mg of fludro-
cortisone. Each subject drank at least 500 ml of water between 9.00hfound evidence of glomerulocystic disease with massively dilated Bow-
man’s spaces with parietal glomerular epithelia expressing PAX2 and and 11.00h; thereafter water intake was ad libitum. Urine volume and
pH were measured on samples collected at hourly intervals. The mini-proliferating cell nuclear antigen. Our further observation of pyknotic
nuclei in tubules prompted quantification of apoptosis using propidium mum pH achieved in each subject on each treatment is shown below.
iodide: point prevalence was increased in obstructed kidneys. Hence
both proliferation and death are upregulated, as we have reported
in human kidney malformations. In obstructed kidneys, medullary
collecting ducts and loops of Henle were reduced with increased urinary
[Na1], [K1], osmolality and [lactate], suggesting altered distal tubule
electrolyte handling and increased medullary anaerobic glycolysis. We
conclude that complex aberrations of morphogenesis, gene expression,
cell turnover and urine composition occur relatively early after fetal
ureteric obstruction. Understanding such mechanisms may allow the
design of therapies to enhance normal nephrogenesis.
Ubiquitin mRNA is not down regulated by the long term correction
of acidosis in humans with chronic renal failure. R.G. Roberts, C.P.F. The data indicate that frusemide administration only provides a reliable
Redfern, and T.H.J. Goodship, Department of Medicine, University of assessment of urinary acidification when combined with a mineralocor-
Newcastle upon Tyne, UK. In chronic renal failure (CRF) metabolic ticoid load.
acidosis is associated with increased whole body protein degradation
(PD) (Am J Physiol 265:E230–E235,1993). In rats this is an effect primar-
ily in skeletal muscle and is linked to an increased expression of the Chronic pyelonephritis. A re-evaluation of prognostic factors for the
Ubiquitin gene (J Clin Invest 97:1–7, 1996). This study was designed to development of renal impairment. T.H.J. Goodship, J.P. Owen, J.T.
see whether this was so in humans with CRF. Acidotic subjects were Stoddart, V. Martinek, D. Geetha, M.K. Ward, and R. Wilkinson, De-
studied initially (acid) and after a month of oral sodium bicarbonate partments of Medicine and Radiology, University of Newcastle upon
(bicarbonate). Protein metabolism was studied using stable isotopes, Tyne. A database of all patients with chronic pyelonephritis (CPN)
leucine (leu) to measure whole body PD and phenylalanine (phe) to under the care of the regional renal unit was established in 1976 and
measure PD across forearm skeletal muscle. Muscle biopsies were since then 330 cases have been entered. Previous studies of CPN have
taken from gastrocnemius to measure the expression of ubiquitin suggested that a poor prognosis is associated with bilateral disease,
mRNA in skeletal muscle. The PD results are shown below, (6sem). hypertension and proteinuria. However, such criteria when evaluated
in patients who already have renal impairment may be self-fulfilling.
In order to establish whether such factors are truly prognostic we haveVenous
reviewed all those patients who presented with a plasma creatinine # 90Bicarbonate PD (leu) PD (Phe)
mmol/l. From the original 330 cases 46 were identified with either incom-PH mmol/l mmol/kg/h mmol/kg/h
plete data or no follow up and were therefore not included in the study.
Acid 7.3160.01 15 61.0 11767 5563 151 patients had a plasma creatinine (Crp) # 90 mmol/l at presentationBicarbonate 7.3860.01 20 61.0 115610 5263 (mean 77 6 1 mmol/l). Compared to those who presented with a Crp .
90 mmol/l (mean 164 6 9 mmol/l) there was no significant difference in
In contrast to previous studies with leucine as a single tracer there mode of presentation but the Crp # 90 group were younger at presentation
was no significant fall in whole body PD measured using either tracer. (Crp # 90, 30 6 1 vs Crp . 90 36 6 1 years, p , 0.01) and there were
There was also no significant difference in phenylalanine exchange fewer males (Crp # 90, M7/F144 vs Crp . 90, M29/F102). At presentation,
across the forearm muscle bed (data not shown). This discrepancy with 28 patients in the Crp , 90 group were hypertensive (.150/100 mm Hg)
previous results led us to suspect that there was an effect of the two compared to 41 in the Crp . 90 group (p , 0.05) and fewer patients
tracers together and for our final two subjects we did not include had bilateral disease (Crp # 90, n 5 42 vs Crp . 90, n 5 88, p , 0.001)
phenylalanine and found the expected fall in PD with bicarbonate or proteinuria on urinalysis (Crp # 90, n 5 22 vs Crp . 90, n 5 67, p ,
therapy (118 6 2 to 76 6 6). Using Northern Blotting we found no 0.001). In the long term (mean follow-up 116 6 6 months) 9 patients
significant change in the expression of the human polyubiquitin gene. in the Crp # 90 group developed a plasma creatinine . 110 mmol/l
This is in contrast to results achieved in rats and in some other catabolic but in only two was this greater than 130 mmol/l (1066 and 379 mmol/l
states in humans. However there are other situations where muscle respectively), both these patients had bilateral disease and proteinuria
catabolism is chronic in which similar results have been described and it at presentation. Therefore, the prognosis for patients with chronic
may be only when the change in pH is acute that changes in proteolytic pyelonephritis presenting to adult nephrologists with a plasma creati-
enzymes are seen at the mRNA level. nine # 90 mmol/l is excellent especially for those with unilateral disease
and no proteinuria.
Assessment of urinary acidification. S.J. Walter, D.G. Shirley, R.J. Un-
win1, and O.M. Wrong1, Division of Biomedical Sciences, Imperial Col- Blood pressure control and renal allograft function. I. Dasgupta, C.J.
lege School of Medicine, Charing Cross Hospital, London UK and Porter, M.J.D. Cassidy, A.G. Morgan, K.M. Rigg, and R.P. Burden,
Centre for Nephrology1, University College, Middlesex Hospital, Lon- Renal Unit, Nottingham City Hospital, Nottingham. Control of hyper-
don UK. The assessment of urinary acidification used most frequently tension is thought to protect renal allograft function. We previously
in the diagnosis of distal renal tubular acidosis involves the administra- reported that blood pressure control (BP) in patients who had lost
their grafts due to biopsy proven chronic vascular rejection was compa-tion of an ammonium chloride load. Although this test consistently
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rable with that of a matched group of patients with functioning allograft seronegative; immunosuppression with antilymphocyte products: Pro-
phylaxis with antiviral therapy recommended. (Grade A recommenda-(Renal Association, Spring meeting 1997). We have now reviewed BP
control in 208 cyclosporin treated functioning renal transplants of more tion)
than 1 year duration from computer records. We compared BP control
in patients with stable allograft function (n 5 89) identified by a positive
reciprocal slope (log) of serum creatinine (1/SCr 5 2.37E–07) with FK506 as primary immunosuppressive therapy in renal transplantation.
R. Preston, S. Ball, T. Cairns, N. Hakim, A. Palmer, V. Papalois, andthose with declining function (n 5 119) with a negative 1/SCr (27.04E–
07). Mean duration of graft function was 5.5 6 3.2 and 5.0 6 2.8 years D. Taube, Renal and Transplant Units. St Mary’s Hospital, Paddington,
London W2 1NY. Although the large multicentre trials comparingrespectively. Serum creatinine at 6 months (SCr), mean systolic (SBP),
mean diastolic (DBP) and mean arterial (MAP) pressures (mm Hg) FK506 with cyclosporin show that FK506 reduces the incidence and
severity of acute rejection in renal allograft recipients there are fewbetween the two groups were compared. Results are shown below.
published single centre studies, particularly in the UK. In this study,
we report our experience over the past 2 years with FK506. 73 patientsSCr SBP DBP MAP
[43 male, 30 female], mean age 43.5 years, including 9 re-transplants(lM ) (mm Hg) (mm Hg) (mm Hg)
and 6 live related donor transplants received FK506 [0.15 mg/kg/day]
Stable graft and prednisolone [0.5 mg/kg/day tapering to 0.15 mg/kg/day at 3
function n 5 89 141.5 650.9 140.2611.6 84.566.2 103.166.1 months]. FK506 dosage was adjusted to maintain trough levels of 10–15
Declining graft ng/ml. In addition 44 patients received azathioprine [1 mg/kg/day]
function n 5 119 134.8 645.5 142.0615.1 84.365.6 103.567.7 and 4 received mycophenolate mofetil [1–2 g/day]. Anti-lymphocyte
preparations [ALG/ATG] were administered to 4 highly sensitised
Patients with declining graft function were further divided into Group 1 patients prophylactically. The mean number of HLA antigen mis-
MAP . 98 mm Hg (n 5 89) and Group 2 MAP . 98 mm Hg (n 5 matches was 2.8. Mean follow up was 14.4 [range 3–24] months. Mean
30). Mean duration of graft function was 5.0 6 0.3 and 4.9 6 0.5 years initial hospital stay was 15.7 [range 6–57] days. 23 patients (31%)
respectively. SCr, SBP, DBP, MAP and slope (log) of reciprocal serum experienced 30 discreet episodes of acute rejection. 4 patients with
creatinine (1/SCr) over the total period of observation (mean 6 sd) vascular rejection or steroid non responsive cellular rejection required
were compared. Results are shown below (ap , 0.0001). ALG/ATG therapy. Patient and allograft survival and allograft func-
tion are shown in the table below.
SCr SBP DBP MAP
(lM ) (mm Hg) (mm Hg) (mm Hg) 1/SCr Mean Mean
plasma FK506Group 1
Months % patient % graft creatinine level**n 5 89 138.7644.3 147.4612.9a 86.663.9a 106.865.5a 29.8E207
post txp survival survival (lmol /l ) (ng/ml )Group 2
n 5 30 123.8647.2 125.967.5a 77.764.4a 93.863.7a 21.3E206 3 (72)* 100 95.8 165 10.2
6 (71) 100 95.8 158 10.2
In conclusion; we have not found any difference in blood pressure 12 (64) 100 95.8 154 10.2
control between patients with stable renal allograft function and those 18 (18) 98.6 94.5 152 8.9
with declining function and despite excellent blood pressure control
* number of patients available for follow up; ** mean FK506 dose 0.13 mg/kg/dayin group 2 compared to group 1 we have not been able to demonstrate
a significant difference in the rate of decline in graft function. One patient died a year post transplantation with disseminated carci-
noma of the breast, having been disease free for 5 years pre transplanta-
tion. Two grafts were lost from renal artery stenosis and one following
Clinical practice guidelines: prevention of cytomegalovirus infection a renal vein thrombosis. No grafts were lost from rejection. Reversible
post-renal transplantation. S.V. Jassal, E. Cole, J. Zaltzman, and J.M. nephrotoxicity occurred in 9 and neurotoxicity in 1 patient. Serious
Roscoe, for the University of Toronto Consensus Group, Toronto, Can- infections occurred in 20 patients [wound 2, pyelonephritis 5, pneumo-
ada. The project objective was to develop comprehensive, standardised nia 2 and CMV 12]. New onset diabetes mellitus occurred in 9 patients.
evidence based guidelines for the use of antiviral therapy in adult Thirty two patients required anti-hypertensive medications. This study
patients undergoing renal transplantation. Treatment options included shows that FK506 is a very effective immunosuppressive agent in renal
the use of medications, at the time of induction therapy or at the transplantation and that our results are comparable with the multicen-
earliest sign of viraemia. Treatments were evaluated by patient and tre trial data.
donor serological groups and the induction regimen used. Outcomes
were measured in terms of control of symptoms and features of disease
over the first six to twelve months after transplantation. The proposed Conversion between tacrolimus and cyclosporin—estimation of dose
benefits of these guidelines include decreased patient costs, morbidity requirements. R.M. Higgins, C. Appleby*, P. Magee*, F.T. Lam, and
and mortality rates. Data from recent epidemiological studies also H. Kashi, Renal Unit and *Pharmaceutical Services, Walsgrave Hospital
suggest that effective preventative strategies may improve graft sur- Coventry. Cyclosporin (CsA) and tacrolimus (Tac) are effective in
vival. Additional costs of prophylaxis were outweighed by savings from renal transplantation. Conversion between the drugs may be indicated
reduced in-patient care and a quicker return to full activity. The develop- for rejection or adverse effects. We examined drug dosages to establish
ment and the cost-implications of the guidelines will be discussed. Arti- the optimum dosing protocol for conversion. We performed 35 conver-
cles, compiled using an extensive MEDLINE search from 1976 to sions; 17 from CsA to Tac for rejection; 15 from Tac to CsA routinely;
July 1997, were reviewed by members of the University of Toronto 3 from Tac to CsA for adverse effects. The starting dose of Tac was
consensus group. The evidence based methods and values of the Cana- 0.15 mg/kg/day, and of CsA 5 mg/kg/day. Drug doses and blood levels
dian Task Force on the Periodic Health Examinations were used. The before conversion and after achieving stable dosing were compared.
final recommendations are: 1) Seronegative recipient; seronegative There were no significant differences according to the direction of
donor; any immunosuppressive regime: No prophylaxis with antiviral conversion, so data from all 35 episodes were pooled:
therapy required. (Grade D recommendation); 2) Seronegative recipi-
ent; seropositive donor; conventional immunosuppression: Prophylaxis
with antiviral therapy recommended. (Grade B recommendation); 3) CsA Tac
Seronegative recipient; seropositive donor; immunosuppression with
Mean drug dosage mg/day (SD) 3196123 9.51 65.99antilymphocyte products: Prophylaxis with antiviral therapy recom-
Mean drug dosage mg/kg/day (SD) 4.4361.56 0.13260.094mended. (Grade A recommendation); 4) Seropositive recipient; donor
Mean drug level ng/ml (SD) 215669 10.2563.04seropositive or seronegative; conventional immunosuppression: Pro-
phylaxis left to the discrimination of the physician in charge. (Grade The dosage requirements in mg/kg/day for CsA and Tac were correlated (r 5
0.67, p , 0.001).C recommendation); 5) Seropositive recipient; donor seropositive or
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Actual dosing after conversion frequently differed from our protocol pg/ml) HPMC IL-6 secretion was 156.9 6 22.4 compared to the additive
starting dose; 24/35 patients (69%) had a Tac dosage requirement value 112 6 15.93 (p , 0.05, n 5 6). Stimulation of HPMC with
outside 0.10–0.20 mg/kg/day, with a range between highest and lowest IFN-g or IL-1b resulted in a time dependent increase in IL-6 mRNA
of 14-fold. 13/35 patients (37%) had a CsA dosage requirement outside expression as assessed by RT/PCR. Actinomycin D chase experiments
3.3–6.7 mg/kg/day, with a range of 4.5-fold. The mean ratio of Tac:CsA revealed that whilst IFN-g increased the half life of IL-6 mRNA the
doses was 30 fold. If the Tac requirement was calculated from the CsA combination IFN-g 1 IL-1b resulted in a further increase in IL-6
dose/30, this was better than dosing by weight in 25/35 cases (71%). mRNA stability. Blocking experiments using specific anti IFN-g recep-
The range of dosage requirement for CsA was less wide than for Tac, tor antibody, significantly reduced the stimulatory activity present in
but there would have been advantage in starting CsA at Tac dose 3 both PDE and PDE 1 IL-1b (by 86.6 and 45.9% respectively). These
30 in those with very high or low Tac requirements. data suggest that the superinduction of HPMC IL-6 synthesis induced
by a combination of PDE and IL-1b may partly be accounted for by
the presence of IFN-g in the peritoneal cavity.
Tunnelled vascular catheters for haemodialysis: the Tesio catheter.
T.R. Ringrose, P.D. Mason, C.G. Winearls, and P.H. Maxwell, Renal
Unit, the Churchill Hospital, Old Road, Headington, Oxford. The Tesio Effects of glucose(PD4), amino-acid dialysate(AA) and icodextrin
twin catheter system (Medcomp, Harleysville,PA) uses internal jugular (ICOD) on fibronectin(FN), TGF-b and cell viability of human perito-
vein placement of two separate silastic cuffed catheters which are neal mesothelial cells(HPMC). J.F. Medcalf, J. Walls, and K.P.G. Har-tunnelled to the anterior chest wall. Since February 1996, the Oxford
ris, Department of Nephrology, Leicester General Hospital, Leicester,renal unit has used Tesio catheters for dialysis patients for whom no
U.K. CAPD has a five year technique survival of less than 50%. Dialy-alternative access is available and for whom dialysis is predicted to be
sate glucose has been implicated in this peritoneal loss. To investigaterequired for more than 3 weeks. Vancomycin prophylaxis and desmo-
the effects of glucose and newer dialysis solutions on extra-cellularpressin were given. Our experience of 98 Tesio catheters in 92 patients
matrix(ECM) production by HPMC, cells were cultured in 50:50 dial-represents a total of 17410 catheter-days. Placement of the catheters
ysis solution and M199 with 0.1% FBS. A lab manufactured dialysatewas uncomplicated in 94 of 98 line insertions (3 failed cannulation due
with the same composition as Dineal PD4(LAB), PD4, AA and ICODto stenosis or thrombosis, 1 damage to catheter during tunnelling).
were tested. Glucose concentration in the LAB was varied betweenThe mean survival time per catheter was 178 days. 38 catheters were
5–40 mmol/L; mannitol was used as an osmotic control. FN and TGF-bstill in use at the time of analysis (38.8%). The causes of redundancy
were measured in the supernatant at 12 hrs by ELISA and corrected foror failure of the catheters are shown below.
cell protein. Cell viability was assessed by LDH release. In a separate
experiment recombinant TGF-b1 was added to LAB with 5 mmolReason for removal/failure n
glucose. Increasing D-glucose incrementally increased FN (15.4% in-
Poor flow 1 crease at 40 mmol/L, p 5 0.043); LAB with 40 mmol/L glucose produced
Sepsis 8 comparable effects to PD4. 40 mmol/L mannitol had no effect. ICOD
Alternative access available 22 stimulated 13.5% less FN than PD4 (P 5 0.03), whilst AA had similar
Death/transplant/recovery 29 effects to PD4 despite containing only 3.4 mmol/L D-glucose. Increas-
ing D-glucose adversely affected cell viability (5 mmol/L 5 2.6%, 40
Infection resulted in the removal of 8 catheters (Staphylococcus aureus mmol/L 5 6.0% LDH release, p , 0.05 ANOVA). LDH release with
6, Streptococcus faecalis 1, Exit site infection 1) representing a rate ICOD was significantly elevated (13.0% vs. 5.6% with PD4 p 5 0.0043),of 0.46 events per 1000 catheter-days. The flow rates achieved were
but with AA was less than PD4 (2.2%, P 5 0.003) and comparableassessed at first use and at 1 and 3 months after the date of insertion.
to LAB with 5 mmol/L D-glucose. There was a trend to increased
TGF-b production with increasing glucose (50.5% increase with 40Mean flow rate mmol/L). AA stimulated substantially more TGF-b than PD4 (322%,n (nl /min) Range
P , 0.0001), whilst ICOD stimulated similar amounts to PD4. Exoge-
First use 60 219 150–300 nous TGF-b increased FN (280% at TGF-b 1 ng/ml, p , 0.0001). In
1 month 59 232 160–350 summary ICOD does not stimulate FN production in HPMC, but
3 month 47 248 150–350 decreases cell viability. AA offers better cell viability, but stimulates
FN, and also TGF-b production. TGF-b stimulates HPMC FN produc-
In our opinion, the use of tunnelled central vein catheters for chronic tion. Clinical enthusiasm for new dialysis solutions should be tempered
haemodialysis is now a viable proposition for cases in which the creation by a potential adverse effects on HPMC viability, and stimulation of
of arterio-venous fistulae is difficult or contra-indicated and is also pro-fibrotic growth factors and ECM.
safer than temporary venous catheters for patients with acute renal
failure likely to require dialysis for more than 3 weeks.
The use of a Fuzzy Control system to prevent intradialytic hypotension.
M.E. Wilkie, L. Edwards, E.J. Lindley, C.B. Brown, and *O. Roher,
Superinduction of interleukin-6 in human peritoneal mesothelial cells Sheffield Kidney Institute, Northern General Hospital, Sheffield, UK
(HPMC): role of interferon-g (IFN-g). J. Witowski, R.L. Robson, J.D. and *B. Braun Melsungen A.G. Germany. We evaluated the prototype
Williams, N. Topley, Institute of Nephrology, UWCM, Royal Infirmary, “Fuzzy Controller (FC)” (B Braun) with 5 patients known to haveCardiff, CF2 1SZ. Previous studies have demonstrated that uninfected
frequent intradialytic hypotensive episodes (IHE). The FC performsperitoneal dialysis effluent (PDE) and the pro-inflammatory cytokines
automatic pulse and blood pressure (BP) recordings every 5 minutesIL-1b or TNFa synergistically stimulate IL-6 synthesis in HPMC sug-
during dialysis, and interprets the relative drop in BP, short term trendgesting that the mesothelium may be the major source of the increased
(hypotension trend) and long term trend (adaption) to make decisionsIL-6 levels during peritoneal inflammation. Intra-peritoneal IFN-g lev-
regarding output values to a hypertonic (20%) saline infusion pumpels are increased during peritonitis this cytokine is known to have
into the extracorporeal circuit. Study design was open. Each patientmodulatory effects on cytokine secretion. We therefore examined the
had 15 dialysis sessions using the FC, randomised to either controlmodulatory effects of IFN-g on HPMC IL-6 secretion. Incubation of
(saline disconnected) or intervention (saline connected). Data col-growth arrested HPMC in the presence of IFN-g resulted in a time-
lected included interdialytic weight gain (IWG), continuous measure-and dose-dependent increase in IL-6 secretion. Following a 24-hour
ments of blood impedance (IPEC 5000-1), relative blood volume usingexposure the IL-6 generation (pg/mg cell protein) was increased from
the Crit-Line blood volume monitor (Inline diagnostics), ultrafiltration11.08 6 2.83 in control to 14.65 6 3.26 in HPMC treated with IFN-g
rate (UFR), pre and post dialysis BP and post dialysis serum sodium.(10 U/ml) (n 5 6, p , 0.05). The IL-6 release in response to IL-1b
IHEs were defined as 5 minutes intervals in which the systolic BP fell(100 pg/ml) was 97.42 6 14.16. Combinations of IFN-g and IL-1b
below 90 mmHg. BP stability was evaluated by calculating the numberresulted in a synergistic increase in IL-6 levels above the predicted
additive values. Following exposure to IFN-g (10 U/ml) 1 IL-1b (100 of dialysis sessions in which the standard deviation (sd) of systolic was
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,8 mmHg. A typical graph is displayed below to demonstrate the use Glomerular macrophages in telescoped nephrotoxic nephritis have
distinct properties and cytokine responses. L-P. Erwig and A.J. Rees,of hypertonic saline infusion required to prevent IHEs.
Department of Medicine and Therapeutics, University of Aberdeen,
Aberdeen. Macrophages (Mφ) are central to the control of inflamma-
tion because they adapt to a local environment by developing sets of
activities that either induce inflammation or promote its resolution.
Relatively little is known about the activities of Mφ within inflamed
glomeruli and so we examined the effect on rat bone marrow derived
macrophages (BMDM) of cytokines known to influence glomerular
inflammation, and have compared the results to those from macro-
phages purified from rats with telescoped nephrotoxic nephritis. IFN-g,
TNF and TGF-b induced distinct sets of properties represented by nitric
oxide (NO) synthesis and expression of b-glucuronidase or insulin-like
growth factor I (Table). IFN-g alone caused little NO generation.
Pretreatment of macrophages with TGF-b, TNF and IL-4 abrogate
the effect of IFN-g priming on NO generation, and conversely IFN-g
primed cells were unresponsive to TGF-b.Control Intervention P
Mean no. of IHEs 4.7 1.0 Data representative of NO/units b-glucuronidase IGF-1
% sessions with systolic SD,8 mm Hg 24 66 five separate experiments of nitrite expression expression
Post dialysis Na (mmol /l) 141.5 145.2 <0.02
Interdialytic weight gain (Kg) 2.8 3.5 n.s. IFN-g primed TNF treated 22.6 1 1
TNF 4.12 11 1111
TGF-b 1.56 1111 1
Control 1.99 11 11The IPEC measurements indicated a plasma half life of 10–15 minutes
for 20% saline infusion. We conclude that use of the Fuzzy Controller
Glomerular macrophages purified from rats at day four of telescopedhelps to maintain blood pressure stability in patients prone to intradia-
NTN generated large amounts of NO but do not express b-glucuroni-lytic hypotension. It is likely that the adverse effect on post-dialysis
dase or IGF-1. Exposure of glomerular Mφ to IFN/TNF immediatelysodium can be controlled by avoiding hypertonic saline infusion during
after purification further increased NO production, whereas TGF-b,the final hour of dialysis.
TNF alone or IL-4 did not alter it compared to unstimulated controls.
Thus Mφ isolated from rats at day four of telescoped NTN behave
like IFN-g primed TNF treated BMDM and, at least temporarily, doCellulose or synthetic membranes for dialysis in End Stage Renal
not respond to stimuli that cause alternative activation. These resultsDisease? C. Daly, I. Khan, L. Vale, M. Campbell, S. Wallace, J. Cody,
have obvious implications for control of glomerular inflammation byC. Donaldson, K. Fitzhugh, P. Lawrence, A. Grant, and A. MacLeod,
cytokines.Department of Medicine and Therapeutics, Health Services Research
Unit and Health Economics Research Unit, University of Aberdeen,
Aberdeen. The nature of the haemodialysis membrane used for treating
Generation of new cell lines to analyse antigen presentation. V.A.ESRD varies. We aimed to determine whether synthetic membranes
Quan, M. Towey, S. Sacks, and A. Kelly, Department of nephrologyoffer clinically important advantages compared with standard cellulose
and transplantation, UMDS, Guy’s Hospital, London, England. Weor substituted cellulose membranes. A systematic literature review
aimed to generate cell lines defective in MHC class II antigen presenta-was carried out using Cochrane methodology searching 5 electronic
tion in order to further analyse this pathway. A20 mouse B-lymphoblas-databases and hand searching Kidney International. Randomised or
toid cells were transfected with a puromycin resistance vector andquasi-randomised controlled trials only were included. Data from the mutated with ICR191. A20 cells are killed when they present antigen22 trials found were summated using meta-analysis (Peto’s Odds Ra- to class II restricted T cell hybridomas. The mutated cells underwenttio—OR and Weighted Mean Difference—WMD). Twenty-two out- selection by adding 1 mg/ml of ovalbumin and 3DO54.8 T cell hybrido-comes measures were sought in 11 broad areas. Nausea and vomiting mas that are restricted to IAd and a peptide from ovalbumin. The T cells
were significantly less with synthetic than with standard cellulose mem- were killed by adding puromycin and the remaining A20 population
branes (OR 0.62, 95% C.I. 0.49–0.78). Predialysis beta2 microglobulin allowed to recover. By the 9th round the A20s no longer died and
concentrations were significantly lower in patients treated with syn- were single cell cloned twice. Of the 16 cell lines analysed, 15 show
thetic membranes, although all studies which showed this effect used reduced ability to present ovalbumin and specific peptide to the select-
high flux synthetic membranes (WMD 14.5, 95% C.I. 11.6 to 17.4). ing hybridoma as measured by IL2 release, requiring between 3 and
The incidence of amyloid was less in patients dialysed for 6 years with .81 times the amount of antigen to obtain a T cell response similar
high flux synthetic membranes (OR 0.05, 95% C.I. 0.01–0.18) (one to the original A20s. Of the 8 lines analysed further: a) 2 show reduced
study only). In the single study which measured triglycerides there was levels of IAd and IEd to 30% of normal on FACS analysis, and reduced
a significant effect in favour of the synthetic (high flux) membrane levels of IA and IE a and b chains on northern hybridisation. b) 3
(WMD 0.660, 95% C.I 1.181–0.139). Serum albumin was higher in show normal levels of IAd and IEd, and near absence of ICAM-1 on
patients treated with synthetic membranes (both low and high flux) FACS analysis. c) 2 have normal levels of IAd, IEd and ICAM-1, normal
(WMD 20.111 95% C.I. 20.210 to 20.013). There was no significant ICAM-1 on sequencing, but require between 3 and 9 times as much
difference between these membranes for any of the other clinical ovalbumin as A20 cells to stimulate various T cell hybridomas through
outcomes measured. Pruritus occurred less frequently with synthetic both IEd and IAd, and up to 32 times as much peptide. We have
membranes than substituted cellulose membranes (OR 0.78,95% C.I. produced a range of mutant lines which will be useful in further analysis
0.66–0.93); and was the only difference found when such membranes of class II antigen presentation.
were compared. Such evidence as we have favours synthetic mem-
branes but we are hesitant to recommend their use because of the small
number of trials (particularly those comparing substituted cellulose A mouse model of experimental autoimmune glomerulonephritis
membranes), the variation in membrane flux and the differences in (EAG). J. Reynolds, D.A. Nour, and C.D. Pusey, Renal Section, Divi-
exclusion criteria (particularly comorbidity). Further randomised con- sion of Medicine, Imperial College School of Medicine, Hammersmith
trolled trials (with economic evaluation), including comparison with Hospital, London W12 0NN. Goodpasture’s, or anti-glomerular base-
substituted cellulose membranes and taking into account membrane ment membrane (GBM), disease presents with rapidly progressive
flux are required. They should concentrate on primary outcome mea- glomerulonephritis and lung haemorrhage, due to autoimmunity to
the NC1 domain of the a3 chain of type IV collagen. In order to investi-sures of importance to patients.
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gate the pathogenesis of Goodpasture’s disease, we have studied a homozygous for disruption of the iNOS gene (2/2), compared with
heterozygous littermates (1/2). A model of accelerated anti GBM gnrat model of experimental autoimmune glomerulonephritis (EAG),
induced by immunisation with homologous GBM. Although this ap- was first developed in the wild type 129SV mouse strain. Anti GBM
gn was induced by preimmunization i.p. with rabbit IgG in Freund’sproach has proved to be of value, the use of a rat model has limitations
for studying molecular mechanisms involved in the development of complete adjuvent, followed by i.v. rabbit anti-mouse GBM globulin
7 days later. This produced heavy albuminuria, glomerular neutrophilglomerulonephritis. We have therefore attempted to develop a mouse
model of EAG, as recently presented by Kalluri et al (JASN 1995; and macrophage infiltration, glomerular thomboses and crescents.
iNOS mRNA, 1LIb mRNA and TNFa mRNA were induced in glomer-6:835). Four different inbred strains of mice, SJL, C57/BL/6, BALB/c
and FVBN, were immunised by a single i.m. injection (with or without uli. Neither early (24 hours) nor full autologous phase (day 6) injury
were affected by iNOS knockout. Survival was no different from 1/2.booster doses), of collagenase-solubilised rat GBM in FCA, at either
10 or 20 mg/kg, and killed at week 12 after immunisation. SJL mice
developed circulating and deposited anti-GBM antibodies, deposits of Urinary
C3 in the glomerulus, albuminuria, elevated serum creatinine, and INOS gl thrombus crescents albumin/
focal necrotizing glomerulonephritis. C57/BL/6, BALB/c and FVBN phenotype n PMN/gl score (%) creatinine
mice developed similar circulating and deposited anti-GBM antibodies,
24 hrs 2/2 10 0.6760.14 2.160.4 0 6 61but minimal albuminuria, and fewer glomerular abnormalities. The
1/2 8 0.5960.07 2.960.2 0 8 62i.m. injection of GBM antigen at a dose of 20 mg/kg, followed by two
Macro-s.c. injections at weeks 2 and 4, was the most effective immunisation
phages/glprotocol. The Table shows mean results for different strains of mice
6 days 2/2 6 1.560.3 2.060.5 1465 2062(n 5 5–10).
1/2 7 1.360.2 1.760.2 1064 2264
Sera Abnormal
iNOS mRNA was absent from nephritic glomeruli in 2/2 mice andAnti-GBM ab Albuminuria creatinine glomeruli
present in 1/2 mice. ILIb and TNFa mRNA were present in both.Strain (OD 405 nm) (lg/day) (lM/L) (%)
Plasma nitrate levels were significantly elevated in 1/2 mice (91 6
SJL 1.45 160* 20** 45* 9nM) compared to 2/2 mice (61 6 4nM) p , 0.001. The equivalent
C57/BL/6 1.50 35 12 15 degree of albuminuria and glomerular inflammation in 2/2 mice and
BALB/c 1.65 18 9 12 1/2 mice indicates that iNOS does not play an essential role in this
FVBN 1.62 17 10 5 form of glomerulonephritis in the mouse.
Normal 0.25 10 8 0
*p , 0.001; **p , 0.01
T lymphocyte adhesion mechanisms within inflamed kidney. S.J. Chak-
ravorty, A.J. Howie1, P. Cockwell, D. Adu, and C.O.S. Savage, Depart-These results demonstrate strain-dependent susceptibility to the devel-
opment of EAG. The model of EAG in the SJL mouse should enable ment of Renal Immunobiology, Centre for Clinical Research in Immu-
nology and Signalling and Department of Pathology1, Medical School,us to make full use of transgenic and knockout mice to investigate the
development of autoimmunity to GBM and the role of inflammatory University of Birmingham, Birmingham, B15 2TT, UK. Interactions
between the leukocyte expressed integrins LFA-1 and VLA-4 andmediators in glomerular injury.
their respective tissue ligands ICAM-1 and VCAM-1 or CS-1 domain
of fibronectin is central to mononuclear cell recruitment to sites of
inflammation. We previously described a modified Stamper-WoodruffThe glomerular epithelial cell—an active participant in immune re-
sponses in the kidney? K.M. Gillespie and P.W. Mathieson, Academic adhesion assay to analyse T cell adhesion to human renal biopsy sec-
tions. We used this system to analyse integrin/ligand requirements inRenal Unit, Southmead Hospital, University of Bristol. Minimal change
nephropathy (MCN) is characterised by proteinuria in the absence of inflammatory vasculitic glomerulonephritis (GN) (n 5 10) and acute
allograft rejection (n 5 5). Immunohistochemical analysis demon-histological damage to the kidney. The T cell has been implicated in
the pathogenesis of this disorder and the T cells of patients have been strated heavy tubulointerstitial expression of ICAM-1 and VCAM-1
and the presence of CD31 T cells in both vasculitic GN and acuteshown to over produce the Th2 cytokine, IL4, as well as vascular
permeability factor (VPF), a potent regulator of capillary permeability. allograft rejection. Glomerular VCAM-1 expression was restricted to
vasculitic GN. There were no CD31 T cells at glomerular sites inThe interaction between the T cell and the kidney is poorly understood.
We have studied gene expression of immune mediators in an SV40 rejection, but substantial numbers in vasculitic GN. Following pre-
activation, KL/4 cells (LFA-1 expressing) and Jurkat cells (VLA-4glomerular epithelial cell (GEC) line and primary culture GECs and
found that the GEC expresses VPF, and a soluble receptor for expressing) co-localised to areas of ICAM-1 and VCAM-1 expression
respectively; Jurkat cells also adhered to VCAM-1 free sites. BlockingVPF(sFLT) which has been shown to act as a specific inhibitor of VPF
activity. This illustrates a mechanism whereby VPF may be autoregu- monoclonal antibodies (mAB) differentially downregulated adhesion
to glomerular and tubulointerstitial sites, with VCAM-1 mediated glo-lated within the GEC. Primary GECs were also shown to express IL4
receptor. It is possible that IL4, overexpressed by the T cell, signals merular and tubulointerstitial adhesion in vasculitic GN inhibited by
up to 90% (p # 0.005) and tubulointerstitial binding in acute rejectionthrough this receptor. The GEC also produces TGFb but not IL12 or
IL12R. We have preliminary data that IL10 is up-regulated in GECs inhibited by 59.1% 6 10 (p # 0.005). 40% of ICAM-1 mediated
adhesion was attenuated in both conditions (p # 0.1). Further, in bothin response to IL4 and that IFNg expression may be modulated by
treatment with exogenous cytokines. These observations have led us inflammatory states, Jurkat cell adhesion was blocked by up to 50%
(p # 0.05) at both glomerular and tubulointerstitial sites using anto hypothesise that the glomerular epithelial cell plays an active part
in immune reactions in the kidney. anti-CS-1 domain mAB. In conclusion; (i) both LFA-1/ICAM-1 and
VCAM-1/VLA-4 mediated interactions are prominent tubulointersti-
tial adhesion processes in both conditions and also at glomerular sites
Lack of inducible nitric oxide synthase does not affect accelerated in vasculitis, (ii) in allograft rejection VLA-4 mediated adhesion at
anti-GMB glomerulonephritis in the mouse. V. Cattell, H.T. Cook, H. glomerular sites is via non-VCAM-1 ligands (e.g. CS-1 containing fi-
Ebrahim, S. Waddington, K.J.J.M. Assman1, X. Wei 2, and F.Y. Liew2, bronectin) and (iii) T cell adhesion to glomerular sites does not occur
Department of Histopathology, ICSM, London, UK, 1Department of in allograft rejection indicating a requirement for a local cofactor (e.g.
Pathology, University Nijmegan, The Netherlands, and 2Department of chemokine) expression for infiltration.
Immunology, University of Glasgow, UK. Nitric oxide is synthesized
in experimental immune complex glomerulonephritis due to local in-
duction of the inducible isoform of nitric oxide synthase (iNOS). To ATP responses in cultured rat proximal tubule cells. M.E.C. Dockrell,
M.I. Noor, A.F. James, and B.M. Hendry, Department of Medicine,determine its role, the course of accelerated anti glomerular basement
membrane (anti GBM) glomerulonephritis (gn) was examined in mice King’s College School of Medicine and Dentistry, London, UK. Extra-
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cellular ATP regulates epithelial transport and has recently been impli- was monitored by creatinine clearance. Animals were pretreated for
24 hours with either N-acetylcysteine (NAC, n 5 16) or placebo (Tris,cated in the coupling between CFTR and chloride transport. We have
investigated the effects of extracellular ATP on [Ca21]i in rat renal n 5 8), and for 72 h post BDL. Sham operation had no significant
effect on renal function. Conversely BDL was associated with a 50%proximal tubule cells in primary culture. Cultures were loaded with
the fluorescent dye Fura 2-AM and single cell responses were detected decrease in creatinine clearance in animals treated with placebo (1.0
to 0.5 ml/min at 48 h). Treatment with NAC significantly amelioratedas a change in the 340/375 nm fluorescence ratio (R), indicating an
alteration in [Ca21]i. The threshold concentrations required to elicit a the renal dysfunction following bile duct ligation such that creatinine
clearance decreased from 1.1 to 0.8 ml/min (p , 0.01 at 48 h).response were also calculated. Exposure of cells to ATP (0.01–100
mM) resulted in heterogeneous responses. Of the 175 cells tested ap-
proximately 55% displayed an increase in R, 20% showed a decrease NAC Placebo
and 25% showed no response. Subsequent experiments investigated Creatinine clearance (ml/min) (ml/min)
the receptor mediating the increase in R. The threshold ATP concen-
Pre-op 1.160.07 1.060.03tration required to elicit a response was 2.4 6 1.2 3 1025 M; the mean
24–48 hours post BDL 0.7 60.04 0.560.02change in R at 1024 M ATP was 0.3 6 0.06. Responses were abolished
48–72 hours post BDL 0.8 60.03 0.560.03by pre-treatment with thapsigargin, suggesting the involvement of in-
tracellular calcium stores. ATP responses were not significantly altered
when performed in the presence of the ATP (P2) receptor antagonists Conclusion: Acute biliary obstruction causes renal dysfunction and
the anti-oxidant NAC can partially prevent the development of renalsuramin or XAMR 0721. Responses to the alternative P2 receptor
agonist UTP or ADP were not significantly different from those to dysfunction. This suggests that oxidant stress may be important path-
way leading to renal dysfunction in this model, and that strategiesATP. The agonist/antagonist profile for these responses is not consis-
tent with any previously reported single P2 receptor and would suggest aimed at repleting cellular glutathione may therefore be useful thera-
peutically.the presence of 2 receptor subtypes, an ATP/UTP receptor (P2Y2), and
an ATP/ADP receptor possibly of P2Y1 subclass. In conclusion, cultured
proximal tubule cells showed heterogeneity in responses to extracellu-
lar ATP, and may posses at least 2 ATP sensitive receptors able to Chronic uraemia is associated with rapid inactivation of calcium cur-
rents in isolated rat ventricular myocytes. P. Donohoe, A.C. McMahon1,elicit an increase in [Ca21]i.
F. Bertaso, H.A. Cramp1, A.M. Mullen1, B.M. Hendry, and A.F. James,
Renal Group, Department of Medicine, King’s College School of Medi-
cine & Dentistry, London. 1Anthony Raine Research Laboratories, St.Altered vascular reactivity in experimental uraemia. T. Savage, A.C.
McMahon, H.A. Cramp, L.R.I. Baker, F.P. Marsh, and M.M. Yaqoob, Bartholomew’s Hospital, London. We examined for the first time car-
diac ventricular Ca21 currents in a rat model of uraemia. Previous workAnthony Raine Research Laboratories, St. Bartholomew’s Hospital,
London, UK. Mechanical forces associated with blood flow play impor- using isolated ventricular myocytes from this model has demonstrated
reduced amplitude and velocity of contraction, impaired relaxationtant roles in the acute control of vascular tone, the regulation of arterial
structure and remodelling, and the localisation of atherosclerotic and altered Ca21 handling. Wistar rats (n 5 8) underwent subtotal (5/6)
nephrectomy. At the time of sacrifice 8 weeks post-surgery there wasplaque. Uraemic syndrome is a proatherogenic process and is expected
to be associated with impaired vascular reactivity. To study this, 9 a 2-fold increase in mean serum urea and creatinine levels in uraemic
(U) rats compared with sham-operated controls (C); U animals weremale wistar rats were rendered uraemic (U) by 5/6th nephrectomy
and 9 control rats (C) were sham operated simultaneously. After 8 also anaemic. Ca21 currents, normalised to cell capacitance, were mea-
sured in isolated ventricular myocytes using standard whole-cell patchweeks a tail-cuff systolic blood pressure (SBP) was recorded and the
animal sacrificed. Isolated femoral arteries were mounted on a pressure clamp techniques, with a Cs1-rich pipette solution. Prepulses were
used to inactivate Na1 current. Inward Cd21-sensitive Ca21 currentsmyograph and myogenic tone assessed over a range of intravascular
pressures (IVP) from 20–160 mm Hg. Biochemically the U rats had a were activated on depolarisations positive to 230mV in myocytes from
both U and C rats and showed a U-shaped current-voltage (I-V) relation2–3 fold increase in serum urea and creatinine compared with C rats
but SBP was the same in both groups (C 97 6 1 mm Hg vs U 98 6 with the maximal inward current at 210 mV. There was no significant
difference in the I-V relations between U (n 5 8) and C (n 5 11)2 mm Hg) compatible with early uraemia. Myogenic tone was signifi-
cantly higher in the uraemic (n 5 9) vessels than the controls (n 5 7) myocytes (U 218.4 6 3.1 pA/pF; C 216.7 6 2.0 pA/pF at 210 mV).
Neither was there any significant difference between U and C myocytes(U 5.8 6 1% vs C 2.5 6 0.5%, p 5 0.017). Further analysis of 6 pairs
showed that when calcium (Ca) free physiological salt solution (PSS) in the voltage-dependent decrease in the time-to-peak current activa-
tion between 220 and 110 mV (U 6.0 6 0.7 ms; C 5.3 6 0.6 ms atwas used to obtain passive diameters in response to raised IVPs, dila-
tory capacity of uraemics was impaired compared with that of controls 210 mV). Ca21 current inactivation was best fitted by the sum of
two exponential components, the slower of which (t2) increased in a(U 243 6 25 mm vs C 318 6 21 mm, p 5 0.01). The actual vessel
lumen diameter at all pressures was smaller in the uraemic vessels voltage-dependent manner between 210 and 110 mV. This may reflect
heterogeneity of Ca21 channel subtypes. U myocytes demonstratedboth in PSS (mean U 600 6 25 mm vs C 691 6 21 mm, p 5 0.009)
and Ca free PSS (mean U 636 6 30 mm vs C 704 6 19 mm, p 5 0.03). significantly faster inactivation of Ca21 current (U t2 5 44.0 6 1.6
msec; C t2 5 52.9 6 4.5 ms at 210 mV, p 5 0.03 using ANOVAThese data are the first demonstration that vascular reactivity is altered
in experimental uraemia as shown by reduced distensibility and in- between 210 and 10 mV). This rapid Ca21 channel inactivation may
contribute to the cardiomyopathy associated with uraemia. Cardiaccreased myogenic tone. Furthermore these changes precede the devel-
opment of hypertension. myocyte ion currents warrant further study as possible contributing
factors to altered cardiac function in uraemia.
N-Acetylcysteine improves renal function in the acute bile duct ligated
rat. S. Holt, R. Marley, D. Goodier, D. Harry, B. Fernando, and K. Up-regulation of the Vitamin d receptor (vdr) in human osteoblastic cells
by non-calcaemic calcitriol analogues. N.J. Schroeder, C.W. McIntyre,Moore, Dept of Medicine, Royal Free Hospital School of Medicine,
London, UK. Renal dysfunction occurs in 10–20% of patients with C.A. Nott, S.M. Dodd, J.M. Burrin1, and J. Cunningham, Departments
of Nephrology and 1Clinical Biochemistry, St. Bartholomew’s and Theobstructive jaundice. We and others have previously demonstrated
that biliary obstruction is accompanied by oxidant stress and subse- Royal London School of Medicine and Dentistry, London E1 2AD UK.
The calcitriol analogues 22-oxacalcitriol (OCT), 19-nor-1,25-dihydroxy-quent lipid peroxidation, although the role of reactive oxygen species
in both liver and renal injury is unknown. Since some products of lipid vitamin D2 (19nor) and 1,25-dihydroxydihydrotachysterol2 (1,25DHT2)
are less calcaemic than the natural hormone and may prove to beproduction may affect renal function directly, we have determined
whether treatment with the antioxidant N-acetylcysteine could amelio- effective in the treatment of uraemic hyperparathyroidism. Their ac-
tions on bone are, however, largely unknown. We previously reportedrate the renal dysfunction in an experimental model of cholestasis.
Cholestasis was induced by bile duct ligation (BDL) of male Sprague that these analogues differ in their effect on the secretion of the cyto-
kine IL6 by human osteoblast cell lines (MG63 and SaOS2); IL6 isDawley rats, and sham operation served as controls. Renal function
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considered important as a osteoblast-osteoclast coupling agent. Be- recombined erythropoietin—simian virus 40 T antigen (Epo-TAg)
transgene. The recombination places T antigen sequence in the contextcause these findings may be the result of differential effects on vitamin
D receptor (VDR) expression, we have now investigated the regulation of all potential regulatory elements of the native erythropoietin gene,
resulting in essentially identical regulation of the erythropoietin andof VDR by these analogues by looking at the expression of VDR
mRNA at 6 and 24 hours using relative RT-PCR and also VDR protein Epo-TAg genes in the kidneys of the heterozygous animals. Three types
of renal injury were studied; ureteric obstruction, global ischaemiaat 24 hours using immunocytochemistry and Western Blotting. At 6
hours VDR mRNA was undetectable in the unstimulated control cells following clamping of the renal pedicle, and focal needlestick injury.
All models of injury were associated with an expansion of the interstitialfrom both MG63 and SaOS2 cell lines. Using GAPDH to determine
relative concentrations, VDR mRNA levels were all equally up-regu- space, which contained an increased number of cells. Alterations ob-
served in the interstitial fibroblast-like cells included an increased num-lated by calcitriol and the analogues in MG63 cells at 6 hours with no
differences in mRNA either between the analogues or doses (1027 M ber and complexity of cellular processes, enhanced expression of the
intermediate filament desmin, and reduced expression of ecto-59-and 10211 M). By 24 hours VDR mRNA was up to 4-fold higher in
sterol treated MG63 cells than control but OCT and 19nor appeared nucleotidase. Following each type of injury there was a focal or general
reduction in the proportion of fibroblast-like cells which could beto be less potent than calcitriol and 1,25DHT2. In SaOS2 cells VDR
mRNA was not detected at 6 hours but was strongly up-regulated at stimulated to express Epo-TAg, in a manner which correlated with
the extent of injury. No other cell type showed Epo-TAg expression.24 hours by the analogues except in the unstimulated control which
had no detectable VDR mRNA. Small concentration dependent differ- Even in severely injured regions some positively staining cells were
present and more could be recruited to express Epo-TAg by severeences were observed but these did not relate to the pattern of IL6
release. Immunocytochemistry and Western Blotting confirmed that anaemic or hypoxic stimulation, demonstrating that cells with the po-
tential for erythropoietin gene expression persist and are not com-in both cell lines there was also up-regulation of VDR protein expres-
sion at 24 hours. IL1, a positive control for IL6 release, was less effective pletely refractory to stimulation.
at stimulating VDR mRNA and protein expression. These data suggest
that the differential effects that these analogues have on IL6 secretion
cannot be explained fully by their effect on VDR expression, and that Inhibition of renal fibroblast proliferation by modulation of p21 ras
GTPases. M.E.C. Dockrell, R. Scott, M.I. Noor, A.F. James, and B.M.other post-transcriptional or post-translational factors are operative.
Hendry, Department of Medicine, King’s College School of Medicine
and Dentistry, London, UK. A range of cytokines have been implicated
in the genesis of progressive renal fibrosis and recent evidence suggestsCalcitriol analogues modulate IL6 gene transcription in osteoblast-like
cells. C.W. McIntyre, N.J. Schroeder, J.M. Burrin1, and J. Cunningham, that the p21(ras) family of proteins function at a point of convergence
of mitogenic signalling by these molecules. Targeting ras may thereforeDepartments of Nephrology and Clinical Biochemistry1, St. Bartholo-
mew’s and the Royal London School of Medicine and Dentistry, London have a role in therapy. Ras proteins undergo activation to a membrane-
bound form by the post-translational modification of the C-terminalE1 2AD UK. We previously reported that the ‘non-calcaemic’ calcitriol
analogues 22-oxacalcitriol (OCT), 19-nor-1,25-dihydroxyvitamin D2 domain; in the present experiments this has been targeted using farnesyl
protein transferase inhibitors (FPTI) such as chaetomellic acid (CMA)(19nor) and 1,25-dihydroxydihydrotachysterol2 (1,25DHT2) have dif-
ferent effects on the release of the putative bone cell coupling agent, and by inhibition of methylation of farnesylated ras C-terminal cysteine
by N-acetyl-S-farnesyl-L-cysteine (AFC). The geranyl-substituted AFCIL6, from human osteoblast cell lines. We have now assessed the effects
of these compounds on IL6 gene transcription. Growth arrested human analogue (AGC) was used as a negative control. Proliferation over 72
hours was assessed by cell number assay (MTS) in a primate renalosteoblast-like cells MG63 and SaOS2 were incubated with calcitriol
or analogue at either 1027 M or 10211 M. Messenger RNA was extracted fibroblast cell line (Vero) in conditions of growth stimulation by serum,
FGF and EGF. CMA (500 mM) and other FPTI inhibited serum andand amplified together with the house-keeping gene GAPDH by RT-
PCR so that relative mRNA concentrations could be determined for growth factor-stimulated growth by 60–90%. CMA was more effective
in the inhibition of serum-stimulated growth than FGF- or EGF-stimu-each time point using scanning densitometry. At 6 hours there was no
detectable IL6 mRNA in SaOS2 cells, consistent with the lack of IL6 lated growth. AFC produced a highly-significant concentration-depen-
dent inhibition of growth; 100 mM AFC inhibited FGF- and EGF-secretion, but in MG63 cells IL6 mRNA concentrations were elevated
over control for those concentrations of analogue that also resulted stimulated growth by .90% and was less potent on serum-stimulated
growth (20% inhibition). AGC at 100–500 mM was inactive. Thesein maximal IL6 secretion: the higher concentration of 1027 M for
calcitriol and 19nor and the lower concentration of 10211 M for OCT results indicate that an intact C-terminal farnesylation process is re-
quired for renal fibroblast proliferation in a variety of growth-stimula-and 1,25DHT2. At 24 hours up-regulation of IL6 mRNA was still
evident with increases of up to 3-fold over control values and the tory conditions and suggest that inhibition of ras proteins can downreg-
ulate proliferation. Current work using antisense oligonucleotidesdifferential pattern maintained—maximal effects were again seen at
1027 M for calcitriol and 19nor but 10211 M for OCT and 1,25DHT2. specifically targeting individual Ha, Ki and N ras mRNA in human and
primate fibroblasts is designed to define the most promising strategy forFor SaOS cells at 24 hours maximal up-regulation of IL6 mRNA was
at 1027 M for all sterols with up to 2-fold increases over control levels. anti-ras gene therapy. Antisense oligonucleotides based on the known
ras gene sequences may prove to be highly effective in the downregula-The positive control IL1, which dramatically increased IL6 secretion,
similarly up-regulated IL6 mRNA concentrations to a greater extent tion of cellular proliferation in the renal interstitium.
than any of the sterols but by no more than 5-fold over control. These
results demonstrate that the increase in IL6 mRNA parallels the re-
Transfer of genetically modified macrophages to the glomerulus insponse previously observed with IL6 release. This suggests that the
nephrotoxic nephritis. D.C. Kluth and A.J. Rees, University of Aber-differential stimulation of IL6 release by these calcitriol analogues is
deen, Department of Medicine and Therapeutics, Institute of Medicallargely due to differences in their effect on gene transcription.
Sciences, Foresterhill, Aberdeen, AB25 2ZD. Glomerular gene transfer
will provide a powerful tool to study the effect and activity of relevant
proteins in glomerular inflammation. Gene transfer though remainsFibroblast-like cells in renal injury show phenotypic changes and have
reduced potential for erythropoietin gene expression. P. Maxwell, D. difficult with few of the viral methods of transfection proving applicable
in the glomerulus. To overcome this problem we have developed aFerguson, L. Nicholls, M. Johnson1, and P. Ratcliffe, Institute of Molecu-
lar Medicine, John Radcliffe Hospital, Oxford and 1Department of method to transfect macrophages ex vivo using recombinant adenovi-
rus and then directly administer the transfected cells into the renalAnatomy, Downing St, Cambridge. Recent studies have defined the
erythropoietin producing cells in normal kidney as the fibroblast-like artery. The rat alveolar macrophage cell line, NR8383, was grown in
Hams F-12 supplemented with 10% foetal calf serum and 10% v/vpopulation. In attempting to understand the pathogenesis of erythro-
poietin deficiency in kidney disease it is important to characterize the L929 conditioned media for 48 hours. The cells were transfected using
Av1BnG, a b-galactosidase producing recombinant adenovirus. Subse-response of these cells to renal injury. To define the potential for
erythropoietin gene expression in injured kidneys, marker gene expres- quent X-gal assay of the cells revealed that 90% of the cells had been
successfully transfected. These genetically modified macrophages weresion was examined at a cellular level in mice bearing a homologously
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used as gene transfer vectors into the glomerulus. Nephrotoxic nephri- abrogated renal injury with creatinine clearance rising to 0.74 6 0.13
ml/min (p , 0.05). Urinary F2-isoprostane excretion increased fromtis was induced in Sprague-Dawley rats (weight 190–200 g) using the
telescoped model. Six hours after induction of the disease 6 3 106 9.0 6 1.4 pg/ml Cr.Cl to 65.3 6 10.9 pg/ml. Cr.Cl. after rhabdomyolysis
(P , 0.05) and this was prevented by alkalinisation (p , 0.01).b-galactosidase transfected macrophages were injected directly into
the left renal artery. The macrophages were prestimulated with 40 ng/ml
lipopolysaccharide (LPS) for 4 hours before injection. Animals were Rhabdo-
killed at 18 hours, 42 hours and 66 hours after the injection and both myolysis
kidneys were analysed for presence of b-galactosidase positive macro- Rhabdo- 1 alkalin-
phages. At 18 hours after the injection 80% of the glomeruli contained Control myolysis isation
at least one b-galactosidase positive macrophage with an average of
Serum creatinine (lmol /l ) 39 60.5 122628.3 88 610.43 labeled macrophages per positive glomerulus. The number of positive
Creatinine clearanceglomeruli fell to 52% at 42 hours after injecting the cells and to 46%
(ml/min) 1.160.01 0.2660.07 0.74 60.13at 66 hours in the diseased animals. By contrast in non diseased animals
Urinary free F2-isoprostanesonly 18% of glomeruli contained transfected cells (with an average of
(pg/ml cr. Cl. ) 9.061.4 65.3610.9 14.2 62.91.8 macrophages per glomerulus) 18 hours after injection of macro-
phages (Relative risk of macrophage in the glomerulus 5.88 diseased
vs. non-diseased, SE 4.35 to 7.94 p , 0.001). There was no evidence To determine whether alkalinisation inhibited lipid peroxidation, Mb
was added to low density lipoprotein (LDL) and incubated at pH 5.5of transfected macrophages in the right kidney, liver, lung or spleen.
This approach provides a simple and effective method for high effi- to pH 8.0. Mb alone caused a 50 fold increase in F2-isoprostane forma-
tion in LDL at pH 5.5, and this was inhibited progressively duringciency macrophage transfection including bone marrow derived macro-
phages. It allows the study of macrophage localisation and trafficking alkalinisation, with 60% inhibition at pH 8.0, p , 0.01. Conclusions:
We conclude that rhabdomyolysis or Mb causes lipid peroxidation andin glomerular inflammation and offers a novel strategy in glomerular
gene transfer. formation of F2-isoprostanes. Since F2-isoprostanes are potent renal
vasoconstrictors, then increased F2-isoprostane formation during rhab-
domyolysis may exacerbate renal injury. The inhibition of Mb-induced
F2-isoprostane formation by alkalinisation provides a novel and alterna-Down-regulation of Osteoblast PTH/PTHrP Receptor mRNA expres-
sion in Renal Failure. M.L. Picton1,2, P.R. Moore1, A.J. Hutchison1, R. tive explanation for the efficacy of this therapeutic procedure.
Gokal 1, A.J. Freemont 2, and J.A. Hoyland 2, 1Dept. of Nephrology,
Manchester Royal Infirmary and 2Dept. of Pathological Sciences, Uni-
versity of Manchester, Manchester, UK. “Skeletal Resistance” to the A laboratory model of toxin-induced Haemolytic Uraemic Syndrome.
C.M. Taylor, J. Williams, D.V. Milford, A.J. Howie, C.J. Lote, A.actions of Parathyroid hormone (PTH) has been demonstrated in renal
failure. It is considered to be important in the pathogenesis of secondary Thewles, J. Wood, and F. Raafat, The Birmingham Children’s Hospital
and University of Birmingham, UK. Verotoxins (VT) produced byhyperparathyroidism and may be important in adynamic renal bone
states. The mechanism of resistance remains unknown, though altered Escherichia coli (VTEC) cause 95% of childhood Haemolytic Uraemic
Syndrome (HUS). Pathogenic details are unclear and there is a needregulation of the PTH/PTHrP receptor has been assumed to be impor-
tant. To investigate this possibility we have used in situ hybridisation for animal models. These are impeded by the different distribution of
the VT receptor, Gb3, between species. We have circumvented thisto examine PTH/PTHrP receptor mRNA expression by osteoblasts in
human bone obtained by transiliac biopsy, comparing high-turnover restriction using ricin which has identical depurinating activity on ribo-
somal RNA to VT but gains cell entry via various galactose receptors.renal bone, high-turnover non-renal bone (healing fracture callus and
Pagetic bone) and normal bone. Bone biopsies were formalin fixed, Adult rats were anaesthetised, cannulated and after recovery GFR
measured by continuous inulin infusion. Ricin was given at a dose ofEDTA decalcified and paraffin wax embedded. A PTH/PTHrP recep-
tor cDNA probe labelled with 35S was used and hybridisation signal 67 mg/kg ip and rats were killed at various times. The kidneys were
perfused in situ before fixation for histological examination by lightrevealed by autoradiography. Density of signal over osteoblasts was
quantified using an image analysis software package. Mean density of and electron microscopy. At 8h consistent, extensive glomerular throm-
bosis was seen, but other organs were unaffected. Capillary loopsPTH/PTHrP receptor mRNA signal over osteoblasts in renal bone
(n 5 10) was only 39.1% of that found in non-renal high-turnover contained fibrin tactoids associated with platelets, and focal areas of
endothelial cell detachment. This was preceded by oliguric renal failure,bone (n 5 4; p , 0.001) and 50% of that found in normal bone (n 5 6;
p , 0.001). Clearly localised signal was seen over actively resorbing haemolysis, thrombocytopenia and a reduction in blood pressure. Ricin
induced a marked and sustained rise in plasma TNFa (at 3h, 253 6osteoclasts in renal bone, Pagetic bone and healing fracture callus.
These results represent the first demonstration of PTH/PTHrP receptor 23 pg/ml, n 5 4: at 7h, 952 6 116 pg/ml, n 5 4) when compared with
TNFa stimulation by lipopolysaccharide 0111:B4 100 mg/kg, ip (3h,mRNA expression by human bone cells, both osteoblasts and osteo-
clasts, in vivo. This also shows for the first time in humans that there 191 6 19 pg/ml n 5 4: 7h, 124 6 19 pg/ml, n 5 4, p , 0.01 at 7h).
This model mimics the clinical and histopathological findings as wellis down-regulation of the PTH/PTHrP receptor at the level of transcrip-
tion in renal failure. Work supported by Baxter Extramural Grant as the TNFa response seen in the human disease. It will permit further
interrogation of the pathogenesis of VTEC-induced HUS. MRC GrantProgram.
G 96 28976
Rhabdomyolysis induces F2-isoprostane formation which is abrogated
by alkalinisation. S. Holt1, V. Darley-Usmar 2, R. Patel 2, J. Morrow 3, L.J. Identification and distribution of the major xenoantigens recognised
by human natural antibodies in the pig kidney. R. Preston, V. Papalois,Roberts 2nd 3, and K. Moore1, 1Royal Free Hospital School of Medicine,
London UK, 2University of Alabama, Birmingham, and 3Vanderbilt Uni- J. Lee, W. McKane, T. Cook, T. Cairns, and D. Taube, Brent Labora-
tory, St Mary’s Hospital, Paddington, London W2 1NY. We and othersversity, Nashville, USA. Urinary alkalinisation is a recognised therapy
for rhabdomyolysis induced renal injury. Myoglobin (Mb) is known have shown that the major target of human anti pig natural antibodies is
the terminal sugar on the pentasaccharide, Gala1-3Galb1-4GlcNacb1-to cause lipid peroxidation in vitro, and some lipid peroxidation prod-
ucts, such as the F2-isoprostanes, are biologically active causing renal 3Galb1-4Glc. The distribution of this antigen in the pig kidney has
previously been determined by the use of the IB4 lectin which bindsvasoconstriction in vivo. These studies tested the hypothesis that rhab-
domyolysis is associated with lipid peroxidation and determined to other carbohydrates as well as Gala1-3Gal. The aim of this study
was to confirm the IB4 lectin findings using specific anti Gala1-3Galwhether alkalinisation inhibits Mb-induced lipid peroxidation. Urinary
F2-isoprostane excretion was increased in patients with rhabdomyloysis antibodies, determine the distribution of these antigens within the pig
kidney and to establish whether human sera recognise any other non(46 6 14 pg/ml Cr.Cl.) compared with controls (16 6 2 pg/ml Cr.Cl,
P , 0.02, n 5 8) indicative of lipid peroxidation. In the glycerol treated Gala1-3Gal antigens. Human anti-Gala1-3Gal produced from pooled
serum passed down an immunoadsorbent column containing syntheticrat model of rhabdomyolysis, creatinine clearance fell from 1.1 6
0.07 ml/min in control animals, to 0.26 6 0.07 ml/min. Alkalinisation sepharose linked Gala1-3Gal carrying oligosaccharides was applied to
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kidney tissue sections from 17 adult blood group O large white pigs. and to the parents. Investigations were undertaken as specified in
.90% cases. Hep-B status (41%), quantitative analysis of proteinuriaAntibody binding was identified with a rabbit anti-human Ig-HRP
conjugate. The intensity and distribution of the antibody binding was (56%) and varicella immunity status (64%) were less well documented.
Prednisolone was given in the correct starting dose in 71% of casesassessed blindly by two independent observers inspecting a minimum
of 10 high power fields per tissue section. Human kidney sections served but the subsequent course varied widely with only 24% following the
recommended regimen and 18% using a tapering regimen. Intravenousas a negative control. Vascular endothelium [inter tubular capillaries,
arterioles and arteries], proximal convoluted tubules [PCTs] but no albumin was used in 39% and fluid restriction in 29% of cases. In
the first year 86% of children relapsed with 34% relapsing beforeglomeruli or distal convoluted tubules [DCTs] stained positive. There
was very little variation between animals. Binding with IgG, particu- completing their initial course of prednisolone and 18% having 4 or
more relapses. Most parents (90%) reported a satisfactory explanationlarly to medullary capillaries was more intense than seen with IgM.
Human anti-pig antibody specific for the pentasaccharide eluted from of NS but many denied being told about immunisations (63%), infec-
tion risks (41%), diet (37%) or steroid side effects (33%). Some didan immunadsorbent column was applied to pig kidney sections as
described above. The intensity and distribution of antibody binding not understand the information they were given on immunisations
(32%) and prednisolone (15%). More than 90% of parents were in-with human anti-pentasaccharide antibody was identical to that ob-
served with unfractionated human anti-Gala1-3Gal antibody. Serum structed in home management. The parents’ lack of information is
disappointing and may reflect either not being given the informationobtained from 5 human adults was depleted of anti-Gala1-3Gal by
multiple passages down Gala1-3Gal immunoadsorbent columns. or problems of recalling information given by doctors. There is a wide
variation in the use of prednisolone and a there is a high relapse rate.Depletion of anti-Gala1-3Gal was confirmed by ELISA and flow cy-
tometry. Whole serum and serum deplete of anti-Gala1-3Gal was then These facts suggest the guidelines need revising.
applied to pig kidney sections as before. No antibody binding was
observed with serum deplete of anti-Gala1-3Gal. Antibody binding
with whole serum was very similar to that observed with eluates ob- Albumin and apolipoprotein B synthesis in nephrotic syndrome. G.L.
Warwick1, T. Demant 2, S. Carr1, C. Mathes2, K. Gutlich2, A. Bedynek2,tained from the immunoadsorbent columns. This study shows that
the Gala1-3Gal epitope expressed on pig vascular endothelium and H. Steinhauer 3, T. Bosch 2, C.J. Packard 4, and D. Siedel 1, 1Dept. of Ne-
phrology, Leicester General Hospital, Leicester; 2Klinikum Grosshadern,proximal convoluted tubules is the only xenoantigen recognised by
human natural antibody, that the terminal pentasaccharide is the most Ludwig-Maximilians Universitat, Munich; 3Carl-Thiem-Klinikum, Cott-
bus; and 4Institute of Biochemistry, Royal Infirmary, Glasgow. Hyperlip-likely target and is predominantly reactive with IgG rather than IgM.
idaemia in nephrotic syndrome has been attributed to a general in-
crease in hepatic protein synthesis but studies of lipoprotein
The oral-facial-digital syndrome type 1 (OFD1), a cause of glomerulo- metabolism using radio-iodinated lipoproteins have found a number
cystic kidney disease (PKD), maps to Xp22.2–Xp22.3. S.A. Feather, of defects in lipoprotein catabolism. The use of stable isotope labeled
R.M. Winter, D. Donnai*, S. Malcolm, and A.S. Woolf, Molecular amino acid tracers permits simultaneous measurement of the synthesis
Genetics, Nephrourology and Clinical Genetics Units, Institute of Child of albumin and apolipoprotein B(apo B). Seven patients with nephrotic
Health, London and *Medical Genetics Unit, St Mary’s Hospital, Man- syndrome(proteinuria . 5 g/day, serum albumin , 30 g/L) and ‘normal’
chester, UK. Key features of OFD1 include malformations of the face, renal function(serum creatinine , 120 micromol/l) were studied. Pa-
oral cavity and digits. Mental retardation and chronic renal failure are tients were excluded if they had other systemic disease or received
included. Approximately 75% of cases are sporadic and it occurs almost immunosuppressive therapy in previous 6 months. Hypolipidaemic
exclusively in females. In familial cases the most likely mode of inheri- drugs, if in use, were stopped temporarily for 1 month prior to the
tance is considered to be X-linked dominant with prenatal lethality in study. L-d3-Leucine was administered IV to fasting subjects either as
affected males. Therefore the OFD1 gene product appears to have a bolus (6.0 mg/kg) or a primed constant infusion (0.6 mg/kg followed
widespread importance in organogenesis and is essential for fetal sur- by 0.6 mg/kg/h). Blood samples were collected frequently over the
vival. We studied two kindreds in which the clinical course was domi- first 12 hours and then over 12 days. Nine control subjects were also
nated by glomerulocystic PKD requiring dialysis and transplantation. investigated although albumin metabolism was only studied in six. Free
Using polymorphic chromosomal markers spaced at approximately 10 amino acids were separated from plasma by protein precipitation and
centimorgan intervals along the X chromosome we mapped the disease cation exchange chromatography. Albumin was separated from plasma
to a region on the short arm of the X chromosome (Xp22.2–Xp22.3) by affinity chromatography using Blue-Sepharose. Four lipoprotein
spanning 19.8 centimorgans and flanked by crossovers with the markers fractions (VLDL1, VLDL 2, IDL, LDL) were separated from plasma
DXS996 and DXS7105. There was a maximum lod score of 3.32 in an by cumulative gradient ultracentrifugation and apo B precipitated se-
“affecteds only” analysis using a marker within the KAL gene (u 5 lectively. Albumin and apo B were then hydrolysed and the d3-leucine
0.0) thereby confirming the location of the gene for OFD1 on the X enrichment measured by gas chromatography-mass spectrometry. The
chromosome. The remainder of the X chromosome was excluded by specific isotope enrichment and the leucine tracer/tracee ratio were
recombinants in affected individuals. The following genes are in the calculated. Multi-compartmental kinetic analysis was carried out using
region and are good candidates for OFD1: KAL (mutated in Kall- the SAAM programmes (simulated analysis and modelling).The main
mann’s syndrome), APXL (linked to the amiloride sensitive sodium results are shown in the table as medians and ranges:
channel), Calbindin 3, CLCN4 (a chloride channel) and GRPR (a
hormone receptor). SSCP analysis has thus far excluded mutations in P
Calbindin 3 to be responsible for OFD1. This study definitively assigns Nephrotic Controls (Kruskal-
this male lethal disease to the X chromosome, maps a further locus (n 5 7) (n 5 9) Wallis)
for human PKD and suggests a possible mouse model for OFD1 as
Albumin synthesisthe X linked dominant Xpl mutant, in which polydactyly and renal
(mg/kg/d ) 5.60 (4.50–8.88) 3.62 (3.36–6.69)* 0.034cystic disease occurs, maps to the homologous region of the mouse X
Albumin fractionalchromosome.
catabolic rate
(pools/d ) 0.172 (0.102–0.259) 0.045 (0.042–0.098)* 0.003
Total apo B syn-Management of Childhood Nephrotic Syndrome: Time for a change?
thesis (mg/kg/d ) 23.7 (12.7–28.3) 14.6 (11.5–24.5) 0.064J.H.C. Evans and E. Long, Children’s Kidney Unit, Nottingham City
Hospital NHS Trust. On behalf of the RCPCH and the BAPN. A *n 5 6 for albumin data in controls
national audit of Steroid Sensitive Nephrotic Syndrome (SSNS) was
undertaken, against the standards published in the consensus statement The main changes in apo B metabolism in nephrotic subjects were
(a) decreased transfer from VLDL 2 → IDL (b) decreased fractionalon the management of SSNS (Arch Dis Child 1994; 64:151–157). One
hundred and eighty eight new cases of SSNS presenting to UK paedia- catabolism of LDL (c) modest increases in apo B production in VLDL1
and VLDL 2. Apo B synthesis(total and in each fraction) did not corre-tricians between 4/95 and 6/96 were reported by a postal notification
form. Data was collected using questionnaires sent to the paediatrician late with either albumin concentration or albumin synthesis. These
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data do not suggest that a generalised increase in protein synthesis is thickness (r 20.90, p 0.006) and trabecular osteoid thickness (r 20.77,
p 0.41), whereas cumulated cyclosporine dose was positively correlatedthe main determinant of hyperlipidaemia in nephrotic syndrome.
with trabecular osteoid surface (r 0.84, p 0.02), trabecular osteoid
volume (r 0.84, p 0.02), and subcortical osteoclasts (r 0.87, p 0.01). A
direct correlation between age and trabecular mineralisation surfacePeripheral capillary filtration capacity is altered in asymptomatic pro-
teinuria. D.M. Lewis, M. Beaman, A.C. Shore1, and J.E. Tooke1, Renal (r 0.77, p 0.43) and trabecular thickness (r 0.88, p 0.01) was also found.
Neither aluminium nor iron was present in any of these bone specimens.Unit, Royal Devon and Exeter Hospital, Exeter and Department of
Vascular Medicine1, University of Exeter, Exeter, UK. Microalbuminu- Regardless of the type of immunosuppressive therapy employed, a
suppression of osteoclast activity in both cortical and trabecular bone,ria has been proposed as a marker of a generalised increase in vascular
permeability in diabetes mellitus, and abnormalities in peripheral capil- and suppression of osteoblast activity in trabecular bone seem to be
present among long-term survivors of renal transplantation. The pro-lary function have been found in the nephrotic syndrome. This study
examined peripheral capillary filtration capacity (CFC) in asymptom- gressive decline in most of the parameters would suggest that calcium
and/or vitamin D replacement therapy may be useful in the setting ofatic, dipstick positive proteinuric patients who were non-diabetic and
non-nephrotic. Eleven subjects were studied (2F, 21–75 years), protein- bone disease associated with long-term renal transplantation.
uria 0.17–1.35 g/l, normal serum creatinine and albumin, with age
and sex matched non-proteinuric controls. Underlying diagnoses: IgA
nephropathy, membranous glomerulonephritis, mesangial prolifera- A prospective assessment of oral versus intravenous pulsed 1-alphacal-
cidol in haemodialysis patients with moderate hyperparathyroidism.tive GN, 2 subjects not biopsied. CFC was measured by a modern
computerised derivative of mercury strain gauge plethysmography. A S. Fletcher, M.J. Wright, K. Bel’eed, J. Bentley, D. Eadington, M.J. Farr,
and L. Sellars, Renal unit, Hull Royal Infirmary, Hull, UK. Uncertaintythigh venous occlusion cuff was inflated in 10 mm Hg steps at 5 minute
intervals. The resulting change in calf volume, measured by strain gauge, persists over the optimal route of administration of vitamin D ana-
logues in haemodialysis patients with moderate to severe hyperparathy-was due initially to venous engorgement, and thereafter fluid filtration.
Gradients of the multiple fluid filtration steps were plotted against cuff roidism. The intravenous route has theoretical advantages over oral
administration. We performed a prospective cross-over study assessinginflation pressures to give CFC and isovolumetric venous pressure
(PVi). CFC was significantly higher in proteinuric subjects than con- pulsed oral and intravenous 1-alphacalcidol in 21 haemodialysis pa-
tients with stable moderate hyperparathyroidism (PTH 100–500 pg/ml).trols: 5.53 (3.53–7.34) vs. 3.39 (2.31–5.28) 3 1023 ml/min/100 g/mm Hg,
N 5 11, p , 0.01. PVi (cuff pressure at which there is no net filtration Daily oral 1-alphacalcidol was converted to an equivalent twice weekly
dose. Each patient was randomised to receive either oral or intravenousacross the capillary bed) was not significantly different: 23.9 (13.6–31.8)
vs. 21.1 (16.3–35.6) mm Hg. Data presented as median (range), Mann- (25% dose reduction if intravenous). Pre-dialysis serum calcium and
phosphate were measured fortnightly and PTH monthly. PhosphateWhitney Test. This study suggests that asymptomatic proteinuria of
various aetiologies may be associated with abnormalities of peripheral binders and 1-alphacalcidol dose were adjusted according to normal
clinical practice to minimise hypercalcaemia (Ca . 2.7 mmol/l) andcapillary blood vessel function, specifically an increase in vascular leaki-
ness to fluids. Whether this will be shown to have any clinical signifi- hyperphosphataemia (PO4 . 2.0 mmol/l). After four months, the mode
cance remains to be seen: the long term cardiovascular health of these of administration was switched with appropriate dose modification and
subjects, and any sequential alterations in these parameters may be measurements repeated for a further four months. 5 patients withdrew
of some interest. (2 hypercalcaemia despite dose reduction, 1 death, 2 patients’ request),
leaving 16 who completed the study (7 male, 9 female; mean age 61,
range 45–76; mean duration of dialysis 47 months, range 8–180). The
Histopathological evolution of bone disease in the long-term renal results are shown below (mean 6 sem).
transplantation. A.M. Cueto-Manzano1, S.J.K. Shaikh1, A.J. Hutchi-
son1, A.J. Freemont 2, and R. Gokal 1, 1Department of Renal Medicine, Calcium Phosphate PTH
Manchester Royal Infirmary and 2Department of Pathology, School of (mmol /l ) (mmol /l ) (pg/ml )
Biological Sciences, University of Manchester. Osteopenia develops
Before study 2.4860.03 1.7360.09 287656.8commonly within the first year of renal transplantation; however, there
Oral 2.5160.03 1.6660.09 207647.2is little data about long-term bone disease and its presentation. In
Intravenous 2.5060.04 1.6760.11 248672.2order to investigate this aspect of renal bone disease, we are studying
renal transplant recipients with iliac bone biopsies at baseline and
one year later. This is a preliminary report of 7 patients. Time from None of these differences are statistically significant. Eight patients
transplantation is 147.3 6 33.0 months, age 48.1 6 13.1 years, and demonstrated hyperphosphataemia with equal frequency on IV and
creatinine clearance 76.6 6 18.3 ml/min. Two patients were on oral (29 vs. 28 episodes); consequently there were numerous adjust-
cyclosporin monotherapy (C), 3 on azathioprine plus prednisolone ments to phosphate binders. More changes were required on intrave-
(AP) and 2 on cyclosporin plus prednisolone (CP). The main results nous dosing (13 increases vs 6 and 1 decrease vs 3). Hypercalcaemia
at baseline and after 1 year of follow-up are shown in the table (results affected 7 patients in each limb of the study (18 episodes on oral vs.
expressed as Z-scores): 15 on IV). In conclusion, no difference was demonstrated in the inci-
Cumulated prednisolone dose was negatively correlated with cortical dence of hypercalcaemia or hyperphosphataemia between the oral
or intravenous routes of administration of pulsed 1-alphacalcidol in
haemodialysis patients with moderate hyperparathyroidism.
Cortical Cortical Trabecular Trabecular Trabecular Trabecular
apposition osteoclast osteoblast osteoclast osteoclast osteoid
rate number surface surface number volume Preliminary comparison of tibial ultrasound velocity with bone mineral
density in dialysis patients with marked hyperparathyroidism and withPts. B A B A B A B A B A B A
healthy volunteers. J. Bernard 1, D. de Takats1, E.V. McCloskey1, M.
1 26.9 26.9 2.7 23.5 29.0 29.2 24.0 24.7 22.4 22.4 23.4 23.7 Wilkie 2, C. Brown2, L. Edwards2, M. El-Nahas2, and J.A. Kanis1, 1The
2 27.6 27.6 21.7 20.8 23.4 25.9 6.5 21.0 3.4 20.6 0.2 21.9 Centre for Metabolic Bone Diseases at Sheffield, Royal Hallamshire
3 24.5 27.1 1.5 4.0 26.5 25.8 3.5 23.5 3.2 22.6 24.0 24.0 Hospital and 2The Sheffield Kidney Institute, Northern General Hospital.
4 23.9 26.8 0.7 24.9 20.5 24.8 1.0 2.0 20.2 2.1 0 24.6 Dual Energy X-ray Absorptiometry (DEXA) is a relatively conven-
5 23.9 27.1 7.4 0.2 9.3 4.5 6.8 5.5 7.1 3.2 3.0 2.5 tional technique which measures bone mineral density (BMD). It has
6 22.2 27.1 1.2 23.5 0.5 25.8 0.5 23.5 1.1 22.6 0.7 23.8 an established place in the diagnosis and management of postmeno-
7 23.8 24.7 3.0 25.3 21.6 28.5 3.3 24.7 3.6 22.9 21.6 24.4 pausal osteoporosis and there is some experience of its use in renal
Mean 24.7 26.8a 2.1 21.9a 21.6 25.0a 2.5 21.4a 2.3 20.7a 22.8 20.7a osteodystrophy. Assessment at one site is treated as representative
SD 0.9 1.9 2.8 3.4 5.9 4.5 3.8 3.9 3.1 2.5 2.5 2.4 of the whole skeleton. Tibial ultrasound velocity (TUV) is a newer
technique for assessment of bone strength. We have previously demon-Abbreviations are: B, before; A, after 1 year follow-up.
a P , 0.05 vs. the corresponding B value by paired Student t-test strated in Paget’s disease that they measure different features of bone
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strength and that in Pagetic bone TUV gives a better measurement capture ELISA. The concentration of CP was determined by radial
of bone quality than DEXA. No such comparisons have been done immunodiffusion (RID) using a commercial kit (Behring NOR-parti-
previously in marked renal hyperparathyroidism. We established a gen) and serum ferroxidase activity (reflecting CP activity) determined
Normal Data Base for the local population by measuring BMD at the by oxidation of o-dianisidine. Free MPO and MPO-CP complex levels
non-dominant hip, and TUV on the same side, in 421 healthy volunteers were consistently approximately 20% lower in plasma than serum,
(mean age 54.3, range 20.1–80.3 yrs; 191M:230F), and used quadratic however storage at room temperature for 4 hours to 7 days prior to
regression to produce age-sex adjusted means and standard deviations. freezing had no effect on the assay results. All patients studied were
We then invited stable dialysis patients with PTH . 1000 nanograms/l male to exclude possible spurious increases in CP levels by exogenous
to undergo the same measurements. Ten patients attended (7 HD, 3 oestrogens. Results shown as mean values 6 standard deviation.
CAPD, mean age 50.3, range 36–59 yrs; 6M:4F). All measurements
were expressed as age-sex adjusted standard deviation units (Z score) Active
for analysis. For BMD the mean Z score was 21.74 (95% CI 22.39 NBD vasculitis Inflammation
to 21.09) and for TUV the mean Z score was 22.62 (95% CI 23.63 (n 5 5) (n 5 5) (n 5 10)
to 21.62). Both methods show a significant reduction in measurements
Anti-MPO titre (NR , 16) % ,5 83621 ,5from age-sex adjusted norms in marked renal hyperparathyroidism
reflecting the expected abnormalities of bone metabolism. BMD and [Free MPO] nM 4.760.6 5.161.0 14.167.5b
TUV Z scores were not closely correlated in individuals (r 5 0.56), [MPO-CP complex] nM 7.661.0 6.460.7 20.369.4b
consistent with the concept that they capture different features of bone [CP] (RID) mg/ml 321657 3956110 4156147
quality. The reductions were greater with TUV but the difference in Ferroxidase activity U/l 95626 147643a 172675a
apparent sensitivity did not reach significance (p 5 0.169). TUV shows CP ferroxidase activity U/mg 0.31260.06 0.3860.06 0.41960.06b
potential as a tool for assessment of skeletal status in this population. ap , 0.05, bp , 0.01
In the presence of anti-MPO antibodies, free MPO may become com-
Medullary sponge kidney. Long-term follow-up of 100 patients. I. Ditt- plexed and so elevated MPO levels are not seen in the serum of vasculitic
mer, M. Donohoe1, and T. Feest, Richard Bright Renal Unit, Southmead patients. The binding of MPO to the autoantibody is known to be of a
Hospital, Bristol BS10 5NB, UK and 1Royal Devon and Exeter Hospital, higher affinity than that to CP and this binding protects MPO from
Exeter, UK. Medullary sponge kidney (MSK) is a congenital disease inactivation by CP. Levels of MPO-CP complexes are not raised in the
characterised by ectatic dilatation of the distal collecting tubules. MSK vasculitic group. There is a trend for lower relative ferroxidase activity
is almost always diagnosed by intravenous urography, the appearances of CP in patients with vasculitis compared to those with inflammation
ranging from medullary blush to the classic “bunch of grapes”. All but this did not reach significance (p 5 0.26), however may further
X-rays were reviewed and the diagnosis confirmed. A full history and contribute to this group’s susceptibility to endothelial cell injury. We
examination was obtained. Biochemical profile, haemoglobin and PTH conclude that measurement of free MPO or MPO-CP complex may
levels were determined. Urine was analysed for amino-acids, protein, be a useful adjuvant in distinguishing active vasculitis from other non-
pyuria (and bactiuria) and 24 hour calcium and oxalate excretion. A immune causes of systemic inflammation, such as infection.
modified urinary acidification test was performed. 100 patients were
studied. Mean follow-up was 14.4 years (1–40 years).
T lymphocyte responses to myeloperoxidase, proteinase 3 and protein-Signs/ Stone Loin Haema- Hyper- Protein- Nephro- ase 3 peptides from patients with ANCA-associated systemic vasculitis.symptoms passage pain turia Pyuria tension uria calcinosis
W.J. King, C.J. Brooks, R. Holder1, P. Hughes, A. Ben-Smith, D. Adu2,
and C.O.S. Savage, Centre for Clinical Research in Immunology andPatients 53 35 57 30 28 17 54
Signalling, 1Department of Statistics, University of Birmingham and
5 patients were noted to have hemihypertrophy (1 case of Beckwith- 2Department of Nephrology, Queen Elizabeth Hospital, Birmingham,
Weidemann syndrome). 10 patients were essentially asymptomatic the B15 2TT, UK. Anti-neutrophil cytoplasmic antibodies (ANCA) with
diagnosis being made on IVU performed for microscopic haematuria specificity for myeloperoxidase (MPO) and proteinase 3 (PR3) are
or hypertension. Mean creatinine was 107 mmol/l (47–205), one patient thought to play a central role in the pathogenesis of systemic vasculitis.
developed renal failure. Mean serum calcium was 2.41 mmol/l, average The presence of activated T cells in vasculitic lesions, the finding of
urinary calcium excretion was 6.1 mmol/24 hour (1.4–15.3). Urinary increased numbers of T cells in peripheral blood of patients and also
calcium excretion was increased in 29% of those with nephrocalcinosis the fact that most ANCA are high affinity IgG antibodies all suggest
compared with 15% of those without. Abnormalities in urine amino- an important role for T cells. Therefore, in this study, we examined T
acid excretion or decreased urinary acidifiying ability occurred in less cell proliferative responses to MPO and PR3 in patients with vasculitis.
than 5% of patients. 30 patients had operative procedures performed, Peripheral blood mononuclear cells (PBMC) were isolated from 45
most commonly ureterolithotomy. A further 14 had percutaneous litho- ANCA-positive patients (Wegener’s granulomatosis (n 5 24) and micro-
tripsy performed. Patients with MSK not only have significant problems scopic polyangiitis (n 5 21)) and 19 controls (IgA nephropathy (n 5
with recurrent renal calculi but also with loin pain not associated 9) and healthy volunteers (n 5 10)). These were cultured with MPO,
with stone passage. We have not found the previously reported high PR3 or whole neutrophil alpha granules and proliferative responses
frequency of urinary abnormalities. assessed after 6, 9 and 11 days. Proliferative responses were also as-
sessed to pools of 25 overlapping peptides covering the entire PR3
sequence. Results were expressed as stimulation indices (SI, i.e. prolif-Serum measurement of myeloperoxidase (MPO), caeruloplasmin (CP)
erative response to antigen/proliferative response to cells only)) andand MPO-CP complexes. S.V. Griffin and C.M. Lockwood, Cambridge
data analysed by repeated measures ANOVA. Our results demon-University Department of Medicine, Addenbrookes Hospital, Cam-
strated significant proliferative responses to PR3 in both patient (p ,bridge. CB2 2QQ. The release of myeloperoxidase (MPO) from acti-
0.001) and control groups (p , 0.01). Moreover, patient proliferativevated neutrophils may not only mediate bacterial killing but cause
responses to PR3 were found to be irrespective of disease activity orendothelial cell damage by catalysis of the production of reactive oxy-
treatment. Significantly higher responses were seen to alpha granulesgen radicals. We have previously described a novel function of caeru-
in the patients compared to the controls (p , 0.001) and two patientsloplasmin (CP), a plasma protein, to act as a specific inhibitor of
responded significantly to MPO. Significant proliferative responsesMPO. Furthermore, we have demonstrated the potential of anti-MPO
were also detected in PBMC from one patient to three of the peptideantibodies, detected in a group of patients with RPGN, to negate this
pools (amino acid sequences 11–16, 121–136 and 215–229) correspond-inhibition. The purpose of this study was to characterise the balance
ing to three of the six important regions recognised by PR3-ANCA.between MPO and CP in the serum of normal blood donors (NBD),
This study shows that T cells from vasculitic patients can proliferatepatients with active anti-MPO vasculitis and a heterogeneous group
to ANCA antigens and is the first to demonstrate T cell responsespatients with systemic inflammation of another cause. Free MPO was
to these antigens from a large panel of well-characterised ANCA-measured by capture ELISA. MPO-CP complexes were initially de-
tected by co-immunoprecipitation and subsequently quantified also by associated vasculitis patients.
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Treatment of vasculitic IgA nephropathy with steroids and immuno- The mean serum half-life for IV NESP was 3 times longer than for
IV EPO, the difference being 16.8 hours (95% CI 9.4–24.2; p 5 0.0008).suppressants. L. Harper, M.A.S. Ferreira1, A.J. Howie1, C.O.S. Savage,
N.T. Richards, J. Michael, and D. Adu, Department of Nephrology The differences in mean AUC and Cl were also significant (p # 0.0004).
The longer mean serum half-life for SC NESP compared to IV NESPand 1Department of Pathology, Queen Elizabeth Hospital, Edgbaston,
Birmingham. The present study set out to assess whether in patients indicates that SC absorption is rate limiting. The peak concentration
of SC NESP is approximately 10% of the IV dose and bioavailabilitywith IgA nephropathy and a vasculitic/crescentic glomerulonephritis,
treatment with steroids and immunosuppressants would preserve renal is approximately 37% by the SC route, which is similar to EPO from
previous studies (Clin. Pharmacol. Ther. 50:702, 1991). The longerfunction by healing vasculitic lesions thereby preventing progression
to glomerular sclerosis. Sixteen patients with IgA nephropathy and a serum half-life for NESP is likely to confer a clinical advantage over
EPO by allowing less frequent dosing in patients treated for anaemia.vasculitic/crescentic glomerulonephritis were treated with a reducing
course of prednisolone (initial dose 60 mg/kg/day). Five patients were
also given cyclophosphamide (2 mg/kg/day) for 3 months followed by
azathioprine (100 mg). One received cyclophosphamide only in addi- High dose chemotherapy for systemic AL amyloidosis. J.D. Gillmore,
J.F. Apperley1, M.B. Pepys, and P.N. Hawkins, Immunological Medi-tion to prednisolone. Ten patients were given azathioprine (100 mg)
in addition to prednisolone. The median duration of treatment was 12 cine Unit and Dept. of Haematology1, Division of Medicine, Imperial
College School of Medicine, Hammersmith Hospital, London, UK.months (range 5–30 months). At the end of treatment each patient
had a second renal biopsy. Following treatment there was a significant Systemic AL amyloidosis presents most commonly with nephrotic syn-
drome or renal failure and has a very poor prognosis (Sem. Haem.reduction in the proportion of glomeruli with acute vasculitic lesions
from a median of 17.4% (range 4.7–57.5%) to 0% (range 0–15.8) (p , 32:45–59, 1995). Only 20% of patients benefit from low dose oral
melphalan and prednisolone (M1P) (Blood 77:257–262, 1991) prompt-0.0001). There was an increase in the proportion of sclerosed glomeruli
after treatment but this did not differ significantly from baseline. The ing interest in more intensive chemotherapy regimens. We studied
median duration of follow-up was 30 months (range 6–74 months). At 39 patients who underwent more intensive chemotherapy (VAD or
both 12 and 24 months there was no significant difference in serum C-VAMP) and compared their response with 76 patients who were
creatinine as compared to pre-treatment serum creatinine. Four pa- treated with M1P. Organ function and survival were significantly better
tients developed end stage renal failure between 36 and 72 months. in the VAD/C-VAMP group, associated with more frequent and rapid
remission of the underlying plasma cell dyscrasias. Prospective serum
Creatinine amyloid P component scintigraphy showed regression of amyloid
% activity % sclerosis (lmol /l ) within as little as 6 months in the VAD/C-VAMP group compared
with 12–18 months in the M1P group. Kaplan-Meier estimates ofPre-treatment 17.4 (4.7–57.5) 13.4 (0–44.4) 21.5 (63–596)
survival for patients with AL amyloidosis are shown below (p , 0.007).Post-treatment 0 (0–15.8) 21.5 (0–90) 105.5 (69–902)
(12 months)
Significance P , 0.0001 P 5 0.37 P 5 0.94
In this retrospective study we show that treatment with steroids and
immunosuppressants leads to healing of vasculitic lesions and may thus
arrest progression of scarring. A controlled prospective trial is required
to determine whether such treatment will reduce the proportion of
patients developing renal failure.
Pharmacokinetics of IV and SC Novel Erythropoiesis Stimulating Pro-
tein (NESP) and IV Poetin alfa (EPO) in CAPD patients. I.C. Mac-
dougall1, S.J. Gray2, O. McEvoy1, C. Breen1, B. Jenkins2, J. Matcham2,
A. Heatherington3, J. Browne 3, and J. Egrie 3, 1Renal Unit, King’s College
Hospital, London; 2Amgen Limited, Cambridge; 3Amgen Inc., Thou-
sand Oaks, USA. NESP is an analogue of EPO which has an increased
circulating serum half-life in animal models compared with EPO. The
aim of this study was to extend these observations to humans. Using These results indicate that there is a brief window of therapeutic oppor-
a double-blind, randomised, cross-over design, the single-dose pharma- tunity in many patients with AL amyloidosis, and suggest that a single
cokinetics of EPO (100 U/Kg) and an equivalent peptide mass of NESP course of high dose chemotherapy followed by peripheral blood stem
were compared following IV bolus in 11 stable CAPD patients (7 cell support may be the most effective approach. This has already been
males, 4 females; aged 27–75 years) with a haemoglobin $ 9 g/dL and shown to be feasible in AL amyloidosis, even in patients with renal
no prior EPO therapy. This was followed by an open-label comparison impairment, and to produce extremely encouraging results (Blood
of the single-dose pharmacokinetics of an equivalent peptide mass of 88:2801–2806, 1996). In association with representatives of each of the
NESP by SC injection in 6 of these patients. Blood samples were taken UK’s haematology transplant centres, we have developed a protocol for
pre-dose, up to 96 hours after each IV bolus and up to 168 hours after the diagnosis, monitoring and treatment of systemic AL amyloidosis,
the SC injection. There was a 28 day washout between dosing periods. including peripheral stem cell transplantation, initially as an open study
Serum levels of NESP and EPO were determined by ELISA after but with a view to performing a controlled clinical trial in the near
subtraction of the baseline endogenous EPO level. Parameters for IV future. A National Registry for AL amyloidosis is proposed.
dosing, expressed as mean 6 se, were estimated after adjustment
for cross-over design effects. Non-compartmental parameters for SC
dosing are expressed as mean 6 se. Prevention of acute inflammation and crescent formation in experimen-
tal crescentic nephritis by blocking tumour necrosis factor-a (TNF-a).
Dose AUC Cl Vd A.M. Karkar, J. Smith, F.W.K. Tam, and C.D. Pusey, Renal Section,
group (ng.h/mL) t1/2z (h) (mL/h/Kg) (mL/Kg) Division of Medicine, Imperial College School of Medicine, Hammer-
smith Hospital, London, UK. Nephrotoxic nephritis (NTN) in Wistar-NESP IV 291.067.6 25.362.2 1.6 60.3 52.462.0
Kyoto (WKY) rats is a model of crescentic nephritis in which glomeru-EPO IV 131.968.3 8.562.4 4.0 60.3 48.762.1
lar injury is dependent on CD81 cells and monocytes/macrophages
that infiltrate glomeruli by day 4. Severe necrotising glomerulonephritis
develops by day 6, with crescent formation in .60% of glomeruliDose Cmax AUC
group Tmax (h) (ng/mL) (ng.h/mL) t1/2z (h) F (%) within 2 weeks, and renal failure by 4 weeks. TNF-a is expressed at
day 4 in glomeruli and interstitium, and excreted in the urine at day
NESP SC 54.1 65.1 0.9460.1 108.2611.0 48.865.2 36.963.0 7. Our aim was to investigate whether blocking of endogenous TNF-a
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would prevent acute glomerular inflammation, and whether continuous of Medicine and Clinical Biochemistry, University of Cambridge, Ad-
denbrooke’s Hospital, and Boyer Center for Molecular Medicine, Yaleneutralisation of TNF-a would prevent formation of crescents and
progression of renal disease. In experiment 1, rats were pre-treated University, New Haven CT, USA. Tumor necrosis factor (TNF) medi-
ates a wide spectrum of biological activities including cytotoxicity, cellwith 400 mg p55-sf2 (soluble TNF receptor) one hour before induction
of nephritis and on a daily basis thereafter; control rats were injected proliferation, antiviral responses, and the activation of many cellular
genes involved in inflammatory and immunoregulatory responses. Thewith PBS. All rats were killed on day 4 following induction of nephritis.
In experiment 2, a similar protocol was followed and treatment with actions of TNF are mediated by two cell surface receptors—TNFR-I
(55 kd) and TNFR-II (75 kd)—which independently activate a diversep55-sf2 continued until day 10. Glomerular cell infiltration and activa-
tion were studied by immunohistology, using markers for macrophages range of signalling pathways. Available evidence suggests that ligand
and/or receptor internalisation may be important in some aspects of(ED1 and ED3), CD81 cells (OX8) and inducible nitric oxide synthase
(iNOS). Results (mean 6 se) are shown below (ap , 0.001, bp , 0.05). TNF signalling, and that after receptor binding TNF is trafficked to
lysosomes for degradation. Using confocal immunofluorescence mi-
croscopy, immunogold electron microscopy, Western blotting of mito-Albumin- Glomerular ED1 OX8 ED3 iNOS
uria thrombosis chondria-enriched subcellular fractions, and I125-TNF ligand binding
studies, we have found that mitochondria contain a novel TNF receptor(mg/20 h) (%) (per 50 glomeruli in section)
of approximately 60 kd that is serologically related to TNFR-II. Fur-
Experiment 1 thermore exogenous TNF is delivered to mitochondria in addition to
Control lysosomes. The TNFR associated protein TRAF2 is also found in
(n 5 6) 69 6 14 30 6 5 538 6 45 49 6 4 142 6 8 98 6 4 mitochondria, indicating that TNF dependent signalling may occur at
p55-sf2 this site. These findings (1) imply that TNF effects on cells may in part
(n 5 6) 22 6 3a 2 6 1a 356 6 24a 19 6 2a 60 6 2a 38 6 4a be due to a direct effect on mitochondria; (2) provide the first evidence
Experiment 2 of mitochondrial receptors for extracellular ligands; and (3) demon-
Control strate the presence of a pathway capable of delivering TNF from cell
(n 5 5) 149 6 6 44 6 7 205 6 18 39 6 1 112 6 6 27 6 6 surface to mitochondria.
p55-sf2
(n 5 5) 16 6 7a 6 6 3a 79 6 13a 27 6 2a 36 6 5a 11 6 3b
Effect of Th2 cytokines on lymphocyte vascular permeability factorIn experiment 2 there was also a marked reduction in endothelial
production. A.P. Parnham, K. Gillespie, and P.W. Mathieson, Univexpression of adhesion molecules ICAM-1 and VCAM-1 in the p55-sf2
Bristol, Southmead Hospital, Bristol, UK. There are many reports oftreated group. Strikingly, continuous inhibition of TNF-a completely
a link between minimal change nephropathy and atopy. Recently thereprevented the development of crescents (per 100 glomeruli: 41 6 5%
are increasing data to suggest a pathogenic role for vascular permeabil-vs 0 6 0%). In conclusion, TNF-a plays an important role in the
ity factor (VPF). We analysed the effect of the principle Th2 cytokines,development of acute glomerular inflammation and crescent formation
interleukins 4, 10 and 13, also associated with atopy, on production ofin NTN in WKY rats, and blocking its effects can prevent disease.
VPF by peripheral blood mononuclear cells (PBMC’s). PBMC’s wereThese results may have therapeutic implications for human nephritis.
separated from whole blood by density centrifugation. They were then
split into 5 wells and incubated for 48 hr at 378C, 5% CO2, without
stimulation, with IL4 10 ng/ml, IL10 10 ng/ml, IL13 10 ng/ml andTacrolimus inhibits TGF-b-mediated fibronectin production by human
Concanavalin A (Con A) 5 mg/ml. Supernatants were removed andmesangial cells. R.S. Chana, D.V. Milford1, I.Z.A. Pawluczyk2, and
VPF levels measured via a commercial ELISA method. RNA wasD.C. Wheeler, Depts of Nephrology, Univ Hosp and 1Children’s Hosp
extracted with guanidium isothiocyanate and the amount of VPF mes-NHS Trusts, Birmingham, and 2Leicester General Hosp, Leicester, UK.
sage estimated using semi-quantitative RT-PCR. IL10 and 13 bothGlomerular scarring involves extensive accumulation of extracellular
tended to decrease VPF production but IL13 had the greater effectmatrix and may be mediated in part by the pro-fibrotic cytokine trans-
and the most consistent, decreasing production in all individuals, asforming growth factor-b (TGF-b). The immunosuppressive drug ta-
well as blunting the stimulation seen with Con A. The action of IL4crolimus (FK 506) binds to an immunophilin (FK binding protein-12)
was variable. VPF RNA production mirrored protein production.which is usually found in association with type I TGF-b receptors. The
These data indicate that the Th2 cytokines IL10 and 13 can directlypresence of tacrolimus may thus perturb TGF-b signalling responses
affect the production of VPF by PBMC’s. IL13 is the most potentand thereby inhibit cytokine-mediated fibrogenesis. To test this hypoth-
inhibitor.esis, growth arrested human mesangial cells were incubated with
TGF-b in the presence and absence of tacrolimus in vitro and fibronec-
tin production measured by ELISA. In preliminary studies, cell viability
Apoptosis and the macrophage infiltrate in protein overload protein-was assessed by determining incorporation of diphenyltetrazolium bro-
uria. M.E. Thomas, N.J. Brunskill, H. Pringle, P.N. Furness, K.P.G.mide, a dye which is cleaved to a blue formazan product by the mito-
Harris, and J. Walls, Renal Unit Laboratories, Leicester General Hospi-chondria of living cells and can be measured spectrophotometrically.
tal, and University of Leicester. Protein overload proteinuria is a modelTacrolimus had no toxic effects on cells at concentrations of up to 200
of heavy proteinuria, in which a macrophage infiltrate is a characteristicng/ml, nor did the drug alone modify fibronectin synthesis. TGF-b (10
early finding. Work by us and others on this model suggested thatng/ml) increased secretion of fibronectin by 31% after 7 days when com-
fatty acids carried on BSA mediate the macrophage infiltrate. We alsopared to control cells grown in RPMI alone although no changes were
postulated that protein overload proteinuria could provoke tubulardetected at earlier timepoints. This effect was enhanced 6.6-fold when
apoptosis and lead to tubular atrophy. To further investigate the delete-tumour necrosis factor a (TNFa) was also present (control cells 3.1 6
rious effects of the fatty acids carried on injected albumin, two grams0.1 vs cytokine primed cells 20.0 6 0.1 mg/ml, mean 6 sem, n 5 4, p ,
per day of fatty acid bearing [FA(1)BSA, n 5 17], delipidated0.001). When compared to cells exposed to cytokines alone, addition
[FA(2)BSA, n 5 17] bovine serum albumin, or saline [n 5 8] wereof tacrolimus (100 ng/ml) significantly inhibited the effect of TGF-b/
injected intraperitoneally into female Lewis rats for 7 days. CorticalTNFa on fibronectin production (8.4 6 0.1 mg/ml, mean 6 sem, n 5 4,
macrophage (MF) infiltration was measured by immunoperoxidasep , 0.001). There was no change in the ratio of secreted to cell associ-
staining. % area stained was measured blindly using the program NIHated fibronectin following the above experimental manipulations.
Image. Apoptosis was measured by in situ end labelling. DenselyThese in vitro results show that tacrolimus inhibits mesangial cell fi-
stained cortical apoptotic nuclei were counted in blinded fashion, usingbronectin production in response to cytokine stimulation and suggest
a particle counting technique with NIH Image. The MF infiltrate wasthat the drug may have a role in the inhibition of glomerular scarring.
peritubular, and was largely confined to the outer cortex, with a rapid
fall off in the infiltrate towards the inner cortex. Injection of
FA(2)BSA ameliorated, but did not abolish, the infiltrate. AnimalsTumour necrosis factor is delivered to a mitochondrial receptor. J.R.
injected with FA(1)BSA, but not those injected with FA(2)BSA orBradley, L. Ledgerwood, N.A. Bright, P. Faraco, S. Jones, S. O’Rahilly,
J. Savidge, K. Smith, K. Wolfreys, J.S. Pober, and J.B. Prins, Department saline, showed evidence of considerable cortical apoptotic activity.
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Results shown are medians (interquartile range, ap , 0.001; bp , 0.001; mediated bystander damage of glomerular endothelium is an early
event. Previously, we have shown heavy intraglomerular expressioncp 5 0.03; dp 5 0.02):
of IL-8 mRNA in ANCA-associated GN and the production of IL-8
by ANCA stimulated neutrophils. We have extended these studies toFA(1)BSA FA(2)BSA Saline
investigate a role for this network in the pathogenesis of ANCA-associ-
MF infiltrate ated GN. In renal biopsy material from patients with ANCA-associated
(% area) 0.49 (0.36–0.95)a 0.17 (0.14–0.30)ab 0.05 (0.03–0.06)b GN (10) there was intraglomerular expression of IL-8 mRNA (by in situ
Apoptotic bodies hybridisation) and protein (by immunohistochemistry) at segmental,
(per 3125 crescentic and parietal epithelial sites. Serial section analysis colocal-
power field ) 15.5 (4–104)cd 3.7 (1–9)c 2.0 (0–6)d ised heavy IL-8 expression to glomeruli with intraglomerular neutro-
phils (CD15 marker). Over 50% of neutrophils were localised at and
FA(1)BSA provoked significantly greater cortical MF influx and within glomerular capillary loops indicating failed trafficking to tissue
apoptosis than FA(2)BSA. The fatty acids carried on BSA are a major IL-8. IL-8 (measured by ELISA) rich cell-free supernatant from anti-
promoter of the MF infiltrate, and may also cause low grade apoptosis. PR3 and anti-MPO ANCA stimulated neutrophils demonstrated po-
Albumin induced apoptosis could be an important cause of tubular tent neutrophil chemotactic activity when compared to unstimulated
cell loss and tubular atrophy. or normal IgG stimulated supernatant (p , 0.001). This effect was
inhibited by up to 90% by a blocking polyclonal IL-8 antibody, indicat-
ing this chemotaxis was IL-8 attributable. Further, in a vertical transmi-
Apoptosis: A mediator of glomerular obsolescence and tubulointersti- gration assay, pre-incubation with supernatant from ANCA stimulated
tial fibrosis? G.L. Thomas, M. Sherif, J. Savill1, and A.M. El Nahas, neutrophils inhibited the transendothelial migration of normal human
Sheffield Kidney Institute, Northern General Hospital Trust, Herries donor neutrophils down an IL-8 gradient (50 ng/ml), when compared
Road, Sheffield, UK. 1Division of Renal and Inflammatory Disease, to neutrophils pre-incubated with unstimulated (p , 0.01) or normal
Dept. of Medicine, University Hospital, Nottingham, UK. Recent studies IgG stimulated neutrophil supernatant (p , 0.05). In conclusion, despite
in experimental proliferative glomerulonephritis (GN) indicate that heavy tissue expression of IL-8 at glomerular sites, the majority of
apoptosis is the major mechanism that mediates the resolution of intraglomerular neutrophils are local to capillary loops, indicating dis-
glomerular hypercellularity during the repair process of experimental ruption of usual trafficking mechanisms. IL-8 produced by ANCA
(GN) (Lab Invest 74:941, 1996). However, the progression of GN stimulated neutrophils is biologically active, inhibits neutrophil endo-
is associated with tubular atrophy and interstitial fibrosis. We have thelial transmigration and is a candidate molecule for frustrated traf-
investigated the role of apoptosis in the pathogenesis of these lesions ficking. Collectively this data supports a pathogenetic role for an
in the model of accelerated nephrotoxic nephritis (NTN) induced in ANCA-neutrophil-IL-8 network in ANCA-associated GN.
Wistar Kyoto (WKY) rats with a single injection of anti-rat glomerular
basement membrane antibody. Groups of rats (n 5 6) were sacrificed
at different time intervals (days 7, 15, 30 & 45 after the induction of Neutrophil binding stimulates the synthesis, release and activation of
NTN) with measurements of proteinuria (UP), creatinine clearance MMP 3 and MMP 2 from endothelial cells in vitro. R.E. Evans, A.
(CrC), histological scoring for glomerulosclerosis (GS), glomerular Clayton, J. Martin, J.D. Williams, M. Davies, and R. Steadman, Institute
inflammation (GI), tubulointerstitial fibrosis (TIF). Cellular apoptosis of Nephrology, Cardiff Royal Infirmary, Newport Road, Cardiff, CF2
was detected by immunohistochemical staining for DNA fragmentation 1SZ. The extravasation of leukocytes at sites of inflammation, is essen-
by in situ nick translation (ApopTag) while cellular proliferation was tial for the clearance of infection and the resolution of disease. Neutro-
detected by staining for proliferating cell nuclear antigen (PCNA). phils (PMN) are often the first cells to leave the circulation and infiltrate
Results are shown in the table (mean 6 sem; ap , 0.05, bp , 0.005) tissues and renal damage as a result of the neutrophil oxidative burst
and lysosomal proteinase release has frequently been implicated in
Parameter Day 0 Day 45 initiating injury. While the process of neutrophil migration through
the endothelium is well described that governing passage across theCrC (mg/min) 0.78 60.05 0.10 60.04
sub-endothelial basement membrane is poorly understood. We haveUP (mg/24 h) 3.2160.19b 154.0612.40b
used isolated human neutrophils and cultured human umbilical veinGS (0 5 normal, 3 5 .75% sclerotic) 0.3260.06 2.73 60.12
(HUV) endothelial cells (EC) to examine the hypothesis that EC playGI (0 5 normal, 3 5 .75% inflamed ) 0.1860.05 1.36 60.08
a direct role in the process of trans-basement membrane passage.TIF (0 5 normal, 3 5 .75% fibrotic) 0.0560.01 2.50 60.03
HUVEC, treated with TNFa, bound PMN and subsequently releasedApop GLOM (% positive cells/
increased amounts of MMP 2 on gelatin-zymography. This release was203 field) Not detectable 0.005 60.004
significantly greater than HUVEC alone at 6 hr and was maximal whenApop TI (% positive cells/203 field ) 0.00760.0007a 1.9560.52a
the PMN:HUVEC ratio was above 10:1. MMP 2 release was partlyPCNA GLOM (% positive cells/
inhibited by anti-CD18 antibodies and was mimicked (in the absence203 field ) 0.09 60.05 Not detectable
of PMN) by cross-linking ICAM-1 on the HUVEC surface with anti-PCNA TI (% positive cells/203 field ) 0.2960.09 0.21 60.13
ICAM-1 antibodies. ICAM-1 cross-linking also stimulated the release
of MMP 3 and the synthesis of mRNA for MMP 3 and MMP 2, suggestingA progressive increase in renal cellular apoptosis was observed in NTN
a direct effect on the de novo synthesis of the proteinases. The bindingkidneys; the glomerular apoptosis peaked at day 15 and was followed
of PMN to HUVEC also resulted in the activation of latent MMP 2by a rapid disappearance of glomerular cells, tubular apoptosis on the
and a second band of activity was observed at around 66 kD on theother hand increased with time until day 45. Glomerular PCNA positive
zymograms. The intensity of this band increased with time and wascells peaked at the height of the inflammatory, proliferative glomerular
inhibited by the use of serine proteinase inhibitors. Neither superoxideresponse (day 7) and was minimal thereafter. Tubular apoptosis corre-
dismutase or catalase inhibited the activation of latent MMP 2. Theselated with the severity of UP (r 5 0.468, R2 5 0.241) and that of TIF
studies indicate a novel mechanism for the induction of endothelial(r 5 0.935, R2 5 0874). Apoptosis may mediate glomerular obsoles-
enzymes which would degrade the collagenous components of base-cence and TIF.
ment membranes. Whether this mechanism is involved in controlling
the extravasation of leukocytes remains to be tested.
Interleukin-8: A pathogenetic role in ANCA-associated glomerulone-
phritis. P. Cockwell, C.J. Brooks, D. Adu, and C.O.S. Savage, Renal
Anti-neutrophil cytoplasmic antibodies (ANCA) induces neutrophilImmunobiology, Centre for Clinical Research in Immunology and Sig-
F-actin assembly and rigidity. Implications for microvascular inflam-nalling, Medical School, University of Birmingham, Birmingham, B15
mation. W.Y. Tse, G.B. Nash1, C.O.S. Savage, and D. Adu, Dept of2TT. In vivo, extravascular interleukin (IL-8) is a major neutrophil
Nephrology, Queen Elizabeth Hospital, Birmingham and Dept ofchemoattractant. However this effect is location dependent as intravas-
Haematology1, University of Birmingham, B15 2TH, UK. Neutrophilscular IL-8 inhibits neutrophil transmigration to the tissue expressed
protein. In ANCA-associated glomerulonephritis (GN) neutrophil- play a key role in mediating the inflammatory lesions of systemic
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vasculitis. Assembly and re-organisation of the actin cytoskeleton is 149 children with MCN was compared with 73, potential bone marrow
donor, controls. There is a highly polymorphic TG repeat in the secondinvolved in neutrophil activation, chemotaxis and rheology. We postu-
lated that ANCA by inducing F-actin polymerization would increase intron of the IL4 gene which has shown linkage to total IgE production.
This region was amplified via the polymerase chain reaction (PCR)neutrophil rigidity leading to less deformable neutrophils which could
become more easily sequestrated in the capillaries. To determine using specific primers, and the products run on a 4% agarose gel. We
identified multiple alleles, on size criteria, but found no differencewhether ANCA can induce neutrophil F-actin polymerization, we mea-
sured the relative F-actin increase using FACS analysis. To establish between patients and controls. Using specific primers the IL4 promoter
from 2306 to 14, in 6 patients and 5 controls, was amplified usingwhether ANCA can alter neutrophil deformability, entry time of neu-
trophils into micropipettes with 4.5 mM diameter was measured. ANCA PCR and the products were cloned into plasmids and sequenced. We
have seen two previously recognised and five novel polymorphisms.led to a dose dependent increase of neutrophil F-actin polymerization,
compared with normal IgG (PR3-ANCA 132 6 8.0%, MPO-ANCA Of the five novel changes two are at sites likely to have functional
significance, the second OAP site and the TATA box. We intend to139 6 6.5%, normal IgG 18.6 6 9.1%, p , 0.01), and this was associated
with a prolonged micropipette entry time. ANCA F(ab9)2 failed to clone these polymorphic promoters into functional reporter assays as
well as looking at their prevalence, using restriction fragment lengthstimulate F-actin polymerization, and whole ANCA IgG-induced
F-actin responses were abolished by monoclonal antibody IV.3 Fab polymorphisms, in patient and control groups.
(anti-FcgRII) (p , 0.01) but unaffected by antibodies to FcgRI or
FcgRIII receptors. Maximum F-actin responses were seen at 10 min-
utes, and responses were inhibited by 5 mg/ml of cytochalasin B (F-actin Mycophenolate mofetil and the suppression of antibody formation.
K.G.C. Smith1, N.M. Isbel 2, M.G. Catton3, J.A. Leydon3, G.J. Becker 2,assembly inhibitor), 200 ng/ml pertussis toxin (heterotrimeric Gi pro-
tein inhibitor), 50 mM genistein (protein tyrosine kinase inhibitor), and R.G. Walker 2, 1Department of Medicine, University of Cambridge
School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK,50 nM wortmannin (phosphatidtylinositol 3-kinase inhibitor)(all p ,
0.001), but not by 70 nM staurosporin (protein kinase inhibitor). De- the 2Department of Nephrology, Royal Melbourne Hospital, Parkville,
Victoria, Australia, and the 3Victorian Infectious Diseases Referencepleting extracellular calcium significantly reduced the ANCA-induced
F-actin response (p , 0.001) and additional chelation of intracellular Laboratory, Fairfield, Victoria, Australia. No conventional immunosup-
pressive agent preferentially inhibits antibody production. Studies incalcium using 50 mM BAPTA-AM had no further inhibitory effect. Our
data suggest that ANCA can induce neutrophil F-actin polymerization experimental animals and in human cells in vitro suggested mycopheno-
late mofetil (MMF) might have such an effect. If this was the case inthrough engagement of FcgRII receptors. This requires heterotrimeric
Gi-like protein activation, tyrosine phosphorylation, phosphatidtyli- vivo it could have significant implications in terms of both MMF toxicity
and the rational design of immunotherapeutic regimens. Subjects werenositol 3-kinase activation and calcium fluxes, but is probably indepen-
dent of other protein kinase activation. Neutrophil rigidity induced by renal transplant recipients (25 patients treated with prednisolone, cyclo-
sporine and azathioprine, and 13 treated with prednisolone, cyclosporineANCA may lead to retention of activated neutrophils in the microvas-
culature, resulting in endothelial damage. and MMF) and 20 normal controls. The three groups received influenza
vaccination and the antibody response to it was measured 4–6 weeks
later using a standard haemagglutination assay. MMF profoundly sup-
pressed the humoral immune response to influenza vaccination whenAntioxidant treatment suppresses injury and iNOS induction in Thy 1
glomerulonephritis (gn). S. Waddington, T. Cook, H. Ebrahim, K. added to prednisolone and cyclosporine. This effect could be seen
when comparing the rise in the mean titre of antibody after vaccination.Mosley, and V. Cattell, Department of Histopathology, ICSM, London,
UK. Acute injury in Thy 1 gn results from attack by complement—fixing It was also reflected in the number of patients mounting responses
deemed to be clinically protective by either demonstrating a four-foldantimesangial cell antibody. Reactive oxygen metabolites (ROM) in-
duced in mesangial cells by complement membrane attack complex rise in titre or an increase in titre to .40. Suppression of the humoral
immune response by MMF has implications for the design of immunisa-may be central to this, and to the induction of iNOS previously demon-
strated in this model (1). We have therefore examined the effects of tion protocols to protect the immunosuppressed, and raises the possibil-
ity that MMF use may be accompanied by more or different infectionsthe antioxidant N. acetyl cysteine (NAC), on injury and iNOS induction
in this model. Thy 1 gn was induced by monoclonal antibody ER4 i.v. than complicate more conventional immunosuppression. More impor-
tantly, consideration should be given to harnessing the relatively spe-2 mg/kg. Rats were given NAC i.p. 1000 mg/kg 1 hour prior to ER4
and killed at 1, 5 and 24 hrs after induction of the model. Glomeruli cific effect of MMF on antibody production to treat antibody-mediated
diseases.were isolated for RT PCR and nitrite (NO2-) generation, and kidney
taken for light and immunohistochemistry. iNOS mRNA, present at
1 hour, was markedly reduced in NAC treated rats. Glomerular NO2-
The use of automated image analysis histology to predict long termsynthesis was significantly reduced at 5 and 24hrs in NAC treated
renal allograft outcome from 6 month protocol biopsies. E. Bailey,compared with untreated rats (3.5 6 0.66 vs 8.2 6 1.1 nMol/2000 gl/
P.N. Furness, M.L. Nicholson, J. Feehally, and K.P.G. Harris, Depart-48 hrs P 5 0.02, and 1.6 6 0.04 vs 3.0 6 0.3, p 5 0.005). Neutrophil
ments of Nephrology, Pathology and Transplantation, University ofinfiltration was abolished at 1hr (NAC 0.5 6 0, untreated 9.6 6 1.6,
Leicester, Leicester, UK. Up to 50% of renal grafts fail within 5 years.per gl, p 5 0.0005) and 5hrs (NAC 0.6 6 0.2 vs 8.9 6 0.5, p , 0.0001)
Histological evaluation of failed grafts demonstrates progressive renaland macrophage infiltration reduced at 5hrs (NAC 1.7 6 0.4 per gl vs
fibrosis (“chronic transplant rejection”). It may be possible to offer12.0 6 1.0, p 5 0.0006) and 24hrs (NAC 0.7 6 0.1 per gl vs 6.6 6 1.6,
specific therapies to delay this process if those grafts at risk could bep 5 0.01). Mesangiolysis was significantly reduced at 5hrs (NAC 45.9 6
identified early. 48 consecutive renal transplant recipients were studied1.3 cells/gl vs 34.4 6 2.1, p 5 0.009). There was no difference in the
retrospectively by analysing changes in 6 month protocol biopsies whichamount of ER4 in the mesangium at 5hrs. We conclude that ROM
were correlated with parameters of graft outcome at 6, 12 and 24production has a significant role in the acute glomerular injury of Thy 1
months post transplantation. Immunostaining for collagen III, tenascingn, and is crucial for the early induction of iNOS mRNA. Whether
and infiltrating leukocytes was performed using an indirect immunoper-the suppression of NO synthesis in this period is responsible for the
oxidase technique. Interstitial area stained (%) was measured blindlyamelioration of injury, as has been previously reported (2), remains
using automated video analysis and the program NIH image on non-to be determined. References: (1) Cattell et al. Exp. Nephrol 1:36,
counterstained sections. % area of collagen III, (but not tenascin or1993; (2) Narita et al. Lab Invest 27:17, 1995.
leukocytes) correlated with 6 month GFR (r 5 20.42, p 5 0.005) and
was predictive of 12 month GFR (r 5 20.32, p 5 0.03). Furthermore,
a % area of collagen III of .40% at 6 months was associated with aNovel polymorphisms of the interleukin-4 promoter. A.P. Parnham,
K.M. Gillespie, and P.W. Mathieson, Academic Renal Unit, Southmead significantly lower GFR at 24 months than a % area of #40% (30.8 6
3.6 vs 44.8 6 3.6 ml/min/1.73m2, p 5 0.01). Donor age correlated withHospital, University of Bristol. Patients with Minimal change nephritis
(MCN) have high Interleukin 4 (IL4) and IgE levels. We have searched collagen III and tenascin staining at 6 months (r 5 0.33, p 5 0.03) but
not with leukocyte staining, and was also predictive of long term graftthe IL4 promoter as well as a proposed enhancer region in the second
intron for polymorphisms which might account for this. DNA from outcome. In conclusion poor long term graft function can be predicted
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using early (6 month) protocol biopsies immunostained for collagen Monocytes bind to fibronectin produced by mesangial cells. R.S. Chana
III. However, the predictive graft changes at this time may reflect and D.C. Wheeler, Department of Nephrology, University Hospital NHS
donor changes rather than those arising de novo in the recipient. Trust, Birmingham, UK. The development of glomerulosclerosis is
associated with accumulation of both monocytes and extracellular ma-
trix within the mesangium. Since activated macrophages possess inte-
Prognosis in renal lupus depends upon renal function at presentation. grins and may stimulate the production of matrix components, these
R. Rustom, A. Crowe, P. Pai, G.M. Bell, and J.M. Bone, Regional processes may be interdependent. In previous studies, binding of U937
Renal Unit Royal Liverpool University Hospital, Liverpool, UK. Over monocytes to cultured human mesangial cells was only partially
25 years, 67 patients presented with systemic lupus erythematosis and blocked by antibodies to adhesion molecules suggesting that other
biopsy proven renal involvement. Of these 52 (39F, 13M) were avail- mechanisms were involved in this interaction. To determine whether
able for analysis 9.7 6 0.8 years from presentation, and 8.4 6 0.2 monocytes might adhere to matrix components synthesised by mesan-
years from treatment. Standard therapy was with pulse intravenous gial cells, experiments were repeated in the presence of appropriate
methylprednisolone followed by oral prednisolone and azathioprine. blocking antibodies. In these studies, anti-fibronectin antibodies inhib-
Five patients were given oral or intravenous cyclophosphamide for a ited adhesion of U937 cells to growth arrested mesangial cells by
variety of reasons. Overall, patient survival at 1, 5, and 8.4 years from 19–57%. Certain cytokines enhance mesangial matrix production and
treatment was 100%, 89% and 72%, & survival off dialysis was 83%, may thereby promote monocyte accumulation. Prestimulation of mes-
69% and 69% respectively. Mortality was greatest in patients on renal angial cells with 10 ng/ml transforming growth factor-b (TGF-b) in
replacement therapy (6/14 patients). Prognosis was most closely related combination with 10 ng/ml tumour necrosis factor a (TNFa) led to a
to renal function on presentation: of 9 patients (7F, 2M) with acute 2.5-fold increase in cell associated fibronectin (13.0 6 0.5 mg/ml vs
or severe chronic renal failure (CRF) (plasma creatinine, pCr, 736.6 6 control 5.1 6 0.4 mg/ml, mean 6 sem, n 5 4, p , 0.001). This was
154 mmol/l, creatinine clearance Cr Cl, 8.6 6 4.6 mllmin, proteinuria, associated with a 1.4–2.3 fold increase in monocyte adhesion. When
pr 6.1 g/24 h), 7 needed dialysis within 6 months, and of 7 (all F) with the cell layer was removed following cytokine stimulation by addition
moderately severe CRF (pCr 201.3 6 24.7 mmol/l, Cr Cl 34.6 6 6.2 of 2.5 mM NH4OH and 0.1% Triton X-100, immunostaining studiesmllmin, pr 2.3 6 0.4 g/24h), 4 needed dialysis within 4 years. By contrast, showed the underlying matrix to be rich in fibronectin. Binding ofof 21 patients (17F, 4M) with nephrotic syndrome and mild renal
monocytes to matrix deposited by TGF-b/TNFa-stimulated cells wasimpairment (pCr 148.3 6 27.4, Cr Cl 62.3 6 12.3 mllmin, pr 7.8 6 1.8
increased 77–99% when compared to that synthesised by control cellsg/24 h), only 2 needed dialysis after 4 months and 4 years. The others
grown in medium alone (p , 0.001). Preincubation of matrix within this group at last followup had a pCr of 113 6 13.5 mmol/l, Cr Cl
a monoclonal anti-human fibronectin antibody substantially reduced61.9 6 5.9 mllmin, pr 0.2 6 0.03 g/24h. Also, of 15 patients with sub-
monocyte binding emphasising the critical role of this matrix compo-nephrotic proteinuria (8F, 7M) (pCr 136.0 6 20.1 mmol/l, Cr Cl 71.2 6
nent. In conclusion, monocytes bind to fibronectin produced by mesan-6.6 mllmin, pr 1.4 6 0.4 g/24 h), only 1 progressed to dialysis after 3
gial cells. Cytokine-mediated increases in matrix production may en-years with no deaths. The others in this group had at last followup
hance monocyte accumulation in the mesangium.pCr 115.5 6 9.8 mmol/l, CrCl 60.9 6 9.5 mllmin, pr 0.1 6 0.01 g/24 h.
This suggests that aggressive treatment with pulse cyclophosphamide
should be limited to those with more severe renal involvement at
Effect of “Uraemic Toxins” on the proliferation of Human Osteoblast-presentation.
Like Cells (SaOS-2) in vitro. M.L. Picton1,2, A.J. Hutchison1, R. Gokal1,
and J.A. Hoyland 2, 1Dept. of Nephrology, Manchester Royal Infirmary
and 2Dept. of Pathological Sciences, University of Manchester, Manches-Intravenous clodronate 300 mg 3 5 days has no deleterious effect on
ter, UK. Certain compounds which accumulate in renal failure havecreatinine clearance in mild to moderate renal impairment. D. de
an adverse effect on the growth of several cell types in vitro. TheseTakats, J. Bernard, E.V. McCloskey, and J.A. Kanis, The Centre for
compounds may be important in modulating cell responses to mitogenicMetabolic Bone Diseases at Sheffield, Ward G1, Royal Hallamshire
stimuli in renal failure. Therefore, we studied the effect of SpermineHospital, Glossop Road, Sheffield S10 2JF. Bisphosphonates are gener-
0.2, 0.4 and 1 mmol/litre; Spermidine 0.2, 0.4 and 1 mmol/litre andally not recommended or are contraindicated in severe renal impair-
Methylguanidine 2, 25 and 50 mmol/litre on the proliferation of humanment defined e.g. as serum creatinine . 440 mmol/l for clodronate
or GFR , 35 mls/min for alendronate. This reflects fears regarding osteoblast-like cells in vitro. SaOS-2 cells were cultured at 378C in
nephrotoxicity and uncertainty about appropriate dosage adjustments. McCoys 5A medium supplemented with 5% FCS. After allowing at-
With clodronate 7 of 65 adverse events reported since 1990 have related tachment for 24 hours medium was removed and replaced with medium
to nephrotoxicity but these appear to be idiosyncratic rather than in which the test substaces had been dissolved at the desired concentra-
related to pre-existing renal impairment. We routinely treat an elderly tion. Medium was changed on alternate days and cells were counted
population with intravenous clodronate (300 mg, in 500mls 5% dex- after 4 days using an electronic cell-counter. The results below repre-
trose or normal saline, daily for 5 days) for various skeletal conditions. sent the mean cell number per well 6 sd of 6 replicates.
We were interested to see if there was any effect on renal function in
terms of creatinine clearance in this population, particularly amongst Test substance
those with pre-existing renal impairment which we defined as creatinine (lmol /l ) N Mean SD
clearance # 50 mls/min prior to treatment. 24 hour urine collections
Spermine 0.2 6 115457 4891were done on all patients prior to intravenous treatment, during the
Spermine 0.4 6 120957 475724 hour period including the last dose and 3 months later. Serum
Spermine 1 6 103790* 3608samples were taken on completion of the collections. 23 patients with
Methylguanidine 2 6 113359 5292clearance # 50 mls/min were available for analysis (55.6–88.4 yrs,
Methylguanidine 25 5 95563* 6093median 77.1 yrs; 4M:19F) with pretreatment clearances of 25–50 mls/
Methylguanidine 50 6 66847* 4278min, median 43 mls/min. The results were analysed by the Wilcoxon
Spermidine 0.2 6 122297 7238matched-pairs signed ranks test, but paired t-tests produced similar
Spermidine 1 6 105967* 12972results. Comparison of pretreatment with end-of-treatment creatinine
Spermidine 2 6 109823* 6017clearances showed a non-significant trend to increased clearance (me-
Control 6 116857 4703dian 43 vs. 46 mls/min, p 5 0.122). There was no significant difference
between end-of-treatment values and those 3 months later (median
Using the Student t-test, we found that in the presence of spermine46 vs. 48 mls/min, p 5 0.81) but comparison of pretreatment with 3
1.0 mmol/l, spermidine 2 mmol/l and methylguanidine at 25 and 50months’ clearances showed a significant tendency to increase (p 5
mmol/l cell number at 4 days was significantly different *, ie p , 0.05.0.0424). This unexpected result could be unrepresentative due to the
Therefore, under these conditions osteoblast proliferation appears tosmall numbers involved but as it stands it is positive evidence against
be significantly inhibited. This study indicates for the first time thata detrimental effect of clodronate given by this regimen at these levels
of renal function. Perhaps the fluid load was beneficial. certain compounds which are known to accumulate in renal failure
Abstracts2108
have the potential to affect the proliferation of osteoblast-like cells in
Hyper-vitro. Work supported by the Baxter Extramural Grant Program.
Normo- cholesterol-
lipidaemic aemic
Nephrotic controls controlsThe nucleotide sequence of the IgA1 hinge region in IgA nephropathy.
(n 5 34) (n 5 27) (n 5 33)M.R. Greer, A.C. Allen, J. Barratt, and J. Feehally, Dept of Nephrology,
Leicester General Hospital, Leicester, UK. We have previously reported Total cholesterol (mmol /l ) 10.50 (4.32) 5.94 (1.92)* 7.08 (0.74)*
abnormal IgA1 O-glycosylation in IgA nephropathy (IgAN) (1), which Triglyceride (mmol /l ) 3.44 (2.27) 2.20 (1.57)** 2.08 (0.88)**
may be pathogenic. Serine and threonine are the only amino acids Vitamin C (micromol /l ) 14.70 (12.30) 25.02 (14.26)** 60.59 (18.51)*
which carry O-glycans; IgA1 has a series of these residues in the 18- DHAA (micromol /l ) 13.84 (10.59) 14.58 (9.16) 5.66 (2.51)*
amino acid hinge region between the CH1 and CH2 domains, and this Vitamin A (mg/l ) 0.80 (0.30) 0.56 (0.12)* 0.72 (0.12)
is the O-glycosylated region. Abnormal IgA1 O-glycosylation may arise Vitamin E (mg/l ) 28.62 (16.34) 15.07 (8.88)* 19.72 (4.68)**
from aberrant post-translational modification, but another possibility is Vit. E/cholesterol ratio 3.00 (2.06) 2.69 (2.08) 2.80 (0.68)
an altered hinge region amino acid sequence, resulting in a different Vit. C/vit. E ratio 0.78 (0.95) 2.06 (1.51)* 3.29 (1.39)*
number of serine/threonine residues available for O-glycosylation.
ANOVA *p , 0.001; **p , 0.01 compared to nephrotic groupTherefore, we analysed the nucleotide sequence of the genomic a1
gene hinge region, and also used RT-PCR to compare the hinge region
mRNA transcripts in IgAN and controls. Mononuclear cells and serum As vitamin C is important in the recycling of vitamin E from its oxidised
to non-oxidised state this may predispose these patients to an increasedwere separated from the blood of patients with IgAN and matched
controls. The O-glycosylation of serum IgA1 was measured by our risk of oxidation of lipoprotein in vivo.
published lectin binding assays (1). For nucleotide sequencing, genomic
DNA was extracted from the cells of 6 patients and 7 controls. The
hinge region was amplified by PCR and analysed by dideoxy-sequenc- Use of a Scoring-Index for pre-angiographic prediction of Renal Artery
Stenosis. D. de Takats1, P. Donohoe 2, M. Ostermann1, C. Sharpe 2, P.ing. In 5 patients and 5 controls, extracted mRNA was converted to
cDNA by reverse transcription, the hinge region amplified by PCR, Sharpstone 2, J. Kingswood 2, R. Burwood 2, T. Doyle 2, H. Walters1, J.
Bernard 3, and J.E. Scoble1, 1The Renal Unit, Dulwich, King’s Health-and the products separated by electrophoresis to compare the size of
the transcripts obtained from each subject. Lectin binding confirmed care, London, 2Royal Sussex County Hospital, Brighton and 3HMCB,
Sheffield. Atheromatous Renal Artery Stenosis (ARAS) is a commonthat these patients had abnormal IgA1 O-glycosylation (p , 0.03 vs
controls). However, the nucleotide sequence of the genomic a1 hinge clinical problem but the only definitive method of diagnosis is renal
angiography. This is accompanied by both financial cost and the riskregion was identical in IgAN and controls, and the hinge region mRNA
transcripts of patients and controls were all the same size. These results of morbidity or mortality. Any means by which its use could be made
more appropriate should be welcomed. A number of risk factors andshow that the genomic a1 hinge region nucleotide sequence is normal
in IgAN and do not suggest any altered transcription of hinge region tests have been found to predict ARAS. We used some of these to
design a scoring-index which we then validated prospectively. ThemRNA. Therefore, aberrant post-translational modification is likely
to be responsible for abnormal IgA1 O-glycosylation in IgAN. scoring-index (possible scores 0–32) was applied prospectively to 50
consecutive patients attending for diagnostic renal angiography as part1. Allen et al. Clin Exp Immunol 1995:100;470.
of their normal clinical management in two centres. Angiography was
principally by trans-femoral aortogram. Interpretation of the films was
blinded to the score. 20 patients had ARAS. The mean scores (6sd)Plasma anti-oxidant vitamin concentrations in nephrotic syndrome.
G.L. Warwick1, H. Waller1, L. Forster 2, S. Tull 2, and G.A.A. Ferns3, were 13.6 (65.1) for patients with ARAS and 9.2 (64.9) for those
without, a significant difference (t-test: mean difference 24.4, 95% CI1Department of Nephrology, Leicester General Hospital; 2Division of
Chemical Pathology, University of Leicester, Glenfield General Hospi- for difference 27.3 to 21.4, p 5 0.004) and a good correlation was found
tal, Leicester; 3Division of Metabolic and Molecular Medicine, Univer- between the pre-angiographic score and the probability of ARAS being
sity of Surrey, Guildford. Nephrotic syndrome is associated with an demonstrated at angiography (r 5 0.9, p 5 0.015). There was no sex
increased risk of coronary artery disease in part mediated by the associ- difference but patients with ARAS were older (mean 70.5 yrs vs. 61.9
ated hyperlipidaemia. Lipoprotein oxidation is thought to favour ath- yrs). This Scoring-Index reliably identified patients who had either a
erosclerosis and recent studies have suggested that dietary supplemen- high or a low probability of ARAS. Used in its present form it might
tation with anti-oxidant vitamins may reduce coronary risk. In this justify the withholding of angiography in patients with low scores or
study we have investigated the plasma levels of lipids and anti-oxidant allow procedure to angioplasty to be anticipated in patients with high
vitamins in a group of nephrotic patients and compared them with scores, but its usefulness is limited by the fact that most patients’ scores
normolipidaemic and hyperlipidaemic controls. Nephrotic syndrome were in the middle of the range not allowing them to be segregated
was defined as proteinuria . 3.5 g/day. Patients were excluded if they effectively. With refinement, however, it could become more discerning
had diabetes mellitus, advanced renal failure (serum creatinine . 250 and so prove an important aid to clinical decision-making.
mmol/l) or were taking hypolipidaemic drugs, immunosuppressive
agents or vitamin supplements. A group of patients with isolated micro-
scopic haematuria, normal serum creatinine and no or minimal changes Screening potential renal transplant recipients for coronary artery dis-
ease. P.G. Atkinson1, P.A. Kalra2, D.J. O’Donoghue2, M.C. Venning1,(including thin membrane nephropathy) on renal biopsy were used as
‘normal’ controls and patients with primary hypercholesterolaemia and C. Ward 1, 1Departments of Nephrology and Cardiology, University
Hospital of South Manchester and 2Department of Nephrology, Hopewere also studied. Blood samples were collected from patients after
an overnight fast. Plasma lipids were measured by standard methods. Hospital, Salford. End-stage renal failure (ESRF) patients, particularly
diabetics, are at increased risk of coronary artery disease (CAD) andVitamins A, C and E and dehydroascorbic acid(DHAA) were mea-
sured by high performance liquid chromatography using previously CAD is the most common cause of death in renal transplant recipients.
There is no evidence based protocol for screening for CAD and thepublished methods. Results are shown in the table as means and sd’s:
The nephrotic group demonstrated the typical abnormalities in plasma prevalence of CAD in these patients is not known. 27 patients referred
for renal transplantation have undergone non-invasive cardiac assess-lipids and lipoproteins. Cholesterol concentrations were significantly
higher than the hypercholesterolaemic controls. They had reduced ment and subsequent coronary angiography. The subjects were as-
sessed clinically for risk factors (age, sex, family history, diabetes,levels of vitamin C compared to both control groups but a higher level
of DHAA compared to hypercholesterolaemic patients. Both vitamin hypertension, dyslipidaemias, smoking habits) and symptoms and signs
of cardiovascular disease. Resting ECG, echocardiography, MUGAE and A were raised in nephrotic patients reflecting the increased
number of lipoprotein particles in which these lipid-soluble vitamins left ventricular ejection fraction, and dipyridamole-technetium SPECT
myocardial perfusion imaging (MPI) were performed on all subjectsare carried. The ratios of vitamin E/cholesterol and vitamin A/choles-
terol were not different. However, the vitamin C/E ratio was signifi- prior to coronary angiography. Exercise ECG testing was not per-
formed in view of the generally poor exercise tolerance of dialysiscantly reduced and remained so if factored for cholesterol (not shown).
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patients and the presence of resting ECG abnormalities, particularly for hypertension, 271 (97.8%) for treatment of cardiac failure and 166
(59.9%) for diabetic nephropathy. 235 (84.8%) GPs checked renalleft ventricular hypertrophy, in many of the patients. None of the
subjects (19 male, 8 female; age 20–70, mean 48.96, SE 1/2 2.86) function prior to initiation of ACE-I therapy, but only 93 (33.6%)
monitored the function adequately thereafter. 42 (15.2%) GPs failedcomplained of angina. Significant CAD was found in 9 patients (8
male, 1 female; age 39–70, mean 54.4, SE 1/2 3.17) at angiography. to assess renal function at any stage. Encouragingly, 234 (84.4%) saw
the need for the development of simple guidelines for renal functionalCAD was detected by MPI in only 4 of these cases, the other 5 repre-
senting false negatives. There were 2 false positive MPI results in monitoring in their patients. An audit of ACE-I therapy was then
undertaken in one large central Manchester practice. ACE-I werepatients with normal coronary angiograms. Of 7 diabetic patients in
the study 4 had CAD; this was associated with signs of peripheral prescribed to 162 patients out of a total of 3625 aged .35 yrs. The
indications for ACE-I were hypertension (118 of 390 hypertensivevascular disease in 3 patients. The aim is to apply the results from
studying 100 patients (56 have been recruited to date) to the develop- patients), cardiac failure (38 of 61 patients with this diagnosis received
ACE-I) and post-MI (6). ACE-I were commenced in hospital in 40ment of an algorithm for screening ESRF patients for CAD prior to
transplantation. The poor performance of non-invasive testing suggests patients and by the GP in 122 patients. Renal function was assessed
pre-ACE-I in 55 (45%) of these latter patients, but in only 35 (29%)selection of patients for angiography will be based on clinical and
demographic factors. after initiation of therapy. 15 (12.3%) patients had .10% increase in
creatinine after ACE-I; therapy was continued in 11 of these without
further monitoring of renal function. These 3 divergent studies high-
light the need for widespread implementation of renal function moni-Influence of pregnancy on graft function after renal transplantation.
A.V. Crowe, C. Gradden, R. Rustom, J.M. Bone, and G.M. Bell, 1Dept. toring protocols to reduce ACE-I-related uraemia in the community.
of Nephrology, Royal Liverpool University Hospital, Liverpool, UK.
The incidence of pregnancy in successful female kidney transplant
recipients is estimated at 2%. All such pregnancies must be considered Identification of risk factors for renal disease in diabetic patients. P.B.
Rylance, E.V. McLelland, J. Odum, M.A. Jackson, S. Walford, B.M.at high risk. Transplant to conception interval of less than 2 years,
hypertension, unstable serum creatinine greater than 150 mmol/l with Singh, J.D. Phillips, and C. Padgham, Renal and Diabetic Units, New
Cross Hospital, Wolverhampton, and Division of Clinical Science, Uni-significant proteinuria are recognised risk factors. We looked at 28
pregnancies from 25 recipients (transplant interval 45.8 6 5.79 months). versity of Wolverhampton. Prevention of diabetic nephropathy requires
identification and correction of risk factors. In a prospective study 220There were 24 live births and 4 spontaneous abortions. 17 recipients
had significant but controlled hypertension. The mean gestational age diabetics with renal disease were identified over an 8 year period.
Clinical features, risk factors, and outcomes were analysed. Type Iwas 31 6 1.75 weeks. The mean serum creatinine, creatinine clearance
and 24 hour urinary protein was recorded at conception, delivery, 3 patients with renal disease compared with Type II. Renal disease pa-
tients were predominantly male (61%); 22% Type I, 78% Type II.months postpartum (ppm) and 1 year ppm. Results (mean 6 sem, n 5
49% of Type II had become insulin-dependent. Development of renal28) are shown below (*p , 0.05).
disease was accelerated in Type II (11 6 8 years), compared with Type I
(23 6 10, p , 0.001). Type II were 20 years older (63v43). 40%3 months 12 months
Type II had non-diabetic renal disease, predominantly hypertension.Conception Delivery ppm ppm
Hypertension ($140/90; 90%v92%), diabetic control, and cholesterol
Serum creatinine were not different. Type II with diabetic nephropathy compared with
(lmol /l ) 166.9 6 22.9 189.6 6 26.9 194.2 6 34.8 217 6 43.2 Type II without nephropathy. 85 Type II with diabetic nephropathy
Creatinine clearance (excluding non-diabetic renal disease) were compared with Type II
(ml /min) 51.9 6 4.1 53.5 6 5.5 53.4 6 5.1 50.1 6 4.5 controls without nephropathy, matched for age, sex, duration of diabe-
Urinary protein tes and ethnic group. Nephropaths were more commonly hypertensive
(g/24 hrs) 0.51 6 0.13 1.24 6 0.39* 0.69 6 0.21 0.57 6 0.18 (96%v58%, p , 0.001) and blood pressure was higher (173/90v150/
81, p , 0.005). However, only 45% nephropaths were on antihyperten-
sives, controls 91%, p , 0.001. Diabetic control was poor, but similar.There was no significant change in serum creatinine and creatinine
clearance before or after pregnancy. However urinary protein in- More nephropaths had defaulted from clinic (44%v8%, p , 0.001),
had previously smoked (51%v24%, p , 0.001), and still smokedcreased significantly at the time of labour (p , 0.05)* but returned
to baseline at 12 months. Mainstay of immunosuppression for grafts (27%v12%, p , 0.02). Diabetics with renal disease are predominantly
Type II, who have accelerated development of renal disease. Age andincluded azathioprine and prednisolone (n 5 12), cyclosporin and
prednisolone (n 5 7), cyclosporin (n 5 2) and cyclosporin/azathioprine/ hypertension may also contribute to development of renal disease.
Whilst diabetic control does not appear to be a risk factor, uncontrolledprednisolone (n 5 3). It is interesting to note there was a significant
increase in serum creatinine and creatinine clearance at all time points hypertension, failure to prescribe or take antihypertensives, defaulting
from clinic and smoking are associated with development of diabeticin the cyclosporin and prednisolone group compared with the azathio-
prine and prednisolone group (p , 0.05). In conclusion pregnancy nephropathy in Type II diabetics.
in renal transplantation is usually favourable. The transient rise in
proteinuria at delivery does not subsequently adversely affect graft
Vancomycin-Resistant Enterococci: Epidemiology and control of anfunction.
epidemic in a Renal Unit. W.D. Plant1, R.J. Winney1, A. Brown2, R.H.
Paton2, S.G.B. Amyes2, G.M. Stevenson2, and R.S. Miles2, 1Dept of Renal
Medicine, Royal Infirmary of Edinburgh NHS Trust & 2DepartmentACE inhibitor prescription and monitoring in General Practice: the
need for guidelines to prevent acute renal dysfunction. M.J. Kum- of Clinical Bacteriology, Edinburgh University, Edinburgh, Scotland.
Glycopeptide-resistant enterococcus species, especially E. faecalis andwenda1, P. MacDowall, M.O. Roland 2, and P.A. Kalra, 1Depts of Medi-
cine, Glan Clwyd Hospital, Rhyl, Renal Medicine, Hope Hospital, Sal- E. faecium, are increasingly important causes of nosocomial infection.
We report an epidemic affecting 25 patients under the care of a univer-ford, and 2General Practice, University of Manchester, UK. ACE-I
continue to be important in the pathogenesis of many cases of acute sity teaching hospital renal service. Vancomycin-resistant strains (VRE)
of E. faecium were cultured in clinical samples from 2 maintenancerenal failure. In 1996 there were 135 new cases of uraemia (creatinine .
500 mmol/l) treated in the Renal Department of Hope Hospital and dialysis patients. Both had multiple medical problems, had spent a
protracted period in hospital, and been treated with vancomycin. TwoACE-I could be implicated in 9 (7.4%). Renovascular disease was only
present in 3 of these patients; the others were elderly (mean age 76 months later, VRE were cultured in clinical samples from 2 other in-
patients. Subsequently all in-patients in areas where these patients hadyrs) and uraemia was due to intercurrent illness with hypovolaemia
in patients receiving ACE-I and other drug (diuretic, NSAID) therapy. been cared for were screened (rectal swab and faecal culture) for VRE.
17/77 (22%) screened patients were colonised and treated as potentiallyTo determine the pattern of ACE-I prescription and renal function
monitoring in General Practice, postal questionnaires were sent to 400 infectious. VRE was isolated in clinical samples from a further 4 pa-
tients. 9 patients died whilst colonised/infected, 12 became free fromGPs in North Wales. 277 (69.3%) replied and all prescribed ACE-I
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colonisation after a period of time and 4 were discharged into the of late deterioration in renal function. 34 children aged median (range)
10.7 (3.4–23.2) years were studied median (range) 7.9 (4.6–15.7) yearscommunity. No patient died directly as a result of VRE infection, but
it may have contributed as an additional clinical problem in those following D1 HUS. All had been treated with fresh frozen plasma
infusions and dialysis if required clinically. GFR and filtration fractionalready seriously ill. Isolates were identified to species level using the
API 20 Strep system. MIC tests and PCR was used to evaluate the (FF) were measured in using standard inulin and para-amino hippuric
acid clearances prior to (mean of 3 clearance periods) and for 30–150resistance genotype of each organism. Relatedness was evaluated using
restriction endonuclease digestion (RED) and pulsed-flow gel electro- minutes (3 clearance periods) following an oral load of 1 g/kg protein
in the form of a hamburger or chickenburger. The highest inulin clear-phoresis. E. faecium was isolated from 21 patients and E. faecalis from
6 patients (some were colonised with both). The outbreak strain was ance of the three post-loading periods was defined as the stimulated
GFR. The RFR was the difference between the stimulated and basalidentified as an E. faecium RED type A with VanA genotype. In the
majority of cases this or a related strain was isolated suggesting that GFR, expressed as a percentage of the basal GFR. Normal values
were taken from published data [2]. 17 technically imperfect studiesthe epidemic resulted from clonal spread of this strain. All colonised
patients were isolated within a single ward area. Segregated dialysis were discarded. The remaining 17 cases had a CV , 15%.
facilities were provided. Patient transfer between clinical areas was
restricted. The frequency of cleaning of surfaces and toilet areas was Median
increased. The use of parenteral and oral vancomycin was severely Test (interquartile range) Normal
curtailed. Rigorous attention was paid to hand-washing and wearing
Baseline GFR (ml/min/1.73 m2) 108.76 (102.24–119.68) 203.9plastic aprons. With this approach the epidemic was contained and no
RFR (% of baseline GFR) 14.95 (10.94–18.46 ) 27.3%new cases have developed in the following 18 months.
Pre protein FF 0.20 (0.17–0.22) 0.2
The median GFR was normal and no child had a GFR , 80 ml/min/Urinary tract infections are overlooked in children under 2 years in
1.73 m2. However, median RFR was only half normal and in 4 casesprimary care. K. Verrier Jones1, M.L. Lee1, and R. Barnes2, Departments
was ,10%. Median FF was normal. In summary, there was no evidenceof 1Child Health and 2Microbiology, University of Wales College of
of hyperfiltration but renal reserve was reduced despite a much lowerMedicine, Royal Infirmary and University Hospital of Wales, Cardiff.
incidence of reduced GFR than expected.The incidence of urinary tract infection (UTI) is greatest in the first
1. Fitzpatrick M et al. Long term renal outcome of childhood haemo-two years of life. It is particularly important to diagnose and treat
lytic uraemic syndrome. BMJ 303:489–492, 1991infections promptly in toddlers and babies because of the increased
2. DeSanto N et al. Renal functional reserve in children with andrisk of renal scarring in this age group. At this age children are not
without renal disease. Nephron 59:1–6, 1991able to localise pain, and symptoms related to micturition are rare
when children are in nappies. Even if UTI is suspected in a sick or
febrile infant, urine collection is difficult and they cannot co-operate.
Does referral to a renal clinic slow the progression of diabetic nephrop-Although 5%–25% of children investigated following UTI have renal
athy? An audit of 100 consecutive referrals. C.J. Burton and T.G.scarring, new scars develop relatively infrequently after the diagnosis
Feest, Richard Bright Renal Unit, Southmead Hospital, Bristol. 100has been established, except when there are recurrent infections, ves-
consecutive patients were referred for diabetic nephropathy over 5ico-ureteric reflux and delays in starting treatment. The aim of this
years to a single nephrologist. Referral was from 8 diabetic clinics andstudy was to confirm our hypothesis that urine infections in children
GPs covering 1.5m population. Renal biopsy was only performed whenunder 2 are overlooked in the community, using the microbiology
there was doubt of diagnosis. Blood pressure, serum cholesterol,database. Urine culture results from in-patients, out-patients and from
HbA1c, and progression of renal failure were analysed. 51% wereprimary care were retrieved from the microbiology computer and ana-
male, 41% insulin dependent, mean age 56 (26–79). 12% were onlysed by source, age and outcome (infected, contaminated or sterile).
inappropriate drugs for the degree of renal function (4 patients onSamples from primary care were reviewed for each practice in relation
metformin and 4 on fibrates). Plasma creatinine was .150 mmol/l into population size.
76% and .500 mmol/l in 28%. Of those with creatinine . 150 mmol/l
33% had undiagnosed hyperparathyroidism (PTH . 20pmol/l). Hyper-
Age ,2 years 2–16 years .16 years Total cholesterolaemia (.6.5 mmol/l) was present in 34%, HbA1c . 7.5%
in 55%. Hypertension, present in 85%, was uncontrolled in 63% age ,In-patient total 1503* 3640 17294 22437
60 years (.140/80) and 53% age . 60 years (.160/90). 45 patients haveInfected 88 374 4081 4543
been dialysed, 25 within less than 6 months of referral. Of those withGP total 342* 2865 18537 21744
creatinine . 150 mmol/l who survived 6 months without dialysis, thereInfected 45 403 4113 4561
were significant improvements in hypertension, cholesterol, and HbA1c.
In primary care, significantly fewer samples were sent from children
Systolic BP Diastolic BP Cholesterol HbA1cunder 2 than for all other age groups, in contrast to the number of
mm Hg mm Hg mmol /l %samples sent after admission to hospital, which was significantly greater
than for other age groups (*p , 0.001). The number of samples sent At referral 159 63 8261 6.260.2 7.9 60.3
from individual practices varied from 0–100, median 4.5. In some prac- After 6/12 148 63 7662 5.760.2 7.0 60.3
tices UTIs in children under 2 years are under-diagnosed because urine Probability ,0.0001 ,0.01 ,0.0001 ,0.005
is not collected. This has serious implications for renal scarring and
its sequelae. Of 41 patients with sufficient data for analysis, 12 showed a significant
improvement in the rate of decline of renal function following referral
to the renal clinic. This is estimated to have saved 11 patient years of
Renal reserve is decreased in the face of normal inulin clearance in dialysis to date, worth approximately £250,000. In conclusion the rate
the long term following childhood diarrhoea associated haemolytic of progression of diabetic nephropathy can be reduced. Nephrology
uraemic syndrome. C. Nevard, C. Turner, N. Dalton, K. Walker, E. clinics are currently the most effective means of achieving this. Referral
Jones, and G. Haycock, Department of Paediatric Nephrology, Guy’s of diabetics to renal clinics is frequently too late even for adequate
and St Thomas’ NHS Trust, London, UK. Diarrhoea associated haemo- preparation for dialysis.
lytic uraemic syndrome (D1 HUS) is the commonest cause of acute
renal failure in childhood. Although 90% of cases appear to recover
normal renal function in the short term, a recent British long term Ambulatory blood pressure and left ventricular hypertrophy in protein-
follow up study [1] suggested an 18% incidence of reduced glomerular uric patients. M. Thomas, S. Carr, and S.J. Carr, Renal Unit, Leicester
filtration rate (GFR) in the long term. We hypothesised that some General Hospital. The decline of renal function in patients with heavy
children might have increased filtration fraction or reduced renal func- proteinuria is slowed by aggressive control of their blood pressure, yet
the best means of assessing their blood pressure is unknown. Lefttional reserve (RFR) despite normal inulin clearance and be at risk
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ventricular hypertrophy (LVH) is an important predictor of cardiovas- ceptable toxicity of the proposed treatments; the other half were unwill-
ing to randomise patients to a “supportive treatment only” group.cular morbidity, but the method of blood pressure measurement which
best correlates with LVH in proteinuric patients is unknown. The Reasons for qualified support were split in a very similar way between
concerns about the ethics of a no treatment group and concerns aboutability of routine clinic BP, standardised clinic BP, nurse initiated
automated BP and 24 hour ambulatory BP (ABPM) measurements toxicity. Estimated numbers of suitable patients varied from 20 per
year to 1 in every 2–3 years. Comments were made by about a third ofto predict LVH in proteinuric patients are the subject of a continuing
study. 13 adults (9 males) with glomerular disease and significant pro- respondents, sometimes in great detail. The most frequent suggestions
concerned use of ACE inhibitors and statins, blood pressure targets andteinuria (median urinary protein 6.3 grams/day) have been studied.
Mean clinic blood pressure was calculated from those recorded by modified entry criteria. Feedback from Renal Association members has
been very useful in finalising the trial protocol, and the trial is nownephrologists in the three clinic visits immediately prior to study entry.
ABPM was performed using a Spacelabs monitor. LV mass was mea- ready to launch. The level of support offered by respondents suggests
that it should be possible to recruit the necessary 120 patients withinsured by echocardiography. The relationships of routine clinic blood
pressures and ABPM to LV mass index (LVMI, grams/m2) are pre- two years.
sented here. LVMI was above the upper limit of normal in 6 of 13
patients (46%). LVMI showed limited correlation with routine BP
measurements (r 5 0.46 and 0.51 for mean systolic and diastolic pres- Factors influencing decision for dialysis selection: a prospective audit.
P.F. Naish1, S.J. Davies1, G.I. Russell 1, A. Pryce2, E. Pendleton2, andsures, respectively). LVMI showed only slightly better correlation with
mean ambulatory whole day systolic BP (r 5 0.52). However, LVMI H. Kennedy2, Departments of 1Nephrology and 2Clinical Audit, North
Staffordshire Hospital Trust, Stoke on Trent, United Kingdom. Prospec-showed quite close correlation with mean whole day diastolic BP (r 5
0.71). A whole day diastolic BP of over 80 mm Hg was associated with tive documentation of factors influencing the decision to select patients
for dialysis has been undertaken in this unit since September 1994.a clearly elevated LVMI (.140 grams/m2). Only two patients had mean
routine diastolic BPs of 100 mm Hg or more, and both had LVH. Thus This report contains information from the first two years. The audit
is part of a prospective study which includes measures of outcomesmost of the proteinuric patients who had LVH had no evidence of
overt poor control of clinic blood pressure. Prevention of LVH in and factors which may influence them. Data analysed for this report
were demographic, original kidney disease and comorbidity (ischaemicpatients with glomerular disease may require aggressive control of BP,
monitored with ABPM. heart disease, peripheral vascular disease, left ventricular (LV) dys-
function, malignancy, systemic collagen vascular disease, diabetes and
other). 167 patients were considered for dialysis during the period,
median age 67 years (range 15–93), 100 male, 67 female. The mainCommunity Nephrology: Audit of screening for renal insufficiency in
a high risk population. Lu Kissmeyer and G.H. Neild, Institute of categories of original renal disease were glomerulonephritis (14.8%),
renovascular disease (14.8%) and diabetic nephropathy (16.6%). Ade-Urology and Nephrology, UCL Medical School, UCL, London. The
rate of acceptance on to dialysis programmes has doubled in the past quate data were available for 153 patients, 110 (71.9%) of whom were
taken onto dialysis. Univariate analysis showed that age, individual10 years and is steadily increasing. Early treatment of progressive
failure can significantly slow the rate of progression. We have investi- comorbidity factors and total number of comorbidity factors were
significantly related to selection decision. The statistical package Gen-gated whether it is feasible to screen for patients in primary care who
are at increased risk of developing renal failure. 12 General Practices eralised Linear Modelling (v.4.8, Royal Statistical Society, 1992) was
used to examine the interactive effects of these variables. This showedfrom inner and greater London were recruited. This achieved a base
population of 71,091 patients. Of these, 2,603 (3.7%) patients, aged that LV dysfunction was the most powerful influence on selection
decision (p . 0.0001), and that there were significant interactions50–75 years, were identified as being either hypertensive or diabetic
or both. We audited their records to see if they had had their blood between this and age, and between age and the possession of any
comorbidity factor. In patients without LV dysfunction, but with orpressure measured and urine tested for protein within 12 months, and
plasma creatinine measured within 24 months. 1359 of 2561 (53.1%) without other comorbidity, age alone did not significantly influence
dialysis selection.audited had had a plasma creatinine measured within 24 months, of
whom 11% (150) had a value above 125 mmol/l. This equates to a
prevalence of renal insufficiency of more than 110,000 patients per
Is maintaining the intracellular:extracellular fluid compartment ratiomillion of this population. Of these, 42 (28%) had been referred to a
an important consideration in Haemodialysis? C.C. Yeng1, S. Baigent 2,Nephrologist. 1298 of the 2,603 patients were audited for blood pressure
and R. Unwin3, 1Imperial College of Science, Technology and Medicine,and 72% (937) had had their blood pressure checked within 12 months.
London, 2Centre for Nonlinear Dynamics and Its Applications, UCL,1140 records were audited for urine protein and 29% (329) of these
London and 3Centre for Nephrology, UCL Medical School, London.patients had had their urine tested within 12 months. Of those who
Profiled dialysis (PD) is one approach to preventing osmotic and chemi-had their urine tested, 14.6% had proteinuria. This study showed that
cal disequilibrium during haemodialysis. Typically an initially raisedit is feasible to detect renal insufficiency at a primary care level and
dialysate sodium concentration serves to offset the fall in extracellularconfirms the high prevalence of chronic renal insufficiency in a high
osmolarity and subsequent loss of extracellular fluid. While PD hasrisk population of patients with diabetes and hypertension.
improved intradialytic tolerance in some patients, it may remove insuf-
ficient quantities of sodium, urea and other solutes, leading to longer-
term complications such as hypertension. We have developed aFeedback from Renal Association members about proposed trial in
membranous nephropathy. Peter Mathieson (on behalf of the Renal bi-compartmental model for a typical PD session, with the aim of
providing a predictive tool to help determine a suitable dialysis profileAssociation Glomerulonephritis Clinical Trials Group), Academic Re-
nal Unit, Southmead Hospital, Bristol. We have designed a multicentre and improve the effectiveness of dialysis. Given a set of patient parame-
ters and machine settings, the model computes the evolution of intracel-clinical trial in which patients with membranous nephropathy whose
renal function is deteriorating will be randomised to one of three lular (IC) and extracellular (EC) volumes and concentrations of sodium
and urea, as well as the total mass of sodium and urea removed, duringgroups: supportive treatment alone; additional cyclosporin 5 mg/kg/
day; or Ponticelli regimen (prednisolone and chlorambucil). We sent a dialysis session. The model has provided a theoretical insight into
the interplay of diffusion, ultrafiltration and osmosis and suggests thatthe draft protocol to practising adult nephrologists identified from the
Renal Association membership list and invited them to indicate (a) an important parameter predicting the tolerance of a patient to PD
might be their intradialytic IC:EC compartment fluid volume ratio.whether they would participate (b) if not why not (c) the number of
suitable patients they would expect to see per year and (d) any com- We are currently investigating methods for establishing equilibrium
volume ratios in normal and ‘routine’ dialysis patients to evaluate thisments on the protocol. 180 nephrologists were sent papers; the response
rate was approximately 64%. Overall, 85 (75.2% of respondents) indi- hypothesis. While maintaining this ratio may be a good strategy for
reducing intradialytic morbidity, it also needs to be accompanied bycated unequivocal support for the trial, 15 (13.3%) unequivocally de-
clined to participate, 13 (11.5%) gave qualified support. Approximately adequate removal of electrolytes and middle molecules for long-term
effectiveness. Optimal control theory may help determine profiles thathalf (8) of those not wishing to participate gave as their reason unac-
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best achieve this compromise, and could suggest improvements of the There was no difference between short and long dialysis in any of the
outcome variables as seen in the table (mean 6 sem).Kt/V ratio and other standard measures of dialysis efficacy.
Treatment duration
Is short duration haemodialysis safe? A systematic review of the evi- Short Long
dence. C. Daly, M. Campbell, J. Cody, C. Donaldson, A. Grant, I.
Duration of dialysis (mins) 14760.26 241 60.19Khan, P. Lawrence, L. Vale, S. Wallace, and A. MacLeod, Department
Delivered Kt/V (UKM) 1.28 60.01 1.28 60.01of Medicine and Therapeutics, Health Services Research Unit and Health
Dry wt (kg) 65.962.8 65.3 62.6Economics Research Unit, University of Aberdeen, Aberdeen. The an-
Plasma creatinine (lmol /l )* 947 653.1 913 652.7nual mortality among U.S. dialysis patients increased as the average
Serum urea (mmol /l )* 26.061.41 24.7 61.8haemodialysis treatment times decreased. The objective of this study
Blood total CO2 (mmol /l )* 21.460.7 22.2 60.52was to ascertain the effect of shortened haemodialysis treatment dura-
Serum Pi (mmol /l )* 1.9660.12 1.86 60.14tion (,10 hours per week) on patient morbidity, mortality and resource
Serum albumin (g/l )* 40.260.72 39.8 60.63use. We undertook a systematic literature review using the Cochrane
PCR (g/kg ideal body weight ) 0.93 60.04 0.89 60.05Collaboration methodology. Literature searching to identify random-
Hb (g/l )* 9.7 60.27 10.060.25ised controlled trials included electronic database searching (five data-
24 hr mean arterial pressure (mm Hg) 103.563.1 100.4 64.3bases), hand-searching of Kidney International, contacting authors and
checking references of studies. A Peto’s odds ratio was calculated for * Pre-dialysis
dichotomous data and a (weighted) mean difference for continuous
This study suggests that over a 3 month period, patient outcome isdata. Only a single study with 165 randomised patients was identified.
not adversely affected by decreased duration of dialysis provided thatThere was no significant difference in mortality (OR 0.53, 95% C.I.
solute clearance is maintained.0.05 to 5.15). Morbidity as reflected by hospitalisation rates was greater
in the short duration dialysis group (OR 2.85, 95% C.I. 1.39 to 5.85).
There was no conclusive difference in the incidence of intradialytic
High flux haemodialysis maintains lower serum Beta-2-microglobulinadverse symptoms between the groups. Blood pressure control was levels than conventional haemodialysis regimes. A. Cruickshank, T.worse in the short duration dialysis group as indicated by predialysis Pickett, K. Farrington, R. Greenwood, J. Tattersall, D. Taube, and A.
systolic blood pressure (mean difference 7.5 mm Hg, 95% C.I. 3.1 to Davenport, Renal units, Lister Hospital, Stevenage, Royal Free Hospital,
11.8), predialysis diastolic pressure (mean difference 2.9 mm Hg, 95% London, St Mary’s Hospital, London. We measured serum Beta-2-
C.I. 0.5 to 5.2), and predialysis mean arterial blood pressure (mean microglobulin (B2m) levels in 283 patients who had received regular
difference 3.4 mm Hg, 95% C.I. 0.0 to 6.9). There may be significantly haemodialysis treatment for at least 3 months at 3 units using different
increased morbidity associated with short duration dialysis. A large modalities: centre 1—73 patients using high flux polysulphone mem-
multi-centred pragmatic randomised controlled trial(s) comparing branes: centre 2—72 patients using low flux polysulphone membranes:
haemodialysis treatment duration policies with minimum exclusion centre 3—138 patients using conventional cuprophane membranes.
criteria and lengthy follow-up is required. In the interim standard Patients with myeloma, light chain disease and other haematological
dialysis duration should remain the recommended treatment. malignancies were excluded. Mean serum B2m levels were lower in
centre 1 (22.3 6 5.4 mg/l) than in centre 2 (43.4 6 13.7 mg/l: p ,
0.001) and centre 3 (37.6 6 13.1 mg/l: p , 0.001). B2m levels were
higher in centre 2 than in centre 3 (p 5 0.003). Mean duration ofAdequacy of haemodialysis—the long and the short of it. G.H Hartley,
dialysis was similar in centres 1 and 3 (39.9 6 36 and 39.8 6 36.9T.H.J Goodship, T. Hawkins, P.R.W. Fawcett, and J.S Tapson, Depart-
months: p 5 ns), but was greater in centre 2 compared to the othersments of Medicine and Medical Physics, University of Newcastle upon
(67.9 6 56.6 months: p , 0.001 cf both). When confined to patientsTyne. Decreased duration of haemodialysis has been implicated as a
dialysed ,50 months, B2m levels and duration were not significantlyfactor responsible for the increased morbidity and mortality reported
different in centres 2 and 3. Estimates of residual renal function (ureain several series. However, there have been no randomised controlled
clearance) were available in all patients at centre 1 and were signifi-trials examining whether duration of dialysis itself adversely affects
cantly correlated with B2m levels (r 5 20.528: p , 0.001). At centresoutcome. In this study we have examined the effect of reducing treat-
2 and 3 B2m levels were correlated with duration of dialysis (r 5 0.279:ment time whilst maintaining constant solute clearance. 14 patients have
p , 0.001). At centre 1 B2m levels were identical in patients dialysedeach been studied for a total period of 36 weeks. They were randomly
for up to 5 years and those dialysed for 5–10 years (22.1 6 5.8 vs. 22.9 6assigned to one of the 4 treatment groups shown below to avoid a
3.9 mg/l). However B2m levels were significantly higher in the lattertreatment carry-over effect.
comparable groups at both centres 2 (45.6 6 8.4 vs. 38.7 6 15.8 mg/l:
p 5 0.033) and 3 (43.6 6 8.8 vs. 36.7 6 13.0 mg/l: p 5 0.006). This
Treatment group Weeks 1–12 Weeks 13–24 Weeks 25–36 data indicates that: firstly, membrane permeability characteristics are
a more important determinant of serum B2m levels in chronic haemodi-A Short Short Long
alysis than membrane chemical composition: secondly, high fluxB Short Long Long
haemodialysis reduces accumulation of B2m in long term treatment.C Long Long Short
The effect of high flux treatment on deposition of dialysis associatedD Long Short Short
amyloid remains to be elucidated.
The dialysis prescription (total Kt/V) was not changed on entering the
study and was maintained during short (#150 min) and long dialysis Outcomes in chronic renal failure requiring dialysis: patients over 75
($240 min) by varying blood flow, dialysate flow and dialyser surface years may fare as well as patients with diabetes. M.C. Venning, N.M.K.
area. The delivered Kt/V was assessed by the measurement of pre Reid 1, J. Barker 1, B. Coyle 1, and the North West Regional Renal Out-
and post dialysis blood urea concentration. To ascertain that solute comes Group, Department of Nephrology, South Manchester University
clearance did not differ in the short and long treatment periods, frac- Hospitals NHS Trust, Manchester, UK, and 1Department of Clinical
tional urea clearance was also assessed once during each treatment Audit, South Manchester University Hospitals NHS Trust, Manchester,
period by measuring both the urea concentration in spent dialysate UK. The North West Regional Renal Outcomes Programme has pro-
and total body water using 3H2O. The measurements used to assess spectively collected outcome data from 1005 patients (614 CAPD,
outcome at the end of each period were a full biochemical and haemato- 253 unit haemodialysis and 138 home haemodialysis patients). Patient
logical profile, protein catabolic rate, 24 hr ambulatory blood pressure, perceived outcome was obtained via a self report health status question-
nerve conduction studies, anthropometry and the Nottingham health naire incorporating the Nottingham Health Profile (6 measures) and
profile. Within patients the delivered Kt/V was uniform throughout Cantril’s ladder (1 measure). Clinical outcome was assessed by renal
unit staff via the Karnofsky Performance Status Scale and length ofthe 3 treatment periods and fractional urea clearance did not vary.
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stay data, thus providing 9 measures in total. Overall, 5 outcomes measured intra-dialytic hypotension (values are mean 6 sem, *p ,
0.05, **p , 0.01 vs. without hypotension).deteriorated with age and 2 outcomes (life satisfaction and emotional
reactions) improved with age (p , 0.05). In the patients (n 5 676)
with standard primary renal disease (SPRD), renal failure attributed Total Free Acyl:free
to hypertension (n 5 132) and diabetic renal disease (n 5 91) 6, 3 and carnitine carnitine carnitine
1 of the outcome measures deteriorated and 1, 2 and 0 improved with (lmol /l ) (lmol /l ) ratio
age respectively. Outcome was significantly worse in 7 of the 9 outcome
Without hypotension 27.062.7 18.862.0 0.5860.06measures (p , 0.05) when diabetic patients were compared to SPRD
With hypotension 18.462.2* 10.961.7** 0.7860.15patients. In contrast, outcome was only found to be significantly worse
in 1 outcome measure (p 5 .015) when patients with hypertension
Low carnitine levels are observed in haemodialysis patients and corre-were compared to the SPRD patients. Outcome in SPRD patients
late with length of time on dialysis not dialysis adequacy or nutrition.over 75 years (n 5 50) was significantly different (p , 0.05) in 2 of
Patients with low levels have poor functional status and intra-dialyticthe 9 outcome measures (one worse one better) when compared to
hypotension which could improve with carnitine supplementation.SPRD patients aged 55-64 (n 5 139). However, there was no statistical
difference on comparison with the SPRD patients aged 65-74 (n 5
154). When SPRD patients over 75 years were compared to the diabet-
Effect of the oral b2 agonist Clenbuterol on lean body mass in CAPDics under and over 55 years (n 5 43 and n 5 48 respectively), their
patients. C.H. Jones, E.J. Will, A.M. Davison and C.G. Newstead,outcomes were better (p , 0.05) in 3 and 5 of the 9 outcome measures
Department of Renal Medicine, St James’s University Hospital, Leeds,respectively. The outcomes programme has confirmed that age and
LS9 7TF. Malnutrition is common in patients on dialysis. Clenbuterol isprimary disease influence outcome. However, those over 75 with stan-
a long acting oral beta 2 agonist used in the management of obstructivedard primary renal disease appear to fare better than diabetics, even
airways disease (unlicensed in the UK). In experimental animals clen-those under 55 years. Rigid age based purchaser criteria for offering
buterol increases lean body mass (LBM) and decreases fat mass, withdialysis may be inappropriate.
no change in total body weight, both in health and disease models. It
has been used by the agricultural industry and by performance athletes
for this reason.We have investigated its effect on LBM in stable CAPDEvaluation of intravenous carnitine in 5 haemodialyis patients. E. Bailey,
patients in a prospective randomised double blind crossover study ofM. Garrues, R.A. Coward, and L.R. Solomon, Department of Renal
clenbuterol (40 mg/day) or placebo each given for 6 months in 8 patientsMedicine, Royal Preston Hospital, Preston, England. Total and free
with persistent unexplained hypoalbuminaemia. All were supple-carnitine levels were measured in 15 long-term (.36 months) haemodial-
mented with a single morning exchange of 1.1% amino acid dialysisysis patients. Acyl carnitine and the acyl to free (AC:FC) carnitine
solution throughout the study. LBM was assessed at baseline and atratio were calculated. All 15 patients were found to be carnitine defi-
completion of each treatment phase by whole body electrical imped-cient (AC:FC ratio . 0.4). 5 patients with the highest AC:FC ratios
ance (measured at 25 frequencies) and anthropometry (derived fromwere given intravenous carnitine supplements for 3 months and its
skinfold thickness at four sites). Results (mean 6 sd), weight and LBMeffect on haemoglobin, cardiac function and quality of life was assessed.
in kg, are shown below (Wilcoxon rank pair test: ap , 0.05, baseline4 out of 5 patients were still carnitine deficient at the end of the
vs intervention; bp , 0.05, placebo vs clenbuterol).treatment period. There was no significant effect on haemoglobin, left
ventricular ejection fraction or quality of life as determined by the
Baseline Placebo ClenbuterolNottingham Health Profile and Cantril’s Ladder. All patients reported
a subjective improvement in general health. We conclude that: 1) 3 ‘Dry’ weight 63.9611.9 63.7611.0 64.2611.4
months treatment with intravenous L carnitine in a dose of 20 mg/kg % fat (anth) 29.869.1 29.2610.9 28.4610.4
post dialysis is insufficient to replenish carnitine stores. 2) There is no % fat (bio) 30.7 67.4 32.969.6 30.168.4b
significant beneficial effect on haemoglobin or cardiac function. This LBM (anth) 44.4 18.0 44.517.1 45.568.2a
may in part be due to the patients remaining carnitine deficient. 3) LBM (bio) 44.0 67.8 41.866.1 44.666.4b
Carnitine supplementation probably does improve quality of life but
out questionnaire was not sensitive enough to detect this objectively. ‘Dry’ weight did not change. Compared to baseline, LBM by anthro-
4) Routine use of carnitine supplementation in long term haemodialysis pometry had increased at the completion of the clenbuterol period,
patients cannot be justified without further evidence of its efficacy. 5) but had not changed in the placebo period. Percent fat mass was
A large placebo-controlled trial is needed. decreased and LBM increased at completion of clenbuterol as com-
pared to completion of placebo, although only bioimpedance measure-
ments showed statistical significance. Substitution of a single daily
Reduced serum carnitine levels in haemo-dialysis patients are associ- amino acid exchange had no effect on LBM in CAPD patients over
ated with intra-dialytic hypotension and reduced functional activity a six month period. Addition of oral clenbuterol at a dose of 40 mg/day
status. S.J. Riley, S. Rutherford, and P.A. Rutherford. Institute of Ne- resulted in a statistically significant increase in LBM when administered
phrology, University of Wales College of Medicine, Wrexham Maelor over the same interval.
Hospital, Clwyd, UK. L-carnitine is a quaternary ammonium com-
pound involved in fatty acid b-oxidation which is essential in tissues
using fatty acids for their energy needs such as skeletal and cardiac Pruritus in patients on peritoneal dialysis. A. Stein1, T.O. Bleiker, J.F.
muscle. Haemo-dialysis patients may develop reduced free carnitine Bourke, J. Lear, R. Mumford, J. Harling, P.E. Hutchinson, J. Walls1,
levels and an increased ratio of acyl:free carnitine because of reduced Dept of Dermatology, Leicester Royal Infirmary; 1Renal Medicine,
dietary intake of meat and dairy products, reduced renal synthesis and King’s College Hospital, KCSMD, London; and 2Dept of Nephrology,
loss during haemodialysis. Certain common clinical conditions in haemo- Leicester General Hospital. Pruritus is one of the complications of end-
dialysis patients (malaise, muscular weakness, cardio-myopathy and car- stage renal failure. Little is known about its pathophysiology. The
diac dysrrhythmias) may be related to carnitine metabolism. The present purpose of this study was to estimate the proportion of peritoneal
study measured serum carnitine levels by specific radio-enzymatic assay dialysis (PD) patients experiencing pruritus; and investigate possible
in 30 adequately dialysed haemodialysis patients (urea Kt/V . 1.6, links between pruritus, renal ‘bone’ disease parameters and the pres-
NPCR . 1.0). 25 patients had low free carnitine or increased ratio of ence of dry skin. Eighty-seven PD patients (50 male, average age 58
acyl:free carnitine compared to normal subjects. Carnitine levels did years) were assessed. Patients were asked to score their pruritus using
not correlate with dialysis adequacy or nutritional status. There were a visual analogue scale (VAS) and a purpose-designed quality of life
significant negative correlations between serum free carnitine and age questionnaire. Patients were examined for signs of skin disease, and
(r 5 0.34, p , 0.05) and length of time on dialysis (r 5 0.37, p , 0.05). the serum total adjusted calcium, phosphate, calcium-phosphate prod-
There were significant correlations between the Karnofsky Activity uct and PTH were measured or calculated. Sixty-two (71%) of patients
Scale score and free carnitine (r 5 0.45, p , 0.05) and acyl:free carnitine had suffered pruritus to some degree over the previous week. Nineteen
(22%) complained that pruritus had interfered to a moderate or severeratio (r 5 20.37, p , 0.05). Patients were sub-divided on the basis of
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degree with day-to-day activities or interpersonal relationships. The been vaccinated were questioned further (Table: Percentages represent
proportion of total number of respondents).degree of pruritus, measured by the VAS, correlated with serum PTH
(p 5 0.004, r 5 0.35, multiple regression analysis). None of the other
parameters measured correlated with degree of pruritus. Presence of Patient Patient
dry skin did not correlate with degree of pruritus. Pruritus is a common unaware Patient Patient felt thought
and disabling problem for PD patients. A correlation between pruritus vaccine doubted vaccination vaccination
and PTH levels was found. was efficacy of was may be
available vaccine unnecessary harmful Others
1993 19 (8%) 5 (3%) 59 (25%) 22 (10%) 11 (5%)
Towards achieving the Renal Association standard for haemoglobin: 1995 3 (1.5%) 8 (5%) 18 (7%) 11 (4%) 10 (4%)
P ,0.001 NS ,0.001 ,0.05 NSAudits from the North West Region. P.A. Kalra, J. Barker1, N.M.K.
Reid1, and the North West Regional Renal Audit Steering Group, Depart-
ment of Nephrology, Salford Royal Hospitals NHS Trust, Hope Hospi- There has been a favourable change in patient attitudes to vaccination
tal, Salford, UK and 1Department of Clinical Audit, South Manchester with fewer patients regarding vaccination as “unnecessary” or “harm-
ful”. It may well be that this underlying change has been the mostUniversity Hospitals NHS Trust, Withington Hospital, Manchester, UK.
important factor in improving vaccine uptake. We will continue toA collaborative programme of regional clinical audit allowed the use
encourage our patients to seek immunisation by an annual postalof Erythropoeitin (EPO) to be evaluated in the dialysis population of
reminder and ongoing patient education. We suggest that primary carethe North West (NW) Region, with particular reference to the agreed
doctors should further improve recall systems to offer these patientsRenal Association standards for haemoglobin (.10 g/dl) and ferritin
vaccination. This may require the setting of targets by the Department(.100 mg/l). The audit methodology was prospective and cross sec-
of Health.tional; the initial audit involved the old NW region, but the re-audit
included dialysis patients within the new regional configuration. Data
was recorded from 750 patients in 1994, and 1428 patients (460 from
Body composition and dialysis times in Haemodialysis patients. A.J.Merseyside) in 1996. EPO use increased between the audits (from
Williams, and A. McArley, Depts. Of Renal Medicine and Dietetics,42% to 55% of the dialysis patients in the old region, but to 52% overall), Gloucestershire Royal Hospital, Gloucester, U.K. The dose of dialysis
as did the proportion of patients achieving target haemoglobin (from affects morbidity and mortality of HD patients, and is probably linked
40% in 1994 to 45% in 1996 or 48% excluding patients in the initiation with nutritional status. A significant proportion of HD patients show
phase of EPO therapy). Proportionately more haemodialysis (HD) evidence of malnutrition. This cross sectional study of anthropometric
patients than Continuous Ambulatory Peritoneal Dialysis (CAPD) indices of haemodialysis patients was undertaken to investigate the
patients received EPO in 1994 (51% vs. 34%) than in 1996 (53% vs. prevalence of malnutrition. Anthropometry, to measure triceps (TSF),
49%) although in 1996 fewer HD patients (45%) than CAPD patients biceps (BSF) skinfold thickness and mid upper arm muscle circumfer-
(61%) achieved target haemoglobin. The proportion of all patients ence (MUAMC), was performed in a random sample of 230 HD pa-
achieving the ferritin standard increased from 65% to 75% between tients in the South West. The median age was 68.0 yrs, (range 18–95),
comprising 142 males and 88 females. Diabetic patients had signifi-1994 and 1996 although there was little change in the proportion of
cantly greater BMI values than non diabetics, (male, n 5 27, 24.9 vsEPO treated patients achieving the standard (72% in 1994 and 74%
22.9, p , 0.01, female n 5 9, 28.5 vs 22.8, p , 0.05) and the TSF andin 1996). Proportionally fewer EPO treated patients had both haemo-
BSF of diabetic males were greater than non diabetics, (p , 0.01, p ,globin and ferritin below the standard in 1996 (13%) than in 1994
0.001, respectively). There were no differences between the skinfold(18%). Perhaps of most significance, of the patients not receiving EPO
thicknesses of the female subgroups. Sixty per cent of male HD patientsin 1996, 396 (57%) had a haemoglobin and 187 (33%) a serum ferritin
were on or below the 10th centile for MUAMC, values of MUAMCbelow target. The audits indicate that the Renal Association standards
for females were similar to the normal population. The TSF of malewould be more readily achieved within this region if a protocol, that
HD patients were similar to the normal population, but 40% of femalefacilitated early recognition of poor responders and focused greater
patients were on, or below, the 10th centile. Those patients who receivedattention on the importance of iron repletion, were to be uniformly
less than 12 hours of HD/week had significantly lower values of serumimplemented. Many dialysis patients who could potentially benefit albumin (36.0 vs 39.0, g/l, p , 0.001), and also differences in body
from EPO still do not receive it. We are working towards a regional composition were noted, in that these patients had significantly lower
protocol through a process of further audit and education. values of MUAMC (males, 23.6 vs 24.5, cms., p , 0.01, females, 22.1
vs 23.5, cms., p , 0.01) and also the TSF in the females was reduced
(12.0 vs 18.4, mm., p , 0.001). These results show that, 1) Male dialysis
patients have evidence of moderately severe malnutrition as shownThe uptake of influenza vaccination by patients receiving renal replace-
by the reductions in somatic protein stores (MUAMC), 2) Femalement therapy. M.J. Wright, K. Bel’eed, S. Bhandari, D. Eadington,
patients have evidence of reduced fat stores (TSF). These changes,M.J. Farr and L. Sellars, Renal Unit, Hull Royal Infirmary, Hull, UK.
together with reduced serum albumin levels, are most pronouced inInfluenza infections cause considerable morbidity among patients with
those patients dialysing for shorter periods.renal failure. Influenza vaccine provides 70–80% protection against
infection. We sought to determine the uptake of vaccination in our
population and to improve it by means of a postal reminder. Patients
Determination of Total Body Water by Anthropometry and the Wat-were questioned in 1994 about their uptake of influenza vaccine during
son formula. A.J. Williams, Dept. Of Renal Medicine, Gloucestershirethe previous autumn. In 1995 a letter was posted to those receiving
Royal Hospital, U.K. Determination of the volume of distribution ofrenal replacement therapy recommending that they seek vaccination. urea (V) used in urea kinetic modeling is generally a derived value,
A further survey was performed in the spring of 1996. In 1994, 228 using the Watson equation, to equate to total body water (TBW). This
patients of a possible 316 responded (72%) whilst 247 patients out of derived value has not been validated for patients suffering with chronic
337 responded in 1996 (71%). We were encouraged to find that vaccine renal failure or on dialysis. A number of studies have found that
uptake had increased from 49% to 79% (P , 0.001). 41 patients anthropometric analysis and bioelectrical impedance are superior
requested vaccination in 1993 compared to 63 in 1995 (26% vs 54% methods to calculate TBW compared to the Watson equation. This
of respondents excluding those offered vaccination; P , 0.001). There study compares the body composition values derived by using the
was a significant rise in the number offered vaccination from 71 to 131 Watson equation to values obtained by anthropometrics in HD pa-
(38% vs 71% of respondents excluding those requesting vaccination; tients. Anthropometric indices of triceps (TSF) and biceps (BSF) skin-
P , 0.001). It appears that our local General Practitioners have im- fold thickness, were taken to calculate body fat by the method of
proved their targeting of high risk patient groups and that our letter Durnin et al. Other calculations include: Lean body mass kg, (LBM) 5
Weight (kg) 2 Body fat (kg), and LBM (kg) 5 TBW (L)/0.73. Measure-was a helpful reminder to our patients. The respondents who had not
Abstracts 2115
ments were performed by 7 trained dieticians, and the interobserver
% of patientscoefficient of variation (sd/mean.100) for TSF and BSF was 3.7%. A
random sample of 230 HD patients in the South West was taken, the Hb,10 Hb 101
median age was 68.0 yrs. (range 18–95), comprising 142 males and 88
Ferr Ferr Ferr Ferrfemales. The correlation coeficients for TBW, LBM and % Body Fat
Centre ,100 1001 , 100 1001determined by anthropometry (A) and Watson formula (W) for males
were 0.92, 0.92 and 0.67 respectively. These values for females were A All patients 14.98 28.09 25.84 31.09
0.92, 0.92 and 0.79. However, the 95% confidence intervals for the Patients not on epo 16.04 24.53 30.19 29.25
difference between the two methods (A-W 6 2sd) for TBW were Patients on epo 14.29 30.43 22.98 32.3
26.28 to 3.56 L (males), and 24.84 to 3.84 L. (females). These values
B All patients 8.22 25 17.43 49.34for LBM were 28.61 to 4.89 kg. (males), and 26.63 to 5.28 kg. (fe-
Patients not on epomales), and for percentage body fat, 27.83 to 13.83 (males), and 28.67
Patients on epoto 11.93 (females). As previous studies have shown the superiority of
C All patients 5.48 34.25 24.66 35.62anthropometric analysis, these results confirm that a degree of caution
Patients not on epo 10.81 18.92 37.84 32.43is needed when using the Watson formula in dialysis patients.
Patients on epo 0 50 11.11 38.89
D All patients 19.37 38.03 20.42 22.18
Effect of late referral to a nephrologist on quality of life of elderly Patients not on epo 13.43 32.84 28.36 25.37
dialysis patients. S.A.C. Harris1, E.A. Brown1, D.L. Lamping 2,4, N. Patients on epo 21.2 39.63 17.97 21.2
Constantinovici 3, L. Henderson4, P. Roderick5, and C. Victor 6, 1Charing
EPO prescription in all dialysis patientsCross Hospital, 2London School of Hygiene and Tropical Medicine,
3Royal Free Hospital School of Medicine, 4KCW Health Commissioning
Agency, 5Wessex Institute of Health Research and Development and at Centre C. The percentage of patients with Hb , 10 not given EPO
6St. George’s Hospital Medical School. Late referral (within 3 months ranges from 11% at Centre D to 29% at Centre C.
of requiring dialysis) to a nephrologist is associated with increased risk • This analysis suggests that some units achieve better results than
of early death on dialysis. This study examined the effect of late referral others from EPO therapy by ensuring patients have adequate iron stores.
on survival and quality of life (QOL) of elderly dialysis patients. 126 • Some centres are giving EPO to large numbers of patients with
patients over 70 years old started maintenance dialysis in 4 North inadequate iron stores.
• Despite similar ferritin figures and EPO usage, unit A achieves betterThames renal units during 1995–96. 17 (13%) died within 3 months
Hb than D, indicating the importance of other factors, possibly Kt/V.of starting. T-tests showed late referral affected survival: the mean
• The percentage of patients with low Hb and high ferritin not offeredtime between referral and first dialysis in 17 patients who died within
EPO varies from 19% to 33%.3 months was 4.0 months (range 0–15.2) compared to 17.3 months
• There is considerable scope for improving practice, improving over-(range 0–107) in the 109 who survived more than 3 months (p 5 0.04).
all Hb, and using EPO more cost-effectively.Of the survivors 45% were late referrals. 77 survivors (35 late referrals)
agreed to enter the QOL study and completed the Medical Outcomes
Study Short Form Health Survey (SF-36) by interview 3 months after
Progress of the National Renal Registry. D. Ansell, T. Feest and thestarting dialysis. Multiple regression analyses were used to examine
Renal Registry subcommittee on behalf of the Renal Association. In thethe effect of late referral on QOL (physical and mental) controlling
last six months the Renal Registry has moved to its own premises andfor comorbidity, albumin and creatinine at the start of dialysis and
employed its own analyst programmer and statistician. It is in themean haemoglobin. There was no significant difference between the
process of connecting to new sites and setting up data transmissionearly and late referrals in terms of QOL. Early referrals were often
links, via the NHS net service. By the end of the year data will befitter at the first dialysis with a higher haemoglobin 10.3 g/dl compared
available from units representing 13.5 million of the English population,to 9.8 (NS), a higher albumin, 34 g/l compared to 31.8 (p 5 0.039) and
plus data transfer from the Scottish Registry. Relocation of the Regis-a lower creatinine, 646 mmol/l compared to 817 (p 5 0.002) even though
try: After completion of the pilot project, it was not possible to continuethey had a higher number of comorbid conditions, 1.68 compared to
at UKTSSA, due to lack of accommodation space. The Renal Registry1.17 (p 5 0.04). The only predictor of physical QOL was comorbidity,
relocated to its own offices at Southmead Hospital in May 1997. This(p 5 0.007). Whereas none of the variables significantly predicted
move has taken time and also been costly. It has forced the Registrymental QOL. This study confirms that the effect of late referral on
to become fully independent, with its own staff, payroll, computersurvival in elderly dialysis patients. However late referral has not been
equipment, software and software/hardware support agreements. Theshown to effect QOL of those who survive.
current cost of running the Registry is around £220,000 per year.
Pop’n Pop’nHaemoglobin, Ferritin and the use of EPO at different centres, the
Sites completed (Ms) In progress (Ms)National Renal Registry. D. Ansell, H. Taylor, S. Cornock, T. Feest
and the Renal Registry subcommittee on behalf of the Renal Association. Bristol 1.5 B’ham (H’lands) 0.5
This is an example of analysis possible when data is available from Gloucester 0.3 Hull 0.7
large numbers of patients in several UK centres. The results should Leeds (St James) 1.5 Middlesbrough 0.7
enable centres to plan and justify changes in practice which may im- Leicester 1.4 Nottingham 0.9
prove patient care and reduce costs. The Hb and ferritin data in the Plymouth 0.4 Stevenage 0.6
first report of data from the Renal Registry presented in March did Sheffield 1.4 Truro 0.3
not address EPO usage. This report explores the inter-relationships Total: 6.5 Total: 3.7
between Hb achieved and serum ferritin and EPO prescription. Inclu- Scotland 5.0
sion criteria: Established ESRF for .90 days and no change in treat-
ment modality within 90 days. Patients on CAPD have a higher Hb Timely Reporting: One of the main criticisms of EDTA Registry has
than those on HD, and an analysis shows that attitudes to prescription been that data was two years out of date at the time of publication.
of EPO (with similar Hb and ferritin) differ between modalities. The The 1997 USRDS report is also based on 1995 patient data. The
EPO prescription differs between centres, with Centre C rarely pre- Australian and Italian Regional Registries are similar. Such delay is
scribing EPO if the ferritin is ,100. inevitable if paper returns are accepted. With a fully electronic data
Unit A achieves a better Hb than D despite similar ferritin distribution return to the Renal Registry, reporting will be on the current year’s
and lower use of EPO. Unit C has higher ferritin and achieves similar data. This will be of help to both providers and commissioners of renal
Hb to D with lower EPO use. The proportion of HD patients with services. Registry Finance: Sponsorship has been raised for 1997. This
has allowed the site installation costs of £4,000 to continue to be fundedHb . 10 without use of EPO varies from 13% at Centre D to 21%
Abstracts2116
directly by the Renal Registry, with no initial outlay by the sites. In Scotland. The Registry is ready for rapid expansion. It will only realise
its potential if other renal units demonstrate their commitment to thefuture, units will be charged an annual fee of £10 per patient registered,
as agreed last year. This is 0.05% of the annual patient treatment cost project by joining as quickly as possible.
Address: Renal Registryand is considerably less than other Registries (e.g. ICNARC), with cost
around 1%. The Future Challenge: The Registry is now independent. Southmead Hospital
Southmead RoadReports on data from 6 renal units have generated interest within the
Renal Association and elsewhere. A full time statistician has been Bristol BS6 6DN, UK
Tel: 0117 959 5665; Fax: 0117 959 5664;employed to facilitate further data analysis. 25% of the English popula-
tion will soon be covered, and there will be a limited data set from E-mail: renalreg@globalnet.co.uk
